


Prospectus

7,000,000 Shares

SEATTLE GENETICS LOGO



Common Stock

Seattle Genetics, Inc. is selling all of the shares of common stock in this offering. This is our initial public offering.

Under an agreement between us and Genentech, Inc., a stockholder of ours with whom we have a license agreement, Genentech has agreed to purchase directly from us at the initial public offering price \$2,000,000 of the common stock sold in this offering. In addition, under an agreement between us and Medarex Inc., a collaborative partner, Medarex has agreed to purchase at the initial public offering price \$2,000,000 of our common stock in a private placement concurrent with this offering. The 7,000,000 shares of common stock being offered by this prospectus include the 285,714 shares being sold to Genentech but exclude the 285,714 shares being sold to Medarex. We will receive the full proceeds and will not pay underwriting discounts with respect to the shares being sold to Genentech and Medarex. Furthermore, Cascade Investment, LLC, one of our principal stockholders, has expressed an interest in purchasing 850,000 shares of the common stock being offered by this prospectus. These shares would be purchased through the underwriters at the initial public offering price.

Our common stock has been approved for listing on the Nasdaq National Market under the symbol "SGEN."

Investing in our common stock involves risks. Please read "Risk Factors" beginning on page 7.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

	Initial Public Offering Price	Underwriting Discount	Proceeds to Seattle Genetics
Per Share to Public	\$7.00	\$0.49	\$6.51
Per Share to Genentech	\$7.00	—	\$7.00
Total	\$49,000,000	\$3,290,000	\$45,710,000

We have granted the underwriters the right to purchase up to an additional 1,007,143 shares of common stock to cover over-allotments.

JPMorgan

CIBC World Markets

Banc of America Securities LLC

March 6, 2001

Table of Contents

	Page
Prospectus Summary	1
Risk Factors	7
Special Note Regarding Forward-Looking Statements	15
About This Prospectus	15
Use of Proceeds	16
Dividend Policy	16
Capitalization	17
Dilution	18

Selected Financial Data	19
Management's Discussion and Analysis of Financial Condition and Results of Operations	21
Business	26
Management	47
Transactions With Executive Officers, Directors and Five Percent Stockholders	57
Principal Stockholders	58
Description of Capital Stock	61
Shares Eligible for Future Sale	64
Underwriting	65
Plan of Distribution	67
Concurrent Private Placement	67
Legal Matters	68
Experts	68
Where You Can Find More Information	68
Index to Financial Statements	F-1

Until March 31, 2001, all dealers that effect transactions in the common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligations to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

Prospectus Summary

In this prospectus, "Seattle Genetics," "we," "us" and "our" refer to Seattle Genetics, Inc., a Delaware corporation, and not to the underwriters. This summary highlights selected information contained elsewhere in the prospectus. You should read the entire prospectus, including "Risk Factors" and the financial data and related notes, before making an investment decision.

Seattle Genetics, Inc.

We discover and develop monoclonal antibody-based drugs to treat cancer and related diseases. Using our monoclonal antibody-based technologies and our expertise in cancer, we have assembled a portfolio of drug candidates targeted to many types of human cancers. We utilize our monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. We are currently testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers. SGN-15 is in three phase II clinical trials in combination with the chemotherapy drug Taxotere. SGN-10 is in two phase I clinical trials, one as a single agent and the other in combination with Taxotere. We have five preclinical product candidates being developed to treat patients with solid tumors, melanoma or blood-cell cancers, commonly known as hematologic malignancies. One of our preclinical product candidates, SGN-14, is being developed by Genentech pursuant to a license agreement. In addition to providing us with the means to discover and develop monoclonal antibody-based product candidates ourselves, our technologies allow us to partner with other companies also developing monoclonal antibodies.

Monoclonal Antibody Therapeutics for Cancer

Monoclonal antibodies are proteins that bind to specific molecules and can be used to target cell populations such as cancer cells. Some monoclonal antibodies are effective as anti-cancer drugs on their own. However, most monoclonal antibodies are not potent enough to be used as anti-cancer agents alone and require additional payloads of drugs or toxins to effectively kill cancer cells. Due to advances in monoclonal antibody technology, monoclonal antibody-based therapeutics have become a rapidly expanding area of drug development. The FDA has approved nine therapeutic antibodies, seven of them in the last three years, with total sales in 1999 in excess of \$1.4 billion worldwide.

Our Monoclonal Antibody-Based Technologies

We have four monoclonal antibody-based technologies: monoclonal antibodies; monoclonal antibodies chemically linked to cell-killing drugs, or monoclonal antibody-drug conjugates; single proteins containing monoclonal antibody and toxin components, or single-chain immunotoxins; and antibody-directed enzyme prodrug therapy, or ADEPT.

- Monoclonal antibodies are generally made in mouse form. Our monoclonal antibodies have been genetically altered to make them appear more human-like to a patient's immune system. Monoclonal antibodies have been shown to be effective either on their own or in combination with chemotherapy in treating hematologic malignancies and solid tumors. Monoclonal antibodies have lower toxicity than chemotherapy and allow for multiple doses or cycles of therapy.
- Monoclonal antibody-drug conjugates are composed of monoclonal antibodies that enter into cells, or internalize, and are linked to potent cell-killing drugs. Our technology uses stable linkers to attach these potent cell-killing drugs to monoclonal antibodies. The cell-killing drugs are inactive until released from the monoclonal antibodies inside the cancer cell, thereby sparing normal tissue.
- Single-chain immunotoxins are comprised of the receptor binding portions of monoclonal antibodies that internalize, combined with toxin components genetically assembled into a single protein. The single-chain immunotoxins internalize and then kill cells by blocking protein production.

- Antibody-directed enzyme prodrug therapy, or ADEPT, represents a novel approach to minimizing drug exposure to normal tissues. This approach involves a single protein containing monoclonal antibody and enzyme components that can localize to solid tumors and activate subsequently administered inactive forms of anti-cancer drugs, or prodrugs, thus locally releasing active drugs that have anti-cancer activity.

Our Product Candidates in Clinical Trials

We are testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with solid tumors.

- Our lead monoclonal antibody-drug conjugate, SGN-15, is composed of a monoclonal antibody called BR96 that binds to a carbohydrate found on many different cancer types, chemically linked to the cell-killing drug doxorubicin. SGN-15 binds to cancer cells and kills them by delivering doxorubicin inside the cell. SGN-15 is currently in three phase II clinical trials in combination with Taxotere to treat patients with breast, colon or prostate cancer. Aventis, the manufacturer and marketer of Taxotere, is co-funding the studies in breast and colon cancer.

- SGN-10 is a single-chain immunotoxin that binds to cancer cells and kills them by delivering a protein toxin inside the cell. SGN-10 is composed of the receptor binding portion of the BR96 monoclonal antibody and a truncated portion of a protein toxin called *Pseudomonas* exotoxin A. SGN-10 is currently in two phase I clinical trials, one as a single agent and the second in combination with Taxotere with co-funding by Aventis. Both studies include patients with breast, lung, colon, prostate, or ovarian cancers.

Our Preclinical Product Candidates

We have five product candidates in preclinical development. These product candidates are:

- SGN-14, our humanized monoclonal antibody targeted to the receptor identified as CD40, being developed by Genentech for patients with hematologic malignancies or other types of cancer;

- SGN-30, our monoclonal antibody targeted to the receptor identified as CD30, being developed for the treatment of patients with hematologic malignancies or other types of disease;

- SGN-17/19, utilizing our ADEPT technology, being developed for the treatment of patients with melanoma;

- novel BR96 monoclonal antibody-drug conjugate, utilizing our stable linkers and high-potency drugs to kill solid tumor cells; and

- novel SGN-30 monoclonal antibody-drug conjugate, utilizing our stable linkers and drugs for targeting and killing of hematologic malignancies that express the CD30 receptor.

Our Strategy

Our objective is to utilize our expertise in cancer and in monoclonal antibody-based technologies to advance our product pipeline and discover new product candidates for the treatment of cancer and related diseases. Our strategy includes initiatives to:

- continue to apply our expertise in monoclonal antibodies to develop anti-cancer therapeutics and to identify novel monoclonal antibodies that bind to new cancer targets;

- utilize our technologies to take highly specific monoclonal antibodies being developed by us or by other companies and make them into product candidates by improving their efficacy;

- continue to develop multiple products simultaneously that target different receptors on cancer cells and utilize multiple mechanisms of action for cell killing, thereby increasing our opportunities to identify successful pharmaceutical drugs;

2

- expand our portfolio of product candidates through in-licensing of products and technologies; and

- enter into corporate collaborations at various stages in the research and development process, enabling us to develop a greater number of product candidates than would otherwise be possible while allowing us to participate in downstream product sales.

Financial History

We incurred net losses of \$7.8 million for the year ended December 31, 2000 and \$2.8 million for the year ended December 31, 1999. We currently do not have any commercial products for sale, and to date we have funded our operations through private equity financings, licensing fees and investment income. We anticipate that our losses will increase for the foreseeable future as we continue to expand our research, development and

clinical trial activities and build additional infrastructure. As of December 31, 2000, we had an accumulated deficit of \$12.8 million.

Corporate Information

We were incorporated in the state of Delaware on July 15, 1997. Our principal executive offices are located at 22215 26th Avenue SE, Suite 3000, Bothell, WA 98021. Our telephone number is (425) 489-4990. Our website is www.seattlegenetics.com. Information contained in our website does not constitute part of this prospectus.

We own or have the right to various trademarks, service marks and trade names used in our business. These include: Seattle Genetics, seagen, SGN-10, SGN-15, SGN-14, SGN-30 and SGN-17/19. This prospectus also includes trademarks, service marks and trade names owned by other companies. These include Taxotere®, Rituxan®, Herceptin®, Mylotarg® and Panorex®.

The Offering

Common stock offered to the public	6,714,286 shares
Common stock to be purchased by Genentech	Genentech is purchasing 285,714 of the shares for sale in this offering directly from us, at the initial public offering price of \$7.00 per share.
Common stock to be purchased by Medarex	Medarex is purchasing 285,714 shares of common stock in a concurrent private placement, at the initial public offering price of \$7.00 per share.
Common stock to be outstanding after this offering	29,253,863 shares
Use of proceeds	To fund preclinical research and development activities, contract manufacturing activities, clinical trial activities and for other general corporate purposes, including capital expenditures and working capital. See "Use of Proceeds."
Proposed Nasdaq National Market symbol	"SGEN"

The number of shares of our common stock outstanding after this offering is based on the number of shares outstanding as of December 31, 2000 and includes 285,714 shares to be purchased directly by Genentech and 285,714 shares to be purchased in a concurrent private placement by Medarex. However, it excludes 1,313,818 shares issuable upon exercise of options outstanding as of December 31, 2000 with a weighted average exercise price of \$2.07 per share and an additional 2,208,605 shares reserved for issuance upon exercise of options which may be granted subsequent to December 31, 2000.

Except as stated in the financial statements or as specifically indicated in this prospectus, all information in this prospectus:

- assumes no exercise of the underwriters' over-allotment option; and
- reflects the conversion of all shares of our outstanding preferred stock on a one-for-one basis into 17,387,072 shares of our common stock upon the closing of this offering.

Summary Financial Data

The summary financial data set forth below should be read in conjunction with the financial statements and notes to our financial statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained elsewhere in this prospectus. The summary balance sheet data as of December 31, 2000 and the summary statements of operations data for the years ended December 31, 1998, 1999, 2000 and for the period from inception (January 1, 1998) to December 31, 2000 have been derived from our audited financial statements appearing elsewhere in this prospectus. The pro forma net loss per share data give effect to the conversion of our preferred stock from its date of original issuance. The pro forma balance sheet data reflect the conversion of our outstanding preferred stock into shares of our common stock upon the closing of this offering. The pro forma as adjusted balance sheet data reflect that conversion and also reflect the sale of 6,714,286 shares of common stock in this offering at the initial public offering price of \$7.00 per share after deducting underwriting discounts and estimated offering expenses, 285,714 shares to be purchased directly by Genentech and 285,714 shares to be purchased by Medarex in a concurrent private placement.

Year Ended December 31,			Cumulative from inception (January 1, 1998) to December 31, 2000
1998	1999	2000	

In thousands, except share data

Statements of Operations Data:

Revenue	\$ —	\$ 1,000	\$ 99	\$ 1,099
Expenses:				
Research and development	1,331	2,469	4,947	8,747
General and administrative	671	859	1,872	3,402
Noncash stock-based compensation expense	347	726	3,138	4,211
Loss from operations	(2,349)	(3,054)	(9,858)	(15,261)
Investment income, net	243	236	2,020	2,499
Net loss	\$(2,106)	\$(2,818)	\$(7,838)	\$(12,762)
Preferred stock deemed dividend and accretion	(5)	(6)	(504)	
Net loss attributable to common stockholders	\$(2,111)	\$(2,824)	\$(8,342)	
Basic and diluted net loss per share	\$ (0.94)	\$ (1.03)	\$ (2.54)	
Weighted-average shares used in computing basic and diluted net loss per share	2,235,997	2,749,212	3,289,731	
Pro forma basic and diluted net loss per share			\$(0.38)	
Weighted-average shares used in computing pro forma basic and diluted net loss per share			20,627,995	

5

As of December 31, 2000

Actual	Pro Forma	Pro Forma As Adjusted
--------	-----------	--------------------------

(unaudited)

*In thousands***Balance Sheet Data:**

Cash, cash equivalents and short-term investments	\$ 24,330	\$ 24,330	\$ 71,300
Restricted investments	3,421	3,421	3,421
Working capital	24,558	24,558	70,968
Total assets	29,874	29,874	76,284
Mandatorily redeemable convertible preferred stock	37,556	—	—
Additional paid-in capital	14,798	52,336	98,739
Total stockholders' equity (deficit)	(8,493)	29,063	75,473

6

Risk Factors

You should carefully consider the following risk factors and all other information contained in this prospectus before purchasing our common stock. Investing in our common stock involves a high degree of risk. If any of the following risks actually occurs we may be unable to conduct our business as currently planned and our financial condition and operating results could be seriously harmed. In addition, the trading price of our common stock could decline due to the occurrence of any of these risks, and you may lose all or part of your investment. Please read "Special Note Regarding Forward-Looking Statements."

Risks Related to Our Business

We have a history of net losses. We expect to continue to incur net losses and may not achieve or maintain profitability. Our limited operating history may make it difficult to evaluate our business and an investment in our common stock

We are a development stage company incorporated in July 1997 and have a limited operating history upon which an investor may evaluate our operations and future prospects. We have incurred net losses since our inception, including net losses of approximately \$2.8 million for the year ended December 31, 1999 and approximately \$7.8 million for the year ended December 31, 2000. As of December 31, 2000, we had an accumulated deficit of approximately \$12.8 million. We expect to make substantial expenditures to further develop and commercialize our product candidates and expect that our rate of spending will accelerate as the result of the increased costs and expenses associated with clinical trials, regulatory approvals and commercialization of our potential products. In the near term, we expect revenues to be derived from milestone payments and sponsored research fees under existing and possible future collaborative arrangements. However, our revenue and profit potential is unproven and our limited operating history makes our future operating results difficult to predict. Consequently, an investment in our common stock must be considered in light of the risks and uncertainties that may be encountered by a development stage biotechnology company, including the need for

substantial capital to support the development of our products and technologies and our ability to manage growth as we hire a substantial number of additional employees to support our planned increase in development activities.

Our product candidates are at an early stage of development and if we are not able to successfully develop and commercialize them, we may not generate sufficient revenues to continue our business operations

All of our product candidates are in early stages of development. Significant further research and development, financial resources and personnel will be required to develop commercially viable products and obtain regulatory approvals. Much of our efforts and expenditures over the next few years will be devoted to SGN-15, SGN-10, SGN-14, SGN-30, SGN-17/19, novel BR96 monoclonal antibody-drug conjugate and novel SGN-30 monoclonal antibody-drug conjugate. These are our only product candidates in preclinical development or clinical trials. We have no drugs that have received regulatory approval for commercial sale. We expect that none of our product candidates will be commercially available in the near term.

Our ability to commercialize our product candidates depends on first receiving FDA approval. The future commercial success of these product candidates will depend upon their acceptance by physicians, patients and other key decision-makers as therapeutic and cost-effective alternatives to currently available products. If we fail to gain approval from the FDA or to produce a commercially successful product, we may not be able to earn sufficient revenues to continue as a going concern.

7

We may continue to need significant amounts of additional capital which may not be available to us

We have consumed limited amounts of cash to date but expect capital outlays and operating expenditures to significantly increase over the next several years as we hire additional employees and expand our infrastructure and preclinical development and clinical trial activities. We believe that the net proceeds from this offering, along with our existing cash and investment securities, milestone payments and research grants, will be sufficient to fund our operations for at least the next two years. However, changes in our business may occur that would consume available capital resources sooner than we expect. If adequate funds are not available to us, we will be required to delay, reduce the scope of or eliminate one or more of our development programs. We do not know whether additional financing will be available when needed, or that, if available, we will obtain financing on terms favorable to our stockholders or us. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us.

Clinical trials for our product candidates are expensive and time consuming and their outcome is uncertain

Before we can obtain regulatory approval for the commercial sale of any product candidate that we wish to develop, we will be required to complete preclinical development and extensive clinical trials in humans to demonstrate its safety and efficacy. Each of these trials requires the investment of substantial expense and time. We are currently conducting a total of five clinical trials of our two most advanced product candidates, and expect to commence additional trials of these and other product candidates. There are numerous factors that could delay each of these clinical trials or prevent us from completing these trials successfully.

Success in preclinical and early clinical trials does not ensure that large-scale trials will be successful nor does it predict final results. Acceptable results in early trials may not be repeated in later trials. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials, even after promising results in earlier trials. Negative or inconclusive results or adverse medical events during a clinical trial could cause it to be redone or terminated. In addition, failure to construct appropriate clinical trial protocols could result in the test or control group experiencing a disproportionate number of adverse events and could cause a clinical trial to be redone or terminated.

The length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by the FDA or another regulatory authority varies significantly. To date, we have limited clinical data and have seen evidence of gastrointestinal toxicity with SGN-15 and SGN-10. Future trials may not show sufficient safety and efficacy to obtain the requisite regulatory approval for these product candidates or any other potential product candidates. Because SGN-15, SGN-10, SGN-14, SGN-30, SGN-17/19, novel BR96 monoclonal antibody-drug conjugate and novel SGN-30 monoclonal antibody-drug conjugate, are our only product candidates in clinical trials or preclinical development at the present time, any delays or difficulties we encounter may impact our ability to generate revenue and cause our stock price to decline significantly.

We may choose to, or may be required to, suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed

Clinical trials must be conducted in accordance with the FDA's guidelines and are subject to oversight by the FDA and institutional review boards at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced under the FDA's Good Manufacturing Practices, and may require large numbers of test patients. Patient enrollment is a function of

8

many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Clinical trials may be suspended by the FDA at any time if the FDA finds deficiencies in the conduct of these trials or it is believed that these trials expose patients to unacceptable health risks.

In addition, we or the FDA might delay or halt our clinical trials of a product candidate for various reasons, including:

- the product candidate may have unforeseen adverse side effects;
- the time required to determine whether the product candidate is effective may be longer than expected;

- fatalities arising during a clinical trial due to medical problems that may not be related to clinical trial treatments;
- the product candidate may not appear to be more effective than current therapies;
- insufficient patient enrollment in the clinical trials; or
- we may not be able to produce sufficient quantities of the product candidate to complete the trials.

Furthermore, the process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive and uncertain. It can vary substantially, based on the type, complexity and novelty of the product involved. Accordingly, our current product candidates or any of our other future product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval, which could reduce our revenue and delay or terminate the potential commercialization of our product candidates.

We currently rely on third-party manufacturers for production of our drug products and our dependence on these manufacturers may impair the development of our product candidates

We do not currently have the ability to manufacture drug products that we need to conduct our clinical trials. For our two product candidates in clinical trials, SGN-15 and SGN-10, we rely on drug products that were produced and vialled by Bristol-Myers Squibb and contract manufacturers retained by Bristol-Myers Squibb. For the foreseeable future, we will continue to rely on contract manufacturers to produce sufficient quantities of our product candidates for use in our clinical trials. If our contract manufacturers fail to deliver the required quantities of our product candidates for clinical use on a timely basis, with sufficient quality, and at commercially reasonable prices, and we fail to find replacement manufacturers or to develop our own manufacturing capabilities, we may be unable to continue development and production of our product candidates.

Contract manufacturers have a limited number of facilities in which our product candidates can be produced. We currently rely on contract manufacturers to produce our product candidates under FDA Good Manufacturing Practices to meet acceptable standards for our clinical trials. Such standards may change, affecting the ability of contract manufacturers to produce our product candidates on the schedule we require for our clinical trials. Contract manufacturers may not perform or may discontinue their business for the time required by us to successfully produce and market our product candidates.

In some circumstances we rely on collaborators to assist in the research and development activities necessary for the commercialization of our product candidates. If our collaborators do not perform as expected, we may not be able to commercialize our product candidates

We intend to continue to develop alliances with third party collaborators to develop and market our current and future product candidates. We may not be able to locate third party collaborators to develop and market other product candidates and we may lack the capital and resources necessary to develop all our product

candidates alone. If our collaborators do not prioritize and commit substantial resources to programs associated with our product candidates, we may be unable to commercialize our product candidates, which would limit our ability to generate revenue and become profitable.

We have a license agreement with Genentech pursuant to which they are developing our lead CD40 targeted drug, SGN-14, to treat patients with hematologic malignancies or other types of cancer. Genentech is also responsible for gaining final approval through the required U.S. and international regulatory authorities to ultimately market the product. At any time, Genentech may terminate the agreement for any reason and return the rights to the CD40 program to us. If Genentech decides not to proceed and we fail to locate a substitute partner, we may not have sufficient capital resources to continue funding the project.

If we are unable to protect our proprietary technology, trade secrets or know-how, we may not be able to operate our business profitably. Similarly, if we fail to sustain and further build our intellectual property rights, competitors may be able to develop competing therapies

Our success depends, in part, on our ability to maintain protection for our products and technologies under the patent laws or other intellectual property laws of the United States, France, Germany, Japan, United Kingdom and Italy, as well as other countries. We have filed four patent applications with the U.S. Patent and Trademark Office for our technologies which are currently pending. We also have exclusive rights to certain issued U.S. patents, and foreign counterpart patents and patent applications in the countries listed above, relating to our monoclonal antibody-based technology. Our rights to these patents are derived from worldwide licenses from Bristol-Myers Squibb and Arizona State University. In addition, we have licensed or optioned rights to pending U.S. patent applications and foreign counterpart patents and patent applications to third parties. The standards which the U.S. Patent and Trademark Office uses to grant patents are not always applied predictably or uniformly and can change. Consequently, the pending patent applications may not be allowed; and if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, any issued patents may not contain claims that will permit us to stop competitors from using similar technology. Similarly, the standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, the protection, if any, given to our patents if we attempt to enforce them or if they are challenged in court is uncertain. In addition, we rely on certain proprietary trade secrets and know-how. We have taken measures to protect our unpatented trade secrets and know-how, including the use of confidentiality and assignment of inventions agreements with our employees, consultants and certain contractors. It is possible, however, that these persons may breach the agreements or that our competitors may independently develop or otherwise discover our trade secrets.

We may incur substantial costs and lose important rights as a result of litigation or other proceedings relating to patent and other intellectual property rights

The defense and prosecution of intellectual property rights, U.S. Patent and Trademark Office interference proceedings and related legal and

administrative proceedings in the United States and elsewhere involve complex legal and factual questions. These proceedings are costly and time-consuming.

If we become involved in any litigation, interference or other administrative proceedings, we will incur substantial expense and it will divert the efforts of our technical and management personnel. An adverse determination may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially reasonable terms, if at all. We may be restricted or prevented from developing and commercializing our product candidates, if any, in the event of an adverse determination in a judicial or administrative proceeding, or if we fail to obtain necessary licenses.

10

Because of the specialized nature of our business, the termination of relationships with our key management and scientific personnel or our inability to recruit and retain additional personnel could prevent us from developing our technologies, conducting clinical trials and obtaining financing.

Since our formation, Dr. Fell and Dr. Siegall have played a significant role in our research efforts. Dr. Fell is Chief Executive Officer and a director of our company and Dr. Siegall is President, Chief Scientific Officer and a director of our company. We are highly dependent on these two individuals, and they have played a critical role in our research and development programs, raising financing and conducting clinical trials. Currently, we have no employment agreements with Dr. Fell or Dr. Siegall. We have obtained key person insurance for Dr. Fell and Dr. Siegall in the amount of \$1.0 million each. However, the sum recovered under such insurance policies may not fully compensate us for any loss of their services. Additionally, we have several scientific personnel with significant and unique expertise in monoclonal antibodies and related technologies, some of whom are irreplaceable. The loss of the services of either of these two key members of our company or these scientific personnel may prevent us from achieving our business objectives.

The competition for qualified personnel in the biotechnology field is intense, and we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. Our future success depends upon our ability to attract, retain and motivate highly skilled employees. In order to commercialize our products successfully, we will be required to expand our workforce, particularly in the areas of manufacturing, clinical trials management, regulatory affairs, business development and sales and marketing. These activities will require the addition of new personnel, including management, and the development of additional expertise by existing management personnel. We face intense competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions. To the extent we are not able to attract and retain these individuals on favorable terms, our business may be harmed.

We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do

The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. We are aware of several pharmaceutical and biotechnology companies that are actively engaged in research and development in areas related to antibody therapy. Some of these companies have commenced clinical trials of antibody products or have successfully commercialized antibody products. Many of these companies are developing products for the same disease indications as we are. Some of these competitors have received regulatory approval or are developing or testing product candidates that do or may in the future compete directly with our product candidates. For example, Genentech, IDEC Pharmaceuticals and American Home Products market products that may compete with ours. Other potential competitors include large, fully integrated pharmaceutical companies and more established biotechnology companies, which have significant resources and expertise in research and development, manufacturing, testing, obtaining regulatory approvals and marketing. Also, academic institutions, government agencies and other public and private research organizations conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing. It is possible that these competitors will succeed in developing technologies that are more effective than those being developed by us or that would render our technology obsolete or noncompetitive.

If our competitors develop superior products, manufacturing capability or marketing expertise, our business may fail

Our business may fail because we face intense competition from major pharmaceutical companies and specialized biotechnology companies engaged in the development of other products directed at cancer. Many

11

of our competitors have greater financial and human resources and more experience. Our competitors may, among other things:

- develop safer or more effective products;
- implement more effective approaches to sales and marketing;
- develop less costly products;
- obtain quicker regulatory approval;
- have access to more manufacturing capacity;
- form more advantageous strategic alliances; or

- establish superior proprietary positions.

In addition, if we receive regulatory approvals, we may compete with well-established, FDA approved therapies that have generated substantial sales over a number of years. We anticipate that we will face increased competition in the future as new companies enter our market and scientific developments surrounding other cancer therapies continue to accelerate.

We have no experience in commercializing products on our own and to the extent we do not develop this ability or contract with a third-party to assist us, we may not be able to successfully sell our product candidates. Additionally, if the market does not accept our products or if reform in the healthcare industry does not provide adequate reimbursement for our products, we may not be able to generate sufficient revenues to maintain our business

We do not have a sales and marketing force and may not be able to develop this capacity. If we are unable to establish sales and marketing capabilities, we will need to enter into sales and marketing agreements to market our products in the United States. For sales outside the United States, we plan to enter into third-party arrangements. In these foreign markets, if we are unable to establish successful distribution relationships with pharmaceutical companies, we may fail to realize the full sales potential of our product candidates.

Additionally, our product candidates may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved product candidate will depend on a number of factors, including:

- establishment and demonstration of clinical efficacy and safety;
- cost-effectiveness of a product;
- its potential advantage over alternative treatment methods; and
- marketing and distribution support for the product.

In addition, government health administrative authorities, private health insurers and other organizations are increasingly challenging both the need for and the price of new medical products and services. Consequently, uncertainty exists as to the reimbursement status of newly approved therapeutics and diagnostics. For these and other reasons, physicians, patients, third-party payors and the medical community may not accept and utilize any product candidates that we develop and even if they do, reimbursement may not be available for our products to enable us to maintain price levels sufficient to realize an appropriate return on our investment in research and product development.

We face product liability risks and may not be able to obtain adequate insurance to protect us against losses

We currently have no products that are available for commercial sale. However, the current use of any of our product candidates in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made directly by consumers and healthcare providers or indirectly by pharmaceutical companies, our corporate collaborators or others selling such products. We may experience financial losses in the future due to product liability claims. We have obtained limited product liability insurance coverage for our clinical trials. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for product candidates in development. However, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.

Risks Related to this Offering

Our stock price may be volatile and you may be unable to sell your shares at or above the offering price

There previously has been no public market for our common stock. Additionally, an active public market for our common stock may never develop or be sustained after the offering. The initial public offering price for our shares will be determined by negotiations between us and representatives of the underwriters and may not be indicative of prices that will prevail in the trading market. The market price of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:

- changes in financial estimates of our operating results by securities analysts;
- fluctuations in the valuation of companies perceived by investors to be comparable to us;
- performance of similar companies; and
- share price and volume fluctuations attributable to inconsistent trading volume levels of our shares.

Furthermore, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. In particular, there has been high levels of volatility in the market prices of securities of biotechnology companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies.

These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may cause the market price of our common stock to decline.

Our existing stockholders have significant control of our management and affairs, which they could exercise against your best interests

Following the closing of this offering, our executive officers and directors and greater than 5% stockholders, together with entities that may be deemed affiliates of or related to such persons or entities, will beneficially own approximately 70% of our outstanding common stock. As a result, these stockholders, acting together, may be able to control our management and affairs and matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying, deferring or preventing a change in control, including a merger, consolidation, takeover or other business combination involving us or discourage a potential acquiror from making a tender offer or otherwise attempting to obtain control, which might affect the market price of our common stock.

13

Because our initial public offering price will be substantially higher than the book value per share of our outstanding common stock, new investors will incur immediate and substantial dilution in the amount of approximately \$4.42 per share

The initial public offering price will be substantially higher than the tangible book value per share based on the total value of our tangible assets less our total liabilities immediately following this offering. Therefore, if you purchase common stock in this offering, you will experience immediate and substantial dilution of approximately \$4.42 per share in the price you pay for the common stock as compared to its tangible book value. Furthermore, investors purchasing common stock in this offering will own only 23.9% of our shares outstanding even though they will have contributed 55.0% of the total consideration received by us in connection with our sales of common stock. To the extent outstanding options to purchase common stock are exercised, there will be further dilution.

Following this offering, a substantial number of our shares of common stock will become available for sale in the public market that may cause the market price of our stock to decline

If our stockholders sell substantial amounts of our common stock (including shares issued upon the exercise of outstanding options and warrants) in the public market following this offering, the market price of our common stock could fall. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a time and price acceptable to us.

Within 180 days after the date of this prospectus, 21,968,149 shares held by existing stockholders and 285,714 shares to be purchased by Genentech, which will be subject to "lock-up" agreements, will become available for sale and an additional 285,714 shares to be purchased by Medarex, which will be subject to both a 180 day lock-up and the expiration of a one-year holding period, will periodically thereafter become available for sale. Please see "Shares Eligible for Future Sale" for a complete description of the number of shares which will become available for future sale.

We have broad discretion in the use of net proceeds from this offering and may not use them effectively

As of the date of this prospectus, we cannot specify with certainty the amounts we will spend on particular uses from the net proceeds we will receive from this offering. Our management will have broad discretion in the application of the net proceeds but currently intends to use the net proceeds as described in the section "Use of Proceeds." The failure by our management to apply these funds effectively could affect our ability to continue to develop and market new product candidates.

14

Special Note Regarding Forward-Looking Statements

This prospectus contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

- our product development programs;
- our clinical development of potential drugs, clinical trials and the regulatory approval process;
- our estimates for future revenues and profitability;
- our estimates regarding our capital requirements and our needs for additional financing;
- our selection and licensing of product candidates;
- our ability to attract partners with acceptable development, regulatory and commercialization expertise;

- the benefits to be derived from corporate collaborations, license agreements and other collaborative efforts, including those relating to the development and commercialization of our product candidates; and

- sources of revenues and anticipated revenues, including contributions from corporate collaborations, license agreements and other collaborative efforts for the development and commercialization of products, and the continued viability and duration of those agreements and efforts.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading "Risk Factors." Also, these forward-looking statements represent our estimates and assumptions only as of the date of this prospectus.

You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. Although Section 27A of the Securities Act of 1933 and the Private Securities Litigation Reform Act of 1995 do not apply to initial public offerings such as ours, we qualify all of our forward-looking statements by these cautionary statements.

About This Prospectus

You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted.

15

Use of Proceeds

We estimate our net proceeds from the sale of 7,000,000 shares of our common stock in this offering to be approximately \$44.4 million, or approximately \$51.0 million if the underwriters' over-allotment option is exercised in full, based on the initial public offering price of \$7.00 per share and after deducting the estimated underwriting discounts and estimated offering expenses. This amount includes \$2.0 million to be received directly from Genentech for the purchase of 285,714 shares at the initial public offering price but does not include the \$2.0 million to be received from Medarex for the purchase of 285,714 shares at the initial public offering price in a concurrent private placement. The underwriters will not receive any commissions or discounts for the shares purchased directly by Genentech or for the shares sold in the concurrent private placement to Medarex.

We currently plan to use the net proceeds from this offering as follows:

- approximately 20-30% for preclinical research and development activities;
- approximately 20-30% for contract manufacturing activities;
- approximately 10-20% for clinical trial activities; and
- the remainder for general corporate purposes, including capital expenditures and working capital to fund anticipated operating losses.

Although we have identified certain ranges above, we have broad discretion to use the proceeds, and may also, when and if the opportunity arises, use a portion of the proceeds to acquire or invest in complimentary businesses, products or technologies. We do not intend to fund short-term expenditures from sources other than this offering. Pending such uses, we intend to invest such funds in a variety of interest-bearing instruments, consisting of U.S. government and agency securities, high-grade U.S. corporate bonds, municipal bonds, mortgage-backed securities, commercial paper and money market accounts.

Dividend Policy

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable future.

16

Capitalization

The following table summarizes our cash, cash equivalents and short term investments, restricted investments and our capitalization as of December 31, 2000:

- on an actual basis;
- on a pro forma basis reflecting conversion of all outstanding shares of our preferred stock on a one-for-one basis into shares of common stock upon the closing of this offering; and
- on a pro forma as adjusted basis reflecting that conversion and the receipt of the net proceeds from the sale of 6,714,286 shares of common stock in this offering at the initial public offering price of \$7.00, excluding underwriting discounts and estimated offering expenses, 285,714 shares of common stock to be purchased directly from us by Genentech at the initial offering price and 285,714 shares of common stock to be purchased by Medarex in a concurrent private placement at the initial offering price.

The number of shares in the table below is based on the number of shares of common stock outstanding as of December 31, 2000 and excludes:

- an aggregate of 1,313,818 shares subject to outstanding options as of December 31, 2000 at a weighted average exercise price of \$2.07 per share under our 1998 stock option plan; and
- an additional 2,208,605 shares reserved for issuance upon exercise of options that may be granted subsequent to December 31, 2000 under our 1998 stock option plan.

This table should be read with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and the accompanying notes appearing elsewhere in this prospectus.

	December 31, 2000		
	Actual	Pro Forma	Pro Forma As Adjusted
<i>In thousands, except share data</i>			
Cash, cash equivalents and short-term investments	\$ 24,330	\$ 24,330	\$ 71,300
Restricted investments	\$ 3,421	\$ 3,421	\$ 3,421
Long-term debt	—	—	—
Mandatorily redeemable convertible preferred stock, \$0.001 par value; 17,450,000 shares authorized, 17,387,072 shares issued and outstanding, actual; 5,000,000 shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted	\$ 37,556	\$ —	\$ —
Stockholders' equity (deficit):			
Common stock \$0.001 par value; 30,000,000 shares authorized, 4,581,077 shares issued and outstanding, actual; 30,000,000 shares authorized, 21,968,149 shares issued and outstanding, pro forma; and 100,000,000 shares authorized, 29,253,863 shares issued and outstanding, pro forma as adjusted	4	22	29
Additional paid-in capital	14,798	52,336	98,739
Notes receivable from stockholders	(408)	(408)	(408)
Deferred stock compensation	(10,194)	(10,194)	(10,194)
Accumulated other comprehensive income	69	69	69
Accumulated deficit	(12,762)	(12,762)	(12,762)
Total stockholders' equity (deficit)	(8,493)	29,063	75,473
Total capitalization	\$ 29,063	\$ 29,063	\$ 75,473

See "Management—Stock Plans," "Certain Relationships and Related Transactions" and the Notes to Financial Statements.

Dilution

If you invest in our common stock, your interest will be diluted to the extent of the difference between the public offering price per share of our

common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. Our pro forma net tangible book value at December 31, 2000 was approximately \$28.5 million, or \$1.30 per share of common stock. Pro forma net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding after giving effect to the conversion of all of our outstanding preferred stock into 17,387,072 shares of our common stock on a one-for-one basis. After giving effect to the issuance and sale of 6,714,286 shares of our common stock in this offering at the initial public offering price of \$7.00 per share, after deducting the underwriting discounts and our estimated offering expenses, after giving effect to the purchase by Genentech of 285,714 shares of common stock directly from us at the initial public offering price and the purchase by Medarex of 285,714 shares of common stock in a concurrent private placement at the initial public offering price, our pro forma as adjusted net tangible book value at December 31, 2000, would have been \$75.5 million, or \$2.58 per share. This represents an immediate increase in net tangible book value of \$1.28 per share to our existing stockholders and an immediate dilution of \$4.42 per share to our new investors purchasing shares of common stock in this offering. The following table illustrates this dilution on a per share basis:

Assumed initial public offering price per share		\$	7.00
Pro forma net tangible book value per share at December 31, 2000		\$	1.30
Increase per share attributable to private placement with Medarex			.05
Increase per share attributable to new investors			1.23
Pro forma as adjusted net tangible book value after the offering			2.58
Dilution per share to new investors		\$	4.42

The following table summarizes on a pro forma as adjusted basis, as of December 31, 2000, the total number of shares of common stock outstanding and the total consideration paid to us and the average price per share paid by our existing stockholders and by new investors purchasing shares of common stock in this offering at the initial public offering price of \$7.00 per share:

	Shares Purchased		Total Consideration		Average Price Per Share
	Number	Percent	Amount	Percent	
Existing stockholders	21,968,149	75.1%	\$ 38,110,678	42.8%	\$ 1.74
Medarex private placement	285,714	1.0	\$ 2,000,000	2.2	\$ 7.00
New investors	7,000,000	23.9	\$ 49,000,000	55.0	\$ 7.00
Total	29,253,863	100.0%	\$ 89,110,678	100.0%	

The above computations are based on the number of shares of common stock outstanding as of December 31, 2000, assumes no exercise of the underwriters' overallotment option and excludes:

- options to purchase 1,313,818 shares outstanding under our 1998 stock option plan with a weighted average price of \$2.07 per share, and
- 2,208,605 shares reserved for issuance upon exercise of options that may be granted subsequent to December 31, 2000 under our 1998 stock option plan.

The issuance of common stock under this plan will result in further dilution to new investors. See "Management—Stock Option Plans," "Transactions With Executive Officers, Directors and Five Percent Stockholders" and the Notes to Financial Statements.

Selected Financial Data

The selected financial data set forth below should be read in conjunction with the financial statements and notes to our financial statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained elsewhere in this prospectus. The selected balance sheet data as of December 31, 1999 and 2000 and the selected statement of operations data for the years ended December 31, 1998, 1999, 2000 and for the period from inception (January 1, 1998) to December 31, 2000 have been derived from our audited financial statements appearing elsewhere in this prospectus. The selected balance sheet data as of December 31, 1998 has been derived from our audited financial statements that are not included in this prospectus. The pro forma net loss per share data give effect to the conversion of our preferred stock from its date of original issuance.

	Year Ended December 31,			Cumulative from inception (January 1, 1998) to December 31, 2000
	1998	1999	2000	

In thousands, except share data
Statements of Operations Data:

Revenue	\$ —	\$ 1,000	\$ 99	\$ 1,099
Expenses:				
Research and development(1)	1,331	2,469	4,947	8,747
General and administrative(1)	671	859	1,872	3,402
Noncash stock-based compensation expense	347	726	3,138	4,211
Loss from operations	(2,349)	(3,054)	(9,858)	(15,261)
Investment income, net	243	236	2,020	2,499
Net loss	\$(2,106)	\$(2,818)	\$(7,838)	\$(12,762)
Preferred stock deemed dividend and accretion	(5)	(6)	(504)	
Net loss attributable to common stockholders	\$(2,111)	\$(2,824)	\$(8,342)	
Basic and diluted net loss per share	\$ (0.94)	\$ (1.03)	\$ (2.54)	
Weighted-average shares used in computing basic and diluted net loss per share	2,235,997	2,749,212	3,289,731	
Pro forma basic and diluted net loss per share			\$ (0.38)	
Weighted-average shares used in computing pro forma basic and diluted net loss per share			20,627,995	

19

	December 31,		
	1998	1999	2000
<i>In thousands</i>			
Balance Sheet Data:			
Cash, cash equivalents and short-term investments	\$ 4,865	\$ 30,363	\$ 24,330
Restricted investments	—	—	3,421
Working capital	4,800	32,796	24,558
Total assets	5,231	33,363	29,874
Mandatorily redeemable convertible preferred stock	6,912	37,036	37,556
Additional paid-in capital	852	1,716	14,798
Stockholders' equity (deficit)	(1,764)	(3,860)	(8,493)

(1)

Operating expenses exclude charges for non cash stock based compensation as follows:

	Year Ended December 31,			Cumulative from inception (January 1, 1998) to December 31, 2000
	1998	1999	2000	
<i>In thousands</i>				
Research and development	\$ 73	\$ 393	\$ 973	\$ 1,439
General and administrative	274	333	2,165	2,772
	\$ 347	\$ 726	\$ 3,138	\$ 4,211

20

Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis by our management of our financial condition and results of operations in conjunction with our financial statements and the accompanying notes included elsewhere in this prospectus. This Management's Discussion and Analysis of Financial Condition and Results of Operations and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those

discussed in "Risk Factors."

Overview

We discover and develop monoclonal antibody-based drugs to treat cancer and related diseases. Using our four monoclonal antibody-based technologies and our expertise in the cancer area, we have assembled a portfolio of drug candidates targeted to many types of human cancers. We utilize our monoclonal antibody-based technologies to increase the potency and efficacy of monoclonal antibodies with specificity for cancer. We are currently testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers. SGN-15 is in three phase II clinical trials in combination with the chemotherapy drug Taxotere. SGN-10 is in two phase I clinical trials, one as a single agent and the other in combination with Taxotere. We have five preclinical product candidates being developed to treat patients with solid tumors, melanoma or hematologic malignancies. One of our preclinical product candidates, SGN-14, is being developed by Genentech pursuant to a license agreement. In addition to providing us with the means to discover and develop monoclonal antibody-based product candidates ourselves, our technologies allow us to partner with other companies also developing monoclonal antibodies.

We commenced operations in 1998 with technologies, patent rights and material for clinical trials received through a licensing arrangement with Bristol-Myers Squibb. Since our formation, our operating activities have been primarily devoted to research and development of our monoclonal antibody-based technologies, preclinical development and clinical trials for SGN-15, a monoclonal antibody chemically linked to cell-killing drugs, or monoclonal antibody-drug conjugate, and SGN-10, a single protein containing monoclonal antibody and toxin components, or single-chain immunotoxin.

Since our inception, we have incurred substantial losses. As of December 31, 2000, we had an accumulated deficit of \$12.8 million. These losses and accumulated deficit have resulted primarily from the significant costs incurred in the development of our monoclonal antibody-based technologies and clinical trial costs of SGN-15 and SGN-10 and, to a lesser extent, general and administrative costs. We expect that our losses will increase for the foreseeable future as we continue to expand our research, development and clinical trial activities and to build additional infrastructure.

We do not currently have any commercial products for sale. To date, we have generated revenues of \$1.0 million from our license agreement with Genentech and \$99,000 from a Small Business Innovative Research grant. In the future, we expect our principal revenues to be from milestone payments and sponsored research fees under existing and possible future collaborative arrangements. Ultimately, we believe our revenue will consist chiefly of commercial product sales. Because a substantial portion of our revenues for the foreseeable future will depend on achieving development and clinical milestones, our results of operations may vary substantially from year to year and even quarter to quarter.

Our operating costs include research and development and general and administrative costs. To date, our research and development costs include expenses for drug discovery and research, preclinical development and clinical trial activities. Our general and administrative costs principally consist of salaries and benefit expenses and facilities related costs. We expect that both our research and development and general and administrative costs will increase in the foreseeable future as we continue to grow our business.

The deemed dividend for the year ended December 31, 2000 resulted from the issuance of Series B convertible preferred stock in April 2000 at prices less than the deemed fair market value at the date of issuance. Additionally, the accretion on convertible preferred stock represents the issuance costs of the Series A and Series B convertible preferred stock which are being amortized by periodic accretion charges. These preferred stock dividend and the accretion amounts increase the net loss attributable to common shareholders.

Noncash stock-based compensation expenses for the years ended December 31, 1998, 1999 and 2000 resulted from stock options granted at exercise prices less than the deemed fair market value of the common stock on the date of grant to employees and consultants. We recorded total deferred stock-based compensation of \$849,000 in 1998, \$829,000 in 1999 and \$12.7 million in 2000. Deferred stock-based compensation is being amortized to expense over the vesting periods of the underlying options, generally four years, by an accelerated method. Based on deferred stock-based compensation recorded as of December 31, 2000, we expect to record amortization for deferred stock-based compensation expense as follows: \$5.5 million in 2001, \$2.8 million in 2002, \$1.4 million in 2003 and \$495,000 in 2004. The amount of deferred compensation expected to be recorded in future periods may decrease if unvested options for which deferred stock-based compensation has been recorded are subsequently cancelled or may increase if future option grants are offered at exercise prices less than the fair market value of the common stock on the date of the grant. In addition, the amount of deferred compensation expense to be recorded in future periods for stock awards granted to non-employees will fluctuate based on the fair value of our common stock in future periods.

In view of our limited operating history, we believe that period to period comparisons of our operating results are not meaningful and you should not rely on them as indicative of our future performance.

Results of Operations

Years Ended December 31, 2000 and 1999

Revenues. Revenues in 2000 were \$99,000, which represents revenue from a Small Business Innovative Research grant awarded to us for the study of monoclonal antibody-based therapies. Revenues in 1999 were \$1.0 million, representing revenue from a license agreement with Genentech effective June 1999.

Research and development expenses. Research and development expenses, excluding noncash stock-based compensation expense, in 2000 were \$4.9 million, an increase of \$2.5 million, or 100%, over 1999. This increase was principally due to an increase of \$813,000 in personnel expenses, an increase of \$487,000 in clinical trials expenses, an increase of \$429,000 in laboratory materials and supplies expenses and \$400,000 in contract manufacturing expenses. The number of research and development personnel increased to 35 at December 31, 2000 from 16 at December 31, 1999. We anticipate that research and development expenses will continue to grow in the foreseeable future as we expand our research, development and clinical trial activities.

General and administrative expenses. General and administrative expenses, excluding noncash stock-based compensation expense, in 2000 were \$1.9 million, an increase of \$1.0 million, or 118%, over 1999. This increase was primarily due to an increase of \$443,000 in administrative personnel expenses, \$208,000 in recruiting expenses and \$120,000 in professional services expenses. The number of general and administrative

personnel increased to 11 at December 31, 2000 from 5 at December 31, 1999. We anticipate that general and administrative expenses will increase in the foreseeable future as we expand our accounting staff and incur additional costs related to becoming a public company, including an investor relations program, directors' and officers' insurance and external audit fees.

Noncash stock-based compensation expense. Noncash stock-based compensation expense in 2000 was \$3.1 million, an increase of \$2.4 million, or 332%, over 1999. The increase is attributable to both

increasing levels of stock option grants and the difference between the deemed fair value as compared to the related exercise prices.

Investment income, net. Investment income, net in 2000 was \$2.0 million, an increase of \$1.8 million, or 756%, over 1999. The increase was due primarily to higher average balances of cash, cash equivalents and short-term investments and restricted investments in 2000 compared to 1999. This was a result of the investment of the proceeds from the sale of Series B convertible preferred stock in December 1999.

Net loss. Net loss in 2000 was \$7.8 million, an increase of \$5.0 million, or 178%, from 1999 as a result of the factors mentioned above.

Years Ended December 31, 1999 and 1998

Revenues. Revenues in 1999 were \$1.0 million and were derived from a license agreement with Genentech effective June 1999. We had no revenue in 1998.

Research and development expenses. Research and development expenses, excluding noncash stock-based compensation expense, in 1999 were \$2.5 million, an increase of \$1.1 million, or 85%, over 1998. 1998 expenses included a licensing fee paid to Bristol-Myers Squibb, with no comparable amount paid in 1999. The increase in 1999 was principally due to a \$892,000 increase in personnel expenses, a \$338,000 increase in facilities related costs, a \$168,000 increase in laboratory materials and supplies expenses, and a \$152,000 increase in clinical trial expenses, offset by the license fee paid in 1998. The number of research and development personnel increased to 16 at December 31, 1999 from 10 at December 31, 1998.

General and administrative expenses. General and administrative expenses, excluding noncash stock-based compensation expense, in 1999 were \$859,000, an increase of \$187,000, or 28%, over 1998. The increase was attributable to higher expense levels as we continued to grow our business. The number of general and administrative personnel increased to 5 at December 31, 1999 from 3 at December 31, 1998.

Noncash stock-based compensation expense. Noncash stock-based compensation expense in 1999 was \$726,000, an increase of \$379,000, or 109% over 1998. The increase is attributable to both increasing levels of stock option grants and the difference between the deemed fair market value as compared to the related exercise prices.

Investment income, net. Investment income, net in 1999 was \$236,000, a decrease of \$7,000, or 3%, over 1998. The decrease was attributable to lower average balances of cash and cash equivalents in 1999 compared to 1998.

Net loss. Net loss in 1999 was \$2.8 million, an increase of \$711,000, or 34%, over 1998 as a result of the factors mentioned above.

Liquidity And Capital Resources

From inception through December 31, 2000, we have funded our operations with \$37.5 million from private equity financings, \$1.0 million from a license agreement with Genentech, \$2.5 million of investment income, net, and \$99,000 from a Small Business Innovative Research grant. At December 31, 2000, cash, cash equivalents and short term investments totaled \$24.3 million and restricted investments amounted to \$3.4 million.

In December 2000 we entered into a ten year lease for a new headquarters and operations facility. In connection with this lease, we have pledged \$3.4 million of our investments as collateral for certain obligations of the lease. The lease terms provide for decreases to the pledge amounts based upon our net worth, as defined, and decreases commencing in the fourth year of the lease.

Our cash, cash equivalents, short term investments and restricted investments are held in a variety of interest-bearing instruments, consisting of U.S. government and agency securities, high-grade U.S. corporate bonds, municipal bonds, mortgage-backed securities, commercial paper and money market accounts.

Net cash used in operating activities for the year ended December 31, 2000 was \$4.5 million and for the year ended December 31, 1999 was \$2.0 million. Our net loss of \$7.8 million for the year ended December 31, 2000 included non-cash charges of \$3.3 million primarily related to amortization of deferred stock compensation and depreciation expense. Cash used in operating activities in 1999 was \$2.0 million compared with \$1.7 million in 1998. Our net loss of \$2.8 million in 1999 included non-cash charges of \$848,000 related primarily to amortization of deferred stock compensation and depreciation expense. We expect cash used in operating activities to increase in the future as we fund our preclinical development, clinical trials and commercialization activities of our product candidates.

Net cash used in investing activities for the year ended December 31, 2000 was \$25.7 million which included \$25.0 million for purchases of short-term and restricted investments, net of proceeds from sale and maturities, as well as \$729,000 for capital expenditures. Net cash used in investing activities in 1999 was \$127,000 for capital expenditures. We expect that our level of capital expenditures will increase in the future as we build additional infrastructure.

Net cash provided by financing activities was \$2.5 million for the year ended December 31, 2000 compared to \$27.6 million for the year ended December 31, 1999. Financing activities in 2000 primarily consisted of \$2.5 million from the collection of subscriptions receivable, \$500,000 from the sale of additional Series B convertible preferred stock, offset by prepaid initial public offering issuance costs of \$557,000. Net cash provided by financing activities was \$27.6 million in 1999 compared to \$6.9 million in 1998. Financing activities included net proceeds of \$6.9 million from the sale of Series A convertible preferred stock in 1998 and \$27.6 million from the sale of Series B convertible preferred stock in 1999.

We currently anticipate that we will use the net proceeds from this offering as follows: approximately 20-30% for preclinical research and development activities, approximately 20-30% for contract manufacturing activities, approximately 10-20% for clinical trial activities and the remainder for general corporate purposes, including capital expenditures and working capital to fund anticipated operating losses.

We expect to incur substantial costs as we continue to expand our research, preclinical development and clinical trials. We expect that the net proceeds from this offering, along with our existing cash and investment securities, milestone payments and research grants, will be sufficient to fund our operations for the next two years. However, during or after this period, if our capital resources are insufficient to meet our capital requirements and expenses, we would need to sell additional equity or debt securities or obtain credit arrangements. Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders. Our future capital needs will depend on many factors including receipt of payments from our collaborators, growth in our research and development activities, the progress associated with preclinical trials and the size, duration and number of clinical trials. Additional costs will be incurred through the expense of preparing, filing, maintaining and enforcing patent claims and other intellectual property rights, modifications in existing or the establishment of new collaboration and licensing arrangements, and clinical trial manufacturing costs.

Our plans include the development of selected internal projects to a point where they may be candidates for corporate collaborations. We will then choose between continuing to develop these projects ourselves or seeking to license them to collaborators. If we choose to develop and commercialize any internal development projects without the assistance of collaborators, the cost would be substantial and would require external financing.

24

We do not have committed external sources of funding and we cannot assure that we will be able to obtain additional funds on acceptable terms, if at all. If adequate funds are not available, we may be required to, among other things:

- delay, reduce the scope of or eliminate one or more of our programs;
- obtain funds through arrangements with collaborators or others that may require us to relinquish rights to technologies or product candidates that we would otherwise seek to develop ourselves; or
- license rights to technologies or lead agents on terms that are less favorable to us than might otherwise be available.

Disclosure About Market Risk

Our exposure to market risk is limited to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term debt securities. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. To minimize risk, we maintain our portfolio of cash, cash equivalents and short term and restricted investments in a variety of interest-bearing instruments including U.S. government and agency securities, high-grade U.S. corporate bonds, municipal bonds, mortgage-backed securities, commercial paper and money market funds. Due to the nature of our short-term and restricted investments, we believe that we are not subject to any material market risk exposure. We do not have any foreign currency or other derivative financial instruments.

Recent Accounting Pronouncements

In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 133, Accounting for Derivative Financial Instruments and for Hedging Activities, or SFAS 133, which provides a comprehensive and consistent standard for the recognition and measurement of derivatives and hedging activities. SFAS 133 is effective for fiscal years beginning after June 15, 2000 and will not have an impact on our results of operations or financial condition when adopted as we hold no derivative financial instruments and do not currently engage in hedging activities.

In December 1999, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 101, or SAB 101, Revenue Recognition, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements filed with the SEC. SAB 101 outlines the basic criteria that must be met to recognize revenue and provides guidance for disclosures related to revenue recognition policies. The adoption of SAB 101 did not have a material effect on our financial position or results of operation.

In March 2000, the Financial Accounting Standards Board issued Interpretation No. 44, or FIN No. 44, "Accounting for Certain Transactions Involving Stock Compensation," an interpretation of the Accounting Principles Board Opinion 25, or APB 25. Among other things, this interpretation clarifies the definition of "employee" for purposes of applying APB 25, "Accounting for Stock Issued to Employees," the criteria for determining whether a plan qualifies as a noncompensatory plan, and the accounting for an exchange of stock compensation awards in a business combination. This interpretation became effective July 1, 2000, but certain conclusions in this interpretation cover specific events that occur after either December 15, 1998 or January 12, 2000. The adoption of FIN No. 44 did not have a material impact on the Company's financial position or results of operations.

25

Business

Overview

We discover and develop monoclonal antibody-based drugs to treat cancer and related diseases. We have four monoclonal antibody-based

technologies: monoclonal antibodies; monoclonal antibodies chemically linked to cell-killing drugs, or monoclonal antibody-drug conjugates; single proteins containing monoclonal antibody and toxin components, or single-chain immunotoxins; and antibody-directed enzyme prodrug therapy, or ADEPT. Our technologies enable us to increase the potency and efficacy of monoclonal antibodies that have specificity for cancer or related diseases but are not potent enough on their own. Using our expertise in cancer and monoclonal antibody technologies, we have constructed a diverse portfolio of drug candidates targeted to many types of human cancer. Our four technologies provide us with the means to discover and develop monoclonal antibody-based drug candidates internally as well as to partner our technology with other companies also developing monoclonal antibodies.

We are testing our two most advanced drug candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other solid tumor cancers. SGN-15 is a monoclonal antibody-drug conjugate that binds to cancer cells and kills them by delivering the drug doxorubicin inside the cell. We are currently testing SGN-15 in three phase II clinical trials in combination with the chemotherapy drug Taxotere. SGN-10 is a single-chain immunotoxin that binds to cancer cells and kills them by delivering a protein toxin inside the cell. We are testing SGN-10 in two phase I clinical trials, one as a single agent and the other in combination with Taxotere. Aventis is co-funding two of the SGN-15 clinical trials and one SGN-10 clinical trial.

We also have five drug candidates in preclinical development for the treatment of patients with solid tumors, melanoma or blood-cell cancers, commonly known as hematologic malignancies, including multiple myeloma and lymphomas. SGN-14 is our humanized monoclonal antibody targeted to the receptor identified as CD40, which we have licensed to Genentech for the development of therapies to treat patients with blood-cell cancers, commonly known as hematologic malignancies, or other types of cancer. SGN-30 is our monoclonal antibody targeted to the receptor identified as CD30, which we are developing for treatment of patients with hematologic malignancies and other types of disease. We are developing SGN-17/19, which utilizes our ADEPT technology, for treatment of patients with melanoma. We are developing two additional drug candidates that utilize our novel monoclonal antibody-drug conjugate technology, specifically our stable linkers and our proprietary, high-potency cell-killing drugs.

Monoclonal Antibodies as Therapeutics

Numerous monoclonal antibodies have been approved for treatment of autoimmune disease, cancer and infectious disease, and represent an important area of novel therapeutic product development. Antibodies are protective proteins released by the immune system's B cells, a type of white blood cell, in response to the presence of a foreign substance in the body, such as a virus. B cells produce millions of different kinds of antibodies with slightly different shapes that enable them to bind to and thereby affect different targets. Antibodies of identical molecular structure that bind to the same target are called monoclonal antibodies. Typically, mice have been used to produce monoclonal antibodies to a wide variety of molecular targets, including targets to which the human body does not normally produce antibodies. In particular, many mouse monoclonal antibodies have been developed as potential therapeutics to neutralize viruses, destroy cancer cells or inhibit immune function.

Although mouse monoclonal antibodies are relatively easy to generate, they have significant drawbacks as therapeutics. Mouse monoclonal antibodies have a relatively short half-life in human patients, requiring them to be administered frequently. Moreover, mouse monoclonal antibodies are not adapted to work effectively with the human immune system and therefore often have limited ability to destroy the target, such as cancer cells. Most importantly, when injected into human patients, a mouse monoclonal antibody is usually recognized by the body's immune system as being foreign. The immune system therefore responds

by rapidly neutralizing the mouse monoclonal antibody and rendering it ineffective for further therapy. These problems have largely prevented mouse monoclonal antibodies from becoming therapeutics.

Recognizing the limitations of mouse monoclonal antibodies, researchers have developed a number of approaches to make them appear more human-like to a patient's immune system. For example, improved forms of mouse monoclonal antibodies, referred to as "chimeric" and "humanized" antibodies, are genetically engineered and assembled from portions of mouse and human antibody fragments. Chimeric antibodies contain approximately 35% mouse sequences and humanized antibodies contain approximately 15% mouse sequences. Additionally, monoclonal antibodies have also been prepared in fully human form. These technologies have enabled scientists to develop antibody products that can be administered to patients repeatedly over time, or on a chronic basis, with reduced adverse responses by the human immune system. Similarly, advances in monoclonal antibody production technologies, such as high productivity fermentation and transgenic plants and animals, have enabled manufacturers to produce monoclonal antibody-based products more cost-effectively. Because of these advances, a large number of monoclonal antibodies are currently undergoing clinical and preclinical investigation. According to a survey conducted by the Pharmaceutical Research and Manufacturers of America, 72 out of 369, or 20% of all biotechnology medicines in clinical trials in 1999 were antibodies. The FDA has approved nine therapeutic antibodies, seven of them in the last three years, with total sales in 1999 in excess of \$1.4 billion worldwide.

Monoclonal Antibodies for Cancer Therapy

Cancer is the second leading cause of death in the United States, resulting in over 550,000 deaths annually. The National Cancer Institute reports that more than 8 million people in the United States have cancer and they estimate that one in three Americans will develop cancer in their lifetimes. Approximately 1.2 million new cases of cancer were diagnosed in 2000 in the United States. Although there are many commercially available products to treat various forms of cancer, most are not curative. Even small improvements in therapies represent precious time for patients dying from cancer, and for many patients, there are no meaningful therapies available.

Monoclonal antibodies have been tested for many years as cancer therapeutics. However, while some monoclonal antibodies have significant antitumor activity as single agents, many are not potent enough on their own. Based on this limitation, much research has been done and two additional approaches to using monoclonal antibodies as cancer therapies have emerged. First, it has been found that when monoclonal antibodies are administered in combination with chemotherapy, the antitumor activity is greater than when either therapy is administered alone. Second, monoclonal antibodies that are linked to cell-killing payloads such as drugs or toxins can more effectively kill cancer cells than monoclonal antibodies alone.

Generally speaking, there are four basic methods for using monoclonal antibodies as cancer therapeutics. Each of the approaches described below capitalizes on a monoclonal antibody's ability to precisely target selected molecules that are displayed in high density on the surface of cancer cells:

- *Blocking Cell Activity*—monoclonal antibodies can be produced that bind to specific molecules on the cell surface known as receptors to prevent undesirable cell responses, such as proliferation of cancer cells;

- *Activating Cell Activity*—monoclonal antibodies can be produced to bind to specific cell surface receptors in order to activate a desired cellular response which may include induction of cell death;

- *Delivering Therapeutic Agents*—monoclonal antibodies can be used to deliver cell-killing payloads, such as drugs, radioactive isotopes and toxins, specifically to cancer cells and tissues while minimizing effects on normal cells; and

- *Delivering Enzymes*—monoclonal antibodies can be used to deliver enzymes to the surface of cancer cells that are able to convert nontoxic forms of anti-cancer drugs, or prodrugs, into cell-killing drugs within tumor tissue.

Approved Monoclonal Antibody Cancer Therapeutics

At the end of 1997, the first monoclonal antibody for cancer therapy, Rituxan, was approved for the treatment of patients with relapsed or refractory, low-grade non-Hodgkin's lymphoma. Rituxan is genetically engineered as a chimeric monoclonal antibody that binds to the CD20 receptor and is jointly marketed in North America by Genentech and IDEC Pharmaceuticals. Worldwide sales of Rituxan were \$279 million in 1999 and \$444 million in 2000. Rituxan is also being evaluated for treatment in combination with chemotherapy.

Late in 1998, Herceptin, the second monoclonal antibody for cancer therapy, was approved. Usable in approximately 25-30% of patients with breast cancer, Herceptin, engineered as a humanized monoclonal antibody and marketed by Genentech, binds to the HER2 receptor. Although Herceptin is active as a single agent, it is more effective in combination with chemotherapy agents such as Taxol where responses are considerably better than could be obtained with either agent alone. Worldwide sales of Herceptin were \$188 million in 1999 and \$276 million in 2000.

Early in 2000, the antibody-drug conjugate Mylotarg, the third monoclonal antibody for cancer therapy, was approved for the treatment of relapsed acute myeloid leukemia. Unlike Rituxan and Herceptin that directly attack and kill cancer cells, Mylotarg binds to cell surface receptor identified as CD33 on cancer cells and delivers a drug payload that enters into and kills the cells. Mylotarg is marketed by the Wyeth-Ayerst division of American Home Products.

Our Monoclonal Antibody Technologies

We focus on developing monoclonal antibody-based therapeutics for the treatment of patients with cancer. Four distinct but related technologies form our core business and provide for the discovery and development of an array of unique monoclonal antibody-based anti-cancer therapeutics. Most monoclonal antibodies have the ability to bind to distinct molecules found on the surface of cells, making them desirable as drugs to treat cancer. However, most monoclonal antibodies are not potent enough as single agents to effectively treat cancer. Our technologies enable us to increase the potency, and the efficacy, of monoclonal antibodies with specificity for cancer or related diseases that are not potent enough on their own. These four technologies are:

- monoclonal antibodies;

- monoclonal antibodies chemically linked to cell-killing drugs, or monoclonal antibody-drug conjugates;

- single proteins containing monoclonal antibody and toxin components, or single-chain immunotoxins; and

- antibody-directed enzyme prodrug therapy, or ADEPT.

Monoclonal Antibodies. Monoclonal antibodies are generally made in mouse form. Our monoclonal antibodies have been genetically modified to reduce or remove their non-human sequences thereby lowering immune response and extending the potential for chronic use in therapy. These monoclonal antibodies can be effective in treating both hematologic malignancies and solid tumors on their own or in combination with chemotherapy. They have lower toxicity than chemotherapy and allow for multiple doses or cycles of therapy. We have several monoclonal antibody candidates in development for treating patients suffering from hematologic malignancies, including SGN-14 targeted to the CD40 receptor and SGN-30 targeted to the CD30 receptor, both of which are currently in preclinical development.

Monoclonal Antibody-Drug Conjugates. Monoclonal antibody-drug conjugates are composed of monoclonal antibodies that are linked to potent cell-killing drugs. We generally select monoclonal antibodies that bind to receptors that cause the conjugates to enter cells, or internalize. The environment inside the cell causes the cell-killing drug to be released from the monoclonal antibody, allowing it to have the desired cell killing effect. Until released in the cell, the cell-killing drug is inactive, thereby sparing normal cells. In evaluating candidates for our monoclonal antibody-drug conjugate program, we look for chimeric, humanized or human monoclonal antibodies that bind strongly to and enter cancer cells and not most normal cells. An important component of these monoclonal antibody-drug conjugates are the linkers that hold and then release the drugs from the monoclonal antibodies. We have a variety of stable linkers and highly potent cell-killing drugs that can be used with our own, as well as other companies' monoclonal antibodies. Our lead monoclonal antibody-drug conjugate, SGN-15, uses our linker technology to attach the cell-killing drug doxorubicin to the BR96 monoclonal antibody. The BR96 monoclonal antibody binds to a carbohydrate that is found in high density on many different cancer cells including breast, lung, colon, prostate, and ovarian. SGN-15 is currently in three phase II clinical trials in combination with Taxotere to treat patients with breast, colon or prostate cancer.

Single-Chain Immunotoxins. Our single-chain immunotoxins are comprised of the receptor binding portions of monoclonal antibodies that internalize, combined with toxin components and genetically assembled into single proteins that kill cells by blocking protein production. These single-chain immunotoxins are specific for solid tumors and hematologic malignancies. In addition, we have a novel ribosome-inactivating protein, Bryodin 1, that is only toxic upon entry to the inside of cells. SGN-10, our leading single-chain immunotoxin, is comprised of BR96 and a protein toxin called *Pseudomonas* exotoxin A. SGN-10 is being evaluated in two phase I clinical trials in patients with breast, lung, colon, prostate, or ovarian cancers.

Antibody-Directed Enzyme Prodrug Therapy, or ADEPT. ADEPT represents a novel approach to minimize drug exposure to normal tissues by using a monoclonal antibody fused to an enzyme. This approach involves the combination of two non-toxic agents to achieve potent antitumor activity while sparing normal tissue. With ADEPT technology, we select monoclonal antibodies that do not internalize but remain bound to the cell surface, distinguishing this technology from our monoclonal antibody-drug conjugate or single-chain immunotoxin technologies. In the first step, a protein containing a monoclonal antibody and enzyme is administered that accumulates on solid tumor masses. This protein converts subsequently administered inactive forms of anti-cancer drugs into potent cell-killing drugs that can penetrate into tumor masses and induce antitumor responses. These effects are significantly greater than those achievable by systemic cell-killing drug administration due to the high drug concentrations that may be achieved within the tumor mass, thereby sparing normal tissue from chemotherapeutic damage. Our lead drug candidate, SGN-17/19, is in development for patients with metastatic melanoma. SGN-17/19 is composed of two agents, SGN-17, a protein containing antibody and enzyme components and SGN-19, a prodrug form of the active compound melphalan. We are conducting ongoing research focused on identifying human enzymes that can activate existing or novel forms of anti-cancer drugs.

Our four technologies provide us with the ability to develop monoclonal antibody-based drug candidates that show antitumor activity alone and direct drugs or toxins to the inside of tumor cells while minimizing the effects on normal tissue. In addition, our technologies allow us to deliver enzymes to tumor cell surfaces that can activate non-toxic forms of inactive anti-cancer drugs into active drugs. These technologies allow us to rapidly convert a variety of our own monoclonal antibodies, as well as monoclonal antibodies from third parties, into drug candidates.

Our Strategy

Our objective is to use our expertise in monoclonal antibodies and our novel technologies to develop our product pipeline and discover new product candidates for the treatment of cancer and related diseases. Our strategy includes initiatives to:

- *Continue to Identify and Develop Novel Monoclonal Antibodies.* In the post-genomic world, thousands of potential new targets are being discovered. Monoclonal antibodies that bind to these targets can be generated rapidly. We believe that monoclonal antibodies will be one of the primary areas for therapeutic development for the foreseeable future, particularly as genomic research identifies new disease targets. We have

focused on the research and development of monoclonal antibodies since our inception and have successfully identified and obtained patent rights for several novel monoclonal antibodies with potential therapeutic applications. We are collaborating with Medarex to produce novel fully human monoclonal antibodies to certain breast cancer and melanoma targets. We will continue to apply our expertise in monoclonal antibodies to identify novel monoclonal antibodies that bind to these new targets.

- *Use Our Technologies to Increase Potency of Monoclonal Antibody Therapeutics.* Monoclonal antibodies make excellent delivery vehicles since they bind specifically to cell surface targets. Our expertise and intellectual property rights can be used to make these highly specific monoclonal antibodies into drug candidates by improving the potency and efficacy of monoclonal antibody-based therapeutics through our monoclonal antibody-drug conjugates and antibody-directed enzyme prodrug therapy, or ADEPT, programs. We are also actively developing additional technologies in these programs for which we plan to file patent applications. Our technology provides us with an opportunity to develop our own product candidates, but also enables us to add significant value to monoclonal antibodies and targets owned by other companies.

- *Develop a Broad Portfolio of Products.* We are developing multiple products for many potential indications simultaneously, thereby increasing our opportunities to identify successful drugs. Our drug candidates utilize multiple mechanisms of action and target a variety of different receptors expressed in several types of cancer cells.

30

- *Acquire Attractive Drug Candidates.* In addition to our own development efforts, we will continue to identify products and technologies to in-license. We believe that we are well positioned to continue to attract in-licensing and acquisition candidates as a result of our demonstrated expertise in monoclonal antibodies. We have successfully in-licensed lead monoclonal antibodies from academic groups as well as from other companies. While we expect that many new product candidates will arise from our internal research programs, we will continue to seek in-licensing opportunities to build our product candidate pipeline.

- *Establish Strategic Collaborations.* We intend to enter into corporate collaborations at various stages in the research and development process. We may seek a corporate collaborator prior to initiating phase II clinical trials or may choose to partner some products at a later stage in order to increase our potential downstream participation in product sales. We believe our collaboration strategy provides us with distinct advantages, including:

- it builds on our fundamental strength in discovery and development of innovative monoclonal antibody-based products and technologies;
- it capitalizes on our corporate partners' strengths in product development, manufacturing and commercialization;
- it enables us to develop a greater number of lead agents and programs than otherwise would be possible; and
- it reduces our financing requirements.

31

Our Clinical and Preclinical Development Programs

We are developing monoclonal antibody-based therapeutics for the treatment of cancer patients. Our research is focused on identifying and characterizing monoclonal antibodies that bind to tumors. Our lead monoclonal antibodies are genetically modified to cause minimal adverse immune system responses. To augment the anti-tumor function of monoclonal antibodies, we link drugs, toxins or enzymes to monoclonal antibodies using our proprietary technologies. After testing our drug candidates in tumor cell culture systems, they are tested in appropriate animal models of human tumors and then clinically in cancer patients.

We currently have two product candidates in clinical development, SGN-15 in phase II trials and SGN-10 in phase I trials, and five product candidates in preclinical development, SGN-14, SGN-30, SGN 17/19, novel BR96 monoclonal antibody-drug conjugate and novel SGN-30 monoclonal antibody-drug conjugate. We are collaborating with Genentech for the development and commercialization of SGN-14. We are also actively engaged in research and discovery of new monoclonal antibodies, targets, linker systems, high-potency drugs and enzymes that can be incorporated into our development portfolio.

The following table summarizes the status of our product candidates currently in clinical trials:

Product Candidate	Technology	Disease/Indication	Development Stage	Specifics	Key Relationships
SGN-15	Monoclonal antibody-drug conjugate	Breast	Phase II	In combination with Taxotere	Co-funded by Aventis*
		Colon	Phase II	In combination with Taxotere	Co-funded by Aventis*
		Prostate	Phase II	In combination with Taxotere	—
		Lung	Phase II planned	In combination with Taxotere	—
		Ovarian	Phase II planned	In combination with Taxotere	—

SGN-10	Single-chain immunotoxin	Breast, lung, colon, pancreas, prostate and ovarian	Phase I	Single agent	—
		Breast, lung, colon, pancreas, prostate and ovarian	Phase I	In combination with Taxotere	Co-funded by Aventis*

* Aventis, the manufacturer of Taxotere, is co-funding the clinical trials but has no rights to SGN-15 or SGN-10.

In addition, we have the following product candidates currently in preclinical and discovery stages:

Product Candidate	Technology	Disease/Indication	Development Stage	Target(s)	Key Relationships
SGN-14	Monoclonal antibody	Hematologic malignancies and other types of cancer	Preclinical	CD40	Genentech development and commercialization collaboration
SGN-30	Monoclonal antibody	Hematologic malignancies	Preclinical	CD30	ICOS manufacturing agreement
SGN 17/19	ADEPT	Melanoma	Preclinical	p97	—
Novel BR96	Monoclonal antibody-drug conjugate	Carcinomas	Discovery	Lewis ^y , Lewis ^y /Lewis ^x	Technology agreements with Applied Molecular Evolution and Genzyme Transgenics
Novel SGN-30	Monoclonal antibody-drug conjugate	Hematologic malignancies	Discovery	CD30	—

Our Product Candidates

SGN-15

SGN-15 is our monoclonal antibody-based drug candidate for treating breast, colon, prostate, lung and ovarian cancers. SGN-15 is a monoclonal antibody-drug conjugate composed of a monoclonal antibody called BR96, genetically modified as a chimeric antibody and chemically linked to the cell-killing drug doxorubicin. BR96 binds to a Lewis^y-related carbohydrate molecule that is expressed at high levels on many cancer cells, including those of the breast, lung, pancreas, ovary and prostate and on some normal cells in the gastrointestinal tract. SGN-15 works by binding to and entering the cell and then releasing its payload of doxorubicin inside the cell. This release is caused by an acidic environment inside the cell that does not exist outside the cell. Normally, doxorubicin is injected into the body and allowed to circulate throughout the body thereby affecting both cancer and normal tissues. In contrast, our method of targeted drug delivery to the inside of a cell allows for relative sparing of normal tissues from the adverse effects of doxorubicin.

Development Status and Clinical Data. SGN-15 has been tested as a single agent in three phase I trials and two phase II trials. Based on data from these initial phase I and phase II trials that included 153 patients, SGN-15, as a single agent, localized to human tumors and has antitumor activity. However, the infrequency of this antitumor activity did not support further development as a single agent. Rather, our strategy with SGN-15 is to utilize it in combination with a chemotherapeutic agent.

In September 1999, we initiated a phase I/II trial to study SGN-15 in combination with Taxotere in patients with breast or colon cancer. The rationale for the trial is based on the outstanding antitumor activity of the taxane family of cell-killing drugs, their unique mechanism of action compared to SGN-15, pre-clinical data showing enhanced anti-tumor efficacy of SGN-15 and taxanes, and their non-overlapping toxicity profiles. In our breast cancer trial, we are enrolling patients that have already failed previous chemotherapy, which possibly may have included taxane therapy. In our colon cancer trial, we are enrolling patients that have failed front-line therapy, or the best available approved therapy, and have little or no alternatives for treatment. In September 2000, we completed the phase I component of the phase I/II SGN-15 trial and established a well-tolerated dose of SGN-15 in combination with Taxotere. We safely treated 16 patients and antitumor responses were observed. We initiated separate phase II trials in breast and colon cancer in October 2000 with 14 patients enrolled in the trial as of December 31, 2000. This trial is presently accruing patients at the University of Alabama, Birmingham Cancer Center, Georgetown University Medical Center in Washington, D.C., and the Georgia Cancer Specialists in Atlanta, Georgia. We plan to accrue a total of 30 patients in our phase II colon cancer trial and 45 patients in our phase II breast cancer trial. In order to achieve rapid marketing approval, our phase III development strategy is focused on designing trials for second-line therapy, or those therapies that are available after the front-line therapies have failed.

We recently initiated a third phase II trial in patients with hormone-refractory prostate cancer in combination with Taxotere, a commonly used chemotherapy for this disease. We have observed a synergistic antitumor effect in testing with SGN-15 and taxanes in preclinical prostate cancer models. Patients entering the trial will be placed into two groups of 100 patients each, those treated with the combination of SGN-15 and Taxotere and those treated with Taxotere alone. We plan to include as many as 15 sites in the U.S., with the Arizona Cancer Center being the lead site. The primary endpoints for the trial are a decrease in tumor size, or an objective antitumor response, a measurement of prostate serum antigen and a quality of life assessment. In phase III, we plan to compare SGN-15 and Taxotere to the standard of care for hormone refractory prostate cancer.

In 2001, we plan to initiate two additional phase II trials using the combination of SGN-15 and Taxotere. In the first trial, we plan to enroll patients with non-small cell lung cancer, which represents approximately 80% of all lung cancers. Response rates from approved front-line therapies in these patients are modest and no therapy is curative. In this trial, we plan to treat approximately 40 patients with the combination of SGN-15 and Taxotere and compare the data to approximately 20 patients that are treated with Taxotere alone. Taxotere is commonly used as a second-line therapy for lung cancer with a response rate of less than

10 percent. Our second trial is focused on patients with ovarian cancer. Taxotere is one of several cell-killing drugs used as part of front-line and second-line therapeutic strategies for treating ovarian cancer. We plan to test the combination of SGN-15 and Taxotere in second-line treatment and in newly diagnosed patients, who have the most advanced stage of ovarian cancer.

SGN-10

SGN-10 is our single-chain immunotoxin in development for treating breast, colon, lung, pancreatic, ovarian and prostate cancers. Although therapies exist for all of these diseases, no curative treatment exists when the disease is in an advanced stage. SGN-10 is engineered to redirect the potent cell killing activity of a protein toxin called *Pseudomonas* exotoxin A from its normal target to cancer cells by genetically deleting its natural binding ability and replacing it with the binding capability of our cancer-targeted BR96 monoclonal antibody. BR96 binds to a Lewis^y-related carbohydrate molecule that is expressed at high levels on many cancer cells, including those of the breast, lung, colon, pancreas, ovary and prostate and on some normal cells in the gastrointestinal tract.

Development Status and Clinical Data. We are currently conducting a single-agent phase I trial in patients with advanced stage solid tumors. The trial is being conducted at the University of Alabama at Birmingham, the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and the University of Chicago Cancer Center. As of December 31, 2000, a total of 52 patients have been enrolled in the trial. Our development strategy for SGN-10 as a single-agent is to identify appropriate disease targets and conduct disease specific phase II trials. Since we have observed that the majority of patients receiving SGN-10 develop an immune response three weeks after treatment has begun, thus limiting the number of effective doses they can receive, we are investigating strategies to limit the adverse immune response towards SGN-10. These include pre-treating patients with agents that suppress the immune system prior to treating with SGN-10. We plan to test those agents that may prevent a specific immune response without inducing global immune suppression.

In July 2000, we initiated a second phase I trial of SGN-10 in combination with Taxotere to determine the optimal combination dose in patients with advanced stage solid tumors. Our strategy for this trial is to identify a safe combination dose of SGN-10 and Taxotere to utilize in phase II and other advanced trials. Currently, our trials are being conducted at Georgetown University Medical School in Washington, D.C., with other sites to be added at a later time.

Our Preclinical Development Program

We have two separate stages of preclinical development; the first stage involves extensive testing of drug candidates and the second stage involves preparation for clinical development. The initial preclinical stage is focused on the production and testing of drug candidates that we have identified in discovery. We generate material for preclinical testing using our small-scale production and purification capabilities. We then subject our drug candidates to a series of experimental tests that include tumor cell culture, antitumor efficacy in animal models of human cancer and safety trials in animals. Based on our knowledge of the mechanism of drug action and the interactions between drugs, we can test whether two drugs work well together or whether they inhibit the activity of each other. We are able to measure whether two drugs can synergize, or if their combined effect is greater than the sum of their individual effects. We can then compare new drug candidates versus existing therapies in animal models of many different cancer types, including solid tumors, melanomas and hematologic malignancies. From the collective information gathered from these preclinical trials, we can determine the effectiveness and safety of each drug candidate in animal models prior to considering trials in humans.

Our second preclinical development stage is focused on preparing drug candidates for clinical trials, including scale-up production for clinical-grade material and eventual commercialization. Our approach is to develop procedures for large-scale manufacturing and quality control of drug candidates prior to outsourcing

or partnering. These standards are compiled in a technology transfer package provided to the selected contract FDA Good Manufacturing Practice manufacturer or corporate partner.

SGN-14 and Related Products

We are collaborating with Genentech to develop a family of anti-cancer agents that target CD40. CD40 is a cell surface receptor that is expressed on a variety of hematologic malignancies such as multiple myeloma, non-Hodgkin's lymphoma and leukemias, certain solid tumors, most notably non-small cell lung, ovarian and bladder cancer, and Kaposi's sarcoma. Our lead anti-CD40 agent is humanized monoclonal antibody SGN-14. Three single-chain immunotoxins, SGN-11, 12 and 18, and an antibody-drug conjugate, SGN-20, are also included in our alliance with Genentech.

SGN-30 and Novel SGN-30 Drug Conjugate

We are developing SGN-30, a monoclonal antibody that targets CD30, for the treatment of hematologic malignancies. CD30 is a cell surface receptor expressed on a variety of hematologic malignancies including Hodgkin's disease, certain leukemias and lymphomas, and in certain immunologic disease indications. We have or are generating chimeric and humanized forms of SGN-30. SGN-30 induces direct anti-cancer activity as a monoclonal antibody. Preclinical trials show that SGN-30 has potent antitumor activity in animal models of human hematologic disease. We are also evaluating high potency monoclonal antibody-drug conjugate forms of SGN-30 in preclinical models. The additional potency of monoclonal antibody-drug conjugates may be useful in treating patients with the most advanced stages of these diseases. The therapeutic utility of SGN-30 and monoclonal antibody-drug conjugate forms of SGN-30 are also being evaluated for use in treating immunologic diseases including multiple sclerosis and lupus.

SGN 17/19

SGN 17/19 is based on our ADEPT technology and is being developed for the treatment of melanoma. ADEPT is an approach to cancer therapy that involves the combination of two non-toxic agents to achieve potent antitumor activity. SGN-17 is a protein containing monoclonal antibody and enzyme components that incorporates the binding site of the monoclonal antibody, L49, and a specific form of the enzyme β -lactamase. L49 is

known to bind to the p97 cell surface molecule, which is non-internalizing and associated with melanoma. p97 is also expressed on many ovarian, breast, and lung carcinomas, although at a lower level. The prodrug, SGN-19, is a form of the chemotherapeutic drug melphalan that has been inactivated through the addition of a chemical group that can be removed by the enzyme β -lactamase. When SGN-17 is injected systemically, it accumulates on the tumor tissue and remains bound at the cell surface. Once SGN-17 has cleared from the circulation, SGN-19 is then administered systemically. SGN-19 is then converted to melphalan in the tumor tissue by the enzyme β -lactamase bound to the surface of cancer cells, resulting in localized release of melphalan.

Novel BR96 Monoclonal Antibody Drug Conjugate

In preclinical tests, we have demonstrated enhanced efficacy and lower dose requirements for BR96 monoclonal antibody-drug conjugates by improving the linker chemistry, which connects cell-killing drugs to monoclonal antibodies, and by using proprietary or patented drugs that are more potent than doxorubicin. Thus, as part of our monoclonal antibody-drug conjugate program, we are working to identify second generation, high potency BR96 monoclonal antibody-drug conjugates that have superior characteristics to that of SGN-15. Through a collaboration with Applied Molecular Evolution, we have also identified mutations in the antibody binding site that result in increased binding affinity and an increase in the number of tumors that are recognized. These mutations have been engineered into a humanized version of the antibody. We are collaborating with Genzyme Transgenics, Inc., to produce monoclonal antibodies in the milk of goats. We believe that large quantities of the recombinant protein could be produced at a reasonable cost using this approach.

35

Our Discovery Programs

We have discovery research programs directed towards identifying and developing new monoclonal antibody-based products and technologies to treat cancer. Our discovery programs are currently focused on identifying novel targets, monoclonal antibodies, monoclonal antibody-drug conjugates, monoclonal antibody-drug conjugate technologies and antibody-directed enzyme prodrug therapies.

LOGO



New Targets and Monoclonal Antibodies

New Targets. We utilize a variety of genomic tools and biologic assays to identify novel human targets for which we can generate specific new monoclonal antibodies. In the post-genomic era in which vast amounts of DNA sequence information is available, the opportunity to identify novel target genes is more accessible than ever before. We focus on genes that are highly expressed in cancer and virally-infected tissue to identify molecules that are located on the surface of cancer cells that may serve as targets for monoclonal antibodies. This may be in the form of monoclonal antibody-drug conjugates as well as single proteins containing monoclonal antibody and enzyme components that can provide for selective anti-cancer prodrug activation within the tumor. In addition to internal discovery efforts, we have an active in-licensing program focused on novel cancer targets to which we generate new monoclonal antibodies.

New Monoclonal Antibodies. We are collaborating with Medarex to use certain breast cancer and melanoma targets to generate novel fully human monoclonal antibodies. These monoclonal antibodies may represent product candidates on their own or may be suited to kill cancer cells by utilizing our technologies such as monoclonal antibody-drug conjugates. We have also established a process whereby in-licensed monoclonal antibodies can be developed into drug candidates. For example, we in-licensed SGN-14 and SGN-30 as

36

mouse monoclonal antibodies, and then genetically modified these monoclonal antibodies to be used alone and/or with our payload technologies. SGN-14 and SGN-30 have been or are in the process of being genetically modified in chimeric and humanized forms. At present, we are evaluating additional opportunities with academic groups and other companies to in-license mouse and genetically modified monoclonal antibodies in chimeric, humanized, or fully human forms.

Additionally, we have monoclonal antibodies that bind to cancer cells and are being evaluated as therapeutic agents. These include the monoclonal antibody BR110 which binds strongly to carcinomas of the lung, colon, breast, and ovary. BR110 binds to the GA-733-1 molecule, a related family member to the target of Panorex, which has shown efficacy in patients with colon carcinoma. Panorex is currently marketed in Germany, and is in phase III trials sponsored by Glaxo in the U.S. BR110 has the ability to internalize cell-killing drug payloads into tumor cells and can be utilized with our monoclonal antibody-drug conjugate technology. We are also using the high-affinity forms of the BR96 monoclonal antibody that react with the Lewis^Y-related and Lewis^X-related molecules that are expressed on most solid tumor types. Specifically, both new BR96 monoclonal antibodies in humanized form and the chimeric form of BR96 are being linked to high potency cell-killing drugs to form monoclonal antibody-drug conjugates. We have also identified monoclonal antibodies that bind to ovarian cancer cells and are in early stages of evaluation.

Monoclonal Antibody-Drug Conjugate Program

We are engaged in the discovery and development of novel, high potency monoclonal antibody-drug conjugates. The key elements for preparing highly effective drug conjugates are monoclonal antibody specificity, drug potency and linker technology.

Monoclonal Antibody-Specificity. We use monoclonal antibodies that strongly bind to cancer cells while minimally binding to normal tissues. For monoclonal antibody-drug conjugates, we use monoclonal antibodies that enter the cell after binding to its surface.

Drug Potency. We have identified two different cell-killing drug types with unique mechanisms of action that are each approximately 1000-fold more potent than doxorubicin, the cell-killing drug component of SGN-15. One of these is a class of drug known as minor groove binders that bind to DNA and inhibit DNA replication, thereby killing cells. Our minor groove binders can be synthesized and conjugated to monoclonal antibodies. This class of cell-killing drug is not subject to pathways found in tumors that make them resistant to chemotherapeutic drugs. We are presently focused on the design and testing of potent minor groove binders that we believe will provide us with a proprietary position in this area. The monoclonal antibody-drug conjugates formed from minor groove binders are highly active at clinically relevant doses.

Our second drug type is known as an anti-mitotic agent since it functions by inhibiting tumor cell division. Auristatin E, a highly potent, synthetic derivative of the natural product Dolostatin 10, has been found to have antitumor activity against human melanoma and lung carcinomas implanted in mice. The chemical structure of Auristatin E contains a chemical group making it available for conjugation with monoclonal antibodies. Due to its properties and our ability to synthesize it, we believe Auristatin E represents a promising candidate for targeted delivery to cancer cells and may also be useful by itself as an antitumor or chemotherapy agent.

Linker Technology. We have obtained rights to a series of proprietary, highly stable, peptide-based linkers with issued worldwide patents. Many of these peptide-based linkers are cleaved by specific enzymes called proteases that function inside cells. Importantly, once cleaved, the linkers are self-degrading so that the released drug is chemically unmodified and has full potency. Monoclonal antibody-drug conjugates using our linkers have been found to be highly effective antitumor agents with long-term stability in human plasma. We have developed several other linker technologies through internal research efforts. Our new linkers include those that allow drugs to be released when they enter the acidic environment within tumor cells, and by several different enzymes within cells. Currently, linkers are produced separately from the cell-

killing drug and monoclonal antibody components of monoclonal antibody-drug conjugates. To simplify production, we have developed linkers that are incorporated directly into the cell-killing drug component.

Antibody-Directed Enzyme Prodrug Therapy; ADEPT

ADEPT is an approach to cancer therapy that involves the combination of two non-cell-killing agents to achieve potent antitumor activity. First, we administer a single protein containing monoclonal antibody and enzyme components that can localize within solid tumor masses. These proteins remain bound to cell surface molecules, and activate subsequently administered inactive anti-cancer drug derivatives. Upon activation, potent drugs are released that can penetrate into tumor masses and induce antitumor responses. The effects are significantly greater than those achievable by systemic cancer drug administration due to the high drug concentrations reached inside the tumor.

We have identified several enzyme and prodrug combinations that lead to high levels of antitumor activity at well tolerated doses. These include recombinant proteins containing monoclonal antibody and enzyme components that activate prodrug forms of existing drugs, including melphalan, mitomycin C, paclitaxel and doxorubicin. We have an ongoing effort to develop human enzymes for prodrug activation, and have identified enzymes capable of activating the clinically approved drug CPT-11, which is used for the treatment of advanced colon cancer.

Single-Chain Immunotoxins

We have prepared a variety of single-chain immunotoxins targeted to molecules expressed on the surface of cancer cells. We have obtained rights to Bryodin 1, a patented ribosome-inactivating protein that is a preferred component compared to toxins currently used in the construction of single-chain immunotoxins. Bryodin 1 is especially useful due to its potency to kill once inside cells and its lack of toxicity to animals.

Corporate Collaborations

Part of our strategy is to establish corporate collaborations with pharmaceutical, biopharmaceutical and diagnostic companies. We plan to collaborate with others, both for the development and commercialization of our own drug candidates and for the potential improvement of collaborators' monoclonal antibodies using our technologies. We focus our efforts on partnering our technologies at various stages in the research and development process. We target collaborators that have the expertise and capability to develop, manufacture, obtain regulatory approval for and commercialize our monoclonal antibody-based products. In our corporate collaborations, we seek to cover our research and development

expenses through research funding, milestone payments and option, technology or license fees. We also seek to retain significant downstream participation in product sales through either profit-sharing or product royalties paid on annual net sales.

Genentech

In June 1999, we licensed our CD40 agents, including SGN-14, SGN-18 and SGN-20, on an exclusive basis to Genentech and granted Genentech an option under specific circumstances to license SGN-11 and SGN-12. SGN-14 is currently in preclinical development for the treatment of patients with hematologic malignancies or other types of cancer. Genentech also has a right of first negotiation to collaborate on SGN-15. Our agreement with Genentech includes joint oversight of development. However, costs and tasks may not be assigned to us without the approval of our representative on the joint oversight committee. We do not anticipate that these costs or tasks will be assigned to us in the future. The business terms of this agreement include potential royalties on net sales as well as other payments of up to \$45.0 million, including \$41.0 million in potential milestone payments on the first product developed. The agreement also provides for milestone payments of up to \$20.0 million and future royalties on net sales of each additional product incorporating our technology. Genentech's obligation to pay us royalties under this agreement terminates on a country-by-country and product-by-product basis upon the later of a specified number of

38

years after the first commercial sale in each country or the last to expire of the licensed patents in each country. The agreement is also subject to earlier termination by Genentech at any time upon 90 days notice or by either party if the other party enters bankruptcy or breaches its material obligations thereunder.

We believe that partnering with Genentech will optimize time to market by utilizing their existing development, manufacturing capabilities, marketing and sales force. As part of this agreement, we sold Genentech 680,272 shares of Series B convertible preferred stock in December 1999 and will sell 285,714 registered shares of common stock to Genentech directly in this offering at the initial public offering price.

Bristol-Myers Squibb

We obtained the rights to some of our technologies and drug candidates through a license agreement with Bristol-Myers Squibb, portions of which are exclusive. Through this license, we secured rights to Bristol-Myers' monoclonal antibody-based cancer targeting program, which includes rights to 24 different patents, eight monoclonal antibodies, chemical linkers, a ribosome-inactivating protein and enabling technologies. Our license encompasses four technologies: genetically modified monoclonal antibodies, monoclonal antibody-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapies. Under this license agreement, we received FDA Good Manufacturing Practices produced and vialled material for two different monoclonal antibody-based therapeutic agents, SGN-15 and SGN-10, which have entered clinical trials. Under the terms of the license agreement, we are required to pay royalties on net sales of future products incorporating the licensed technology. Our obligation to pay royalties under this agreement terminates on a product-by-product and country-by-country basis upon the later of ten years after the first commercial sale in each country or the last to expire of the licensed patents in each country. The last of the licensed issued patents will expire in 2018, although our obligation to pay royalties to Bristol-Myers may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination if either of the parties breaches its material obligations thereunder.

A portion of the technology we have licensed from Bristol-Myers is derived through sublicenses of technology from the following third parties:

Enzon. We have sublicensed rights to single-chain antigen binding molecules from Enzon, Inc. This technology is used in SGN-10. We have semi-exclusive rights to the Enzon technology, subject to the rights of several existing Enzon licensees, as well as our obligation to make biannual payments to maintain this semi-exclusivity through 2003. Under the terms of our sublicense with Enzon, we are also required to make milestone payments and pay royalties on net sales of products incorporating technology sublicensed from Enzon. Our obligation to pay royalties under this agreement terminates on a country-by-country basis upon the last to expire of the licensed patents in each country. The last of the licensed issued patents will expire in 2007, although our obligation to pay royalties to Enzon may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination if either party breaches its material obligations thereunder.

Applied Molecular Evolution. We have sublicensed exclusive rights to certain humanized forms of the BR96 monoclonal antibody from Applied Molecular Evolution. Under the terms of our sublicense, we are required to make milestone payments and royalties on net sales of products incorporating technology sublicensed from Applied Molecular Evolution. Our obligation to pay royalties under this agreement terminates on a product-by-product and country-by-country basis upon the later of ten years after the first commercial sale in each country or the last to expire of the licensed patents in each country. The last of the licensed issued patents will expire in 2015, although our obligation to pay royalties to Applied Molecular Evolution may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination if either of the parties breaches its material obligations thereunder.

39

Medarex. We are collaborating with Medarex to produce fully human monoclonal antibodies to certain breast cancer and melanoma antigen targets identified by us over the next three years in order to develop and commercialize monoclonal antibody-based products. The agreement calls for joint development of at least half of our breast cancer antigens and a specific melanoma antigen. There will be a joint steering committee composed of members of both companies to make development decisions concerning jointly developed monoclonal antibody product candidates. Under the agreement, all development, manufacturing, and clinical costs of jointly developed products and all net profits or net losses will be shared by us and Medarex. Each of us has the right to opt out of the joint development of any antigen target and receive instead certain milestone and royalty payments on net sales. The agreement terminates upon the later of one year after completion of the research activities thereunder or the date on which neither party is exploiting any jointly developed products. The agreement is also subject to termination if either party enters bankruptcy or breaches its material obligations thereunder. As part of this agreement, we will sell to Medarex \$2.0 million of our common stock at the initial public offering price in a private placement concurrent with this offering.

We have also licensed and intend to continue to license product and marketing rights from selected commercial, research and academic

institutions in order to capitalize on the capabilities and technology bases of these entities, including the following:

ICOS Corporation. In October 2000, we entered into a license agreement with ICOS Corporation for non-exclusive rights to use the CHEF expression system, a DNA sequence we may use to manufacture SGN-30. Under the terms of our agreement with ICOS, we are required to make milestone payments and pay royalties on net sales of products manufactured using the CHEF expression system. Our obligation to pay royalties under this agreement terminates upon the expiration of the last to expire of the licensed patents, which will occur in 2017, although our obligation to pay royalties to ICOS may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination if either party enters bankruptcy or defaults in the performance of any material provision thereunder.

Mabtech AB. In June 1998, we obtained exclusive worldwide rights to a monoclonal antibody that recognizes CD40 from Mabtech AB. Under the terms of our license with Mabtech, we are required to make a milestone payment and pay royalties on net sales of products incorporating technology licensed from Mabtech. Our obligation to pay royalties under this agreement terminates ten years after the first commercial sale of a product incorporating Mabtech's technology. The agreement is also subject to earlier termination if either party breaches its material obligations thereunder.

University of Miami. In September 1999, we entered into an exclusive license agreement with the University of Miami, Florida, covering an anti-CD30 monoclonal antibody that is the basis for two new drug candidates targeted to hematologic malignancies and immune system disease. Under the terms of our license with the University of Miami, we made an up-front payment and are required to make milestone payments, annual maintenance fee payments and pay royalties on net sales of products incorporating technology licensed from the University of Miami. Our obligation to pay royalties under this agreement terminates ten years after the first commercial sale of a product incorporating the University of Miami's technology. The agreement is also subject to earlier termination by the University of Miami if we enter bankruptcy or by either party if the other party breaches its material obligations thereunder.

Arizona State University. In February 2000, we entered into a license agreement with the Arizona State University covering the cell-killing agent Auristatin E, a synthetic derivative of the natural product Dolastatin 10. We intend to use Auristatin E as a component of new monoclonal antibody-drug conjugates. We are also testing Auristatin E in preclinical models to determine whether it qualifies for single-agent clinical development. Under the terms of our license with Arizona State University, we are required to make milestone payments, annual maintenance fee payments and pay royalties on net sales of products incorporating technology sublicensed from Arizona State University. Our obligation to pay royalties under

this agreement terminates on a country-by-country basis upon the last to expire of the licensed patents in each country, which will occur in 2014, although our obligation to pay royalties to Arizona State University may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination if either of the parties enters bankruptcy or breaches its material obligations thereunder.

Aventis Pharmaceuticals. Aventis co-funds three different clinical trials using two of our drug candidates, SGN-15 and SGN-10. In the SGN-15 program, which is being tested in combination with the widely used chemotherapeutic agent Taxotere, Aventis is funding 50% of the clinical trial costs directly to the clinical sites and providing Taxotere drug product. The SGN-15 trials that are part of the Aventis co-funding agreement include a phase I/II trial in breast or colon cancer patients for which the phase I was completed in September 2000 and two separate phase II trials in breast and colon cancers initiated in October 2000. As part of the SGN-10 program, Aventis is co-funding a phase I trial in patients including those with breast, colon, lung, prostate, ovarian or pancreatic cancer. In this setting, SGN-10 is being tested in combination with Taxotere to determine the appropriate dose and disease indication for later stage clinical testing. Aventis is funding 50% of the clinical trial costs directly to the clinical centers and providing Taxotere drug product. Aventis does not obtain any rights or options to SGN-15 or SGN-10 under the co-funding arrangement.

Genzyme Transgenics. We have agreed to collaborate with Genzyme Transgenics to determine clinical and commercial potential for a form of the humanized monoclonal antibody hBR96-2. Under the terms of the agreement, Genzyme Transgenics will supply us with hBR96-2 and we will perform experiments to evaluate the material. If development is continued by us, we will use good faith efforts to negotiate with Genzyme Transgenics to enter into a supplier agreement for manufacturing of hBR96-2.

Creative Biomolecules. In September 1998, we entered into a non-exclusive license agreement with Creative Biomolecules, Inc. for the rights to use single-chain antibody technology. We use this technology in SGN-10. Under the terms of this license agreement, we are required to make milestone payments, annual maintenance fee payments and pay royalties on net sales of products incorporating technology licensed from Creative Biomolecules. Our obligation to pay royalties under this agreement terminates on a country-by-country basis upon the last to expire of the licensed patents in each country, which will occur in 2015, although our obligation to pay royalties to Creative Biomolecules may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents, subject to extension if we use technology licensed under subsequently issued divisional patents. The agreement is also subject to earlier termination if either party breaches its material obligations thereunder.

Brookhaven Science Associates, LLC. In January 1998, we entered into a non-exclusive license agreement with Brookhaven Science Associates, operator of Brookhaven National Laboratory, to secure the rights to use the T7 promoter, a DNA sequence we use to manufacture SGN-10. Under the terms of this agreement, we are required to make annual maintenance fee payments and pay royalties on net sales of products manufactured using the T7 promoter. Our obligation to pay royalties under this agreement terminates upon the last to expire of the licensed patents, which will occur in 2017, although our obligation to pay royalties to Brookhaven may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination by Brookhaven if we breach our material obligations thereunder and by us at any time upon six months notice.

Public Health Service. In September 1998, we entered into a non-exclusive license agreement with the Public Health Service for the rights to use truncated forms of a protein toxin called *Pseudomonas* exotoxin, one of which is a component of SGN-10. Under the terms of this agreement, we are required to make milestone payments and pay royalties on net sales of products incorporating technology licensed from the Public Health Service. Our obligation to pay royalties under this agreement terminates upon the last to

expire of the licensed patents, which will occur in 2016, although our obligation to pay royalties to the Public Health Service may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination by the Public Health Service if we enter bankruptcy or by either party if the other party breaches its material obligations thereunder.

Genentech; Cabilly License. In January 2000, we entered into a co-exclusive license with Genentech for rights to use chimeric monoclonal antibodies targeted to Lewis^x. We are currently using this technology in our product candidate SGN-15. We are performing collaborative research in lieu of an up-front cash payment, and are required to make milestone payments and must make minimum annual royalty payments beginning in 2003 under the terms of the license agreement. Our obligation to pay royalties under this agreement terminates on a country-by-country basis upon the last to expire of the licensed patents in each country, which will occur in 2006, although our obligation to pay royalties to Genentech may continue for a longer period of time to the extent that we use technology derived from pending patent applications or other subsequently issued patents. The agreement is also subject to earlier termination if either party enters bankruptcy. Genentech may terminate the agreement if we breach our material obligations thereunder and we may terminate the agreement at any time.

During the next 24 months, we expect to pay up to an aggregate of approximately \$600,000 in annual maintenance fees and milestone payments under all of our license and collaboration agreements combined. We do not expect to pay any royalties on net sales of products under any of these agreements for at least the next several years. The milestone payments could be substantially higher and the royalties could be payable earlier if we file or receive regulatory approvals or achieve commercial sales sooner than expected.

Patents and Proprietary Technology

Our success will depend in large part on our and our licensors' abilities to:

- obtain patent and other proprietary protection for antigens, antibodies, adjuvants and delivery systems;
- defend patents once obtained;
- preserve trade secrets; and
- operate without infringing the patents and proprietary rights of third parties.

We intend to seek appropriate patent protection for our proprietary technologies by filing patent applications in the United States and certain other countries. As of December 31, 2000, we owned or had licensed 24 issued United States patents, and 7 pending United States patent applications.

These patents and patent applications are directed to certain monoclonal antibodies, drug candidates, linker technologies, monoclonal antibody-drug conjugate technologies, immunotoxin technologies, monoclonal antibody-enzyme and prodrug technologies and enabling technologies. Although we believe our patents and patent applications provide a competitive advantage, the patent positions of pharmaceutical and biopharmaceutical companies are highly uncertain and involve complex legal and factual questions. For example, there is substantial uncertainty regarding the potential for patent protection for gene fragments or genes without known function or correlation with specific diseases. We and our corporate collaborators or licensors may not be able to develop patentable products or processes. We and our corporate collaborators or licensors may not be able to obtain patents from pending patent applications. Even if patent claims are allowed, the claims may not issue, or in the event of issuance, may not be sufficient to protect the technology owned by or licensed to us or our corporate collaborators.

Our or our corporate collaborators' current patents, or patents that issue on pending applications, may be challenged, invalidated, infringed or circumvented, and the rights granted in those patents may not provide proprietary protection or competitive advantages to us.

Patent applications in the United States have been maintained in secrecy until patents issue and patent applications in certain foreign countries generally are not published until many months or years after they are filed. Scientific and patent publication often occurs long after the date of the scientific developments disclosed in those publications. Accordingly, we cannot be certain that we or one of our corporate collaborators was the first to invent the subject matter covered by any patent application or that we or one of our corporate collaborators were the first to file a patent application for any such invention.

Our commercial success depends significantly on our ability to operate without infringing patents and proprietary rights of third parties. A number of pharmaceutical companies, biotechnology companies, universities and research institutions may have filed patent applications or may have been granted patents that cover technologies similar to the technologies owned, optioned by or licensed to us or our corporate collaborators. We cannot determine with certainty whether patents or patent applications of other parties may materially affect us or our corporate collaborators' ability to make, use or sell any products.

The existence of third-party patent applications and patents could significantly reduce the coverage of the patents owned, optioned by or licensed to us or our corporate collaborators and limit our or our corporate collaborators' ability to obtain meaningful patent protection. If patents containing competitive or conflicting claims are issued to third parties, we or our corporate collaborators may be enjoined from pursuing research, development or commercialization of products or may be required to obtain licenses, if available, to these patents or to develop or obtain alternative technology. In addition, other parties may duplicate, design around or independently develop similar or alternative technologies to ours, our corporate collaborators or our licensors. If another party controls patents or patent applications covering our products, we and our corporate collaborators may not be able to obtain the rights we need to those patents or patent applications in order to commercialize our products.

Litigation may be necessary to enforce patents issued or licensed to us or our corporate collaborators or to determine the scope or validity of another party's proprietary rights. United States Patent Office interference proceedings may be necessary if we and another party both claim to have invented the same subject matter.

We could incur substantial costs if:

- litigation is required to defend against patent suits brought by third parties;
- we participate in patent suits brought against or initiated by our corporate collaborators;
- we initiate similar suits; or
- we participate in an interference proceeding.

In addition, we or our corporate collaborators may not prevail in any of these actions or proceedings. An adverse outcome in litigation or an interference or other proceeding in a court or patent office could:

- subject us to significant liabilities;
- require disputed rights to be licensed from other parties; or
- require us or our corporate collaborators to cease using certain technology.

We also rely on trade secrets and proprietary know-how, especially when we do not believe that patent protection is appropriate or can be obtained. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions agreement before beginning their employment, consulting or advisory relationship with us. These agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of their relationship with us except in limited circumstances. These agreements also generally provide that we shall own all inventions conceived by the individual in the course of rendering services to us.

We work with others in our research, development and commercialization activities. Disputes may arise about inventorship and corresponding rights in know-how and inventions resulting from the joint creation or

use of intellectual property by us and our corporate partners, licensors, scientific collaborators and consultants. In addition, other parties may circumvent any proprietary protection we do have. As a result, we may not be able to maintain our proprietary position.

Government Regulation

Our products are subject to extensive regulation by numerous governmental authorities, principally the FDA, as well as numerous state and foreign agencies. We need to obtain clearance of our potential products by the FDA before we can begin marketing the products in the United States. Similar approvals are also required in other countries.

Product development and approval within this regulatory framework is uncertain, can take a number of years and requires the expenditure of substantial resources. The nature and extent of the governmental premarket review process for our potential products will vary, depending on the regulatory categorization of particular products. We believe that the FDA and comparable regulatory bodies in other countries will regulate monoclonal antibody products and related pharmaceutical products as biologics. The necessary steps before a new biological product may be marketed in the United States ordinarily include:

- preclinical laboratory and animal tests;
- submission to the FDA of an investigational new drug application which must become effective before clinical trials may commence;
- completion of adequate and well controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use;
- the submission to the FDA of a biologics license application; and
- FDA review and approval of the biologics license application prior to any commercial sale or shipment of the product.

Preclinical tests include laboratory evaluation of the product, as well as animal trials to assess the potential safety and efficacy of the product. Preclinical tests must be conducted by laboratories that comply with FDA regulations regarding good laboratory practices. The results of preclinical

tests, together with manufacturing information, analytical data and proposed clinical trial protocols, are submitted to the FDA as part of an investigational new drug application, which must become effective before the commencement of clinical trials. The investigational new drug application will automatically become effective 30 days after receipt by the FDA unless the FDA indicates prior to the end of such 30-day period that the proposed protocol raises concerns that must be resolved to the satisfaction of the FDA before the trials may proceed. In such case, we cannot assure you that this resolution will be achieved in a timely fashion, if at all. In addition, the FDA may impose a clinical hold on an ongoing clinical trial if, for example, safety concerns arise, in which case the trial cannot recommence without FDA authorization under terms sanctioned by the agency.

Clinical trials involve the administration of the product to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials are conducted in accordance with good clinical practices under protocols that detail the objectives of the trial, inclusion and exclusion criteria, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Each protocol must be submitted to the FDA as part of the investigational new drug application. Further, each clinical trial must be reviewed and approved by an independent institutional review board at the institutions at which the trial will be conducted. The institutional review board will consider, among other things, ethical factors and the safety of human subjects. The institutional review board may require changes in a protocol, and there can be no assurance that the submission of an investigational new drug application will enable a trial to be initiated or completed.

Clinical trials generally are conducted in three sequential phases that may overlap. In phase I, the initial introduction of the product into healthy human subjects or patients, the product is tested to assess safety,

metabolism, pharmacokinetics and pharmacological actions associated with increasing doses. Phase II usually involves trials in a limited patient population to:

- determine the efficacy of the potential product for specific, targeted indications;
- determine dosage tolerance and optimum dosage; and
- further identify possible adverse reactions and safety risks.

If a compound is found to be effective and to have an acceptable safety profile in phase II evaluations, phase III trials are undertaken to evaluate further clinical efficacy in comparison to standard therapies, within a broader patient population, generally, at geographically dispersed clinical sites. Phase I, phase II or phase III testing may not be completed successfully within any specific period of time, if at all, with respect to any of our potential products. Furthermore, the FDA or an institutional review board or we may suspend a clinical trial at any time for various reasons, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

The results of pharmaceutical development, preclinical trials and clinical trials are submitted to the FDA in the form of a biologics license application for approval of the manufacture, marketing and commercial shipment of the biological product. The testing and approval process is likely to require substantial time, effort and resources, and there can be no assurance that any approval will be granted on a timely basis, if at all. The FDA may deny a biologics license application if applicable regulatory criteria are not satisfied, require additional testing or information, or require postmarket testing and surveillance to monitor the safety or efficacy of the product. In addition, after marketing approval is granted, the FDA may require post-marketing clinical trials, which typically entail extensive patient monitoring and may result in restricted marketing of an approved product for an extended period of time.

Please see the table in "Our Clinical and Preclinical Programs" on page 32 for a complete description of the status of our FDA applications for our product candidates.

Competition

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Many third parties compete with us in developing therapies to treat a variety of cancers including hematologic malignancies, carcinomas and melanoma. They include:

- pharmaceutical companies,
- biotechnology companies;
- academic institutions; and
- other research organizations.

Many of these competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than us. In addition, many of these competitors have become more active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our programs.

We are aware of specific companies that have competitive technology. These companies include the Wyeth-Ayerst division of American Home Products and Immunogen, both of which have monoclonal antibody-drug conjugate technology. Wyeth-Ayerst markets the monoclonal antibody drug conjugate Mylotarg, for which they received approval in early 2000, for patients with acute myelogenous leukemia. While we are not

developing lead agents for that exact disease, Wyeth may apply their technology to other monoclonal antibodies that may compete with our lead agents. Immunogen has certain monoclonal antibody-drug conjugates in development that compete with our lead agents in clinical trials and in preclinical development. Immunogen also has established partnerships with outside companies to allow them to utilize Immunogen's monoclonal antibody-drug conjugate technology. These outside companies may compete with our lead agents in development. We believe that our technology in the monoclonal-antibody drug conjugate area, specifically our stable linkers and highly potent, synthetically accessible cell-killing drugs, compete favorably with the technologies that are in use at Wyeth and Immunogen.

We expect that competition among products approved for sale will be based, among other things, on efficacy, reliability, product safety, price and patent position. Our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:

- advance our technology platforms;
- license additional technology;
- maintain a proprietary position in our technologies and products;
- obtain required government and other public and private approvals on a timely basis;
- attract and retain key personnel; and
- enter into corporate partnerships.

Manufacturing

We received pharmaceutical-grade SGN-15 and SGN-10 from Bristol-Myers Squibb for our previous and ongoing clinical trials. In addition, we have contracted with ICOS Corporation to develop cell lines expressing the SGN-30 product candidate and to manufacture preclinical and clinical supplies of SGN-30 that we believe will be sufficient through phase II clinical trials. We believe that our contract manufacturing relationship with ICOS, together with the existing product we received from Bristol-Myers Squibb, will be sufficient to accommodate clinical trials through phase II of our most advanced product candidates. However, we may need to obtain additional manufacturing arrangements, if available on commercially reasonable terms, or increase our own manufacturing capability to meet our future needs, both of which would require significant capital investment.

Facilities

Our headquarters are in Bothell, Washington, where we lease approximately 15,000 square feet of laboratory, discovery, research and development and general administration space, with monthly payments of \$44,764. The lease for this facility expires in December 2001. We recently entered into a lease for 63,900 square feet of space, with monthly payments of \$161,028 for the first 12 months, to be developed into mixed laboratory and office space in Bothell, Washington. We expect to complete a build-out of this space in the summer of 2001 and intend to relocate our headquarters to this new facility when it is available.

Legal Proceedings

We are not a party to any material legal proceedings.

Employees

As of December 31, 2000, we had 46 employees, 15 of whom hold degrees at the doctoral level. Of these employees, 35 are engaged in or directly support research, development and clinical activities and 11 are in administration and business development positions. Each of our employees has signed a confidentiality agreement and none are covered by a collective bargaining agreement. We have never experienced employment-related work stoppages and consider our employee relations to be good.

Management

Executive Officers and Other Key Employees, Directors and Scientific Advisors

The names and ages of our executive officers and other key employees, directors and scientific advisors as of December 31, 2000 are as follows:

Name

Age

Position(s)

Executive Officers and Other Key Employees and Directors

H. Perry Fell	43	Chief Executive Officer and Director
Clay B. Siegall	40	President, Chief Scientific Officer and Director
Tim J. Carroll	49	Chief Financial Officer
Amy P. Sing	42	Senior Director, Medical Affairs
Peter S. Senter	49	Senior Director, Chemistry
Alan F. Wahl	45	Senior Director, Biochemistry
Charles P. Waite, Jr. (1)(2)	45	Director, Chairman of the Board
Michael F. Powell (2)	46	Director
Karl Erik Hellström (1)	66	Director
Louis C. Bock (1)(2)	35	Director
Marc E. Lippman	56	Director and Scientific Advisor

Scientific Advisors

Albert F. LoBuglio	62	Scientific Advisor
Oliver Press	48	Scientific Advisor

(1)
Member of Compensation Committee

(2)
Member of Audit Committee

H. Perry Fell co-founded Seattle Genetics. Dr. Fell has served as our Chief Executive Officer and as one of our directors since our inception. Dr. Fell also served as our President from inception to June 2000. Prior to co-founding Seattle Genetics, Dr. Fell was with the Bristol-Myers Squibb Pharmaceutical Research Institute as a Research Scientist from June 1986 to April 1989 and Director of the Molecular Immunology Department from April 1989 to December 1997. Dr. Fell received an M.B.A. from the University of Washington, a Ph.D. in Immunology from the University of Texas Health Science Center at Dallas, Southwestern Medical School and a B.S. in Microbiology from the University of Texas at Arlington. Dr. Fell has authored 30 scientific papers and holds six patents.

Clay B. Siegall co-founded Seattle Genetics. Dr. Siegall has served as our Chief Scientific Officer and as one of our directors since our inception and as our President since June 2000. Dr. Siegall also served as our Executive Vice President from inception to June 2000. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator from February 1991 to January 1995 and as a Principal Scientist from January 1995 to December 1997. From February 1988 to February 1991, Dr. Siegall was a Staff Fellow/Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. Dr. Siegall has authored 63 scientific papers and holds seven patents. He serves on the Editorial Board of three scientific journals and is a member of the Scientific Board of Counselors for the Cancer Treatment Research Foundation. Dr. Siegall was given the Pierce Award in 1995 for his efforts in the field of targeted toxins.

Tim J. Carroll has served as our Chief Financial Officer since July 2000. Prior to joining us, Mr. Carroll was Chief Financial Officer of ARIS Corporation, a technology firm, from August 1999 to July 2000 and with its predecessor company, fine.com, an internet development company, from June 1998 to August 1999.

Mr. Carroll served as Vice President of Strategic Planning and Investor Relations for Multiple Zones International, a direct marketer of technology products, from April 1996 to May 1998. Mr. Carroll was Vice President of Financial Reporting and Investor Relations for the Hillhaven Corporation, now Vencor, Inc., a health care service firm, from January 1989 to April 1996. Mr. Carroll was a Senior Auditor with Deloitte & Touche, a national accounting firm, from December 1975 to January 1980. Mr. Carroll received his B.S. in Accounting from the University of Washington and is a certified public accountant.

Amy P. Sing has served as our Senior Director for Medical Affairs since June 2000. Previously, Dr. Sing served as our Medical Director from January 1999 to June 2000. Prior to joining Seattle Genetics, Dr. Sing served as Medical Director of Medical Affairs and Clinical Research at CellPro, Inc., a biotechnology firm, from May 1997 to December 1998. Before joining CellPro, she was a faculty member at the University of Washington and the Fred Hutchinson Cancer Research Center in Pediatrics and Pediatric Hematology/Oncology from July 1994 to February 1997. Dr. Sing trained in Pediatric Hematology/Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington from July 1990 to June 1994, and in Pediatrics at the Children's Hospital in Boston, MA from July 1987 to June 1990. She received an M.D. from Stanford University School of Medicine and a B.A. in Anthropology from Amherst College.

Peter S. Senter has served as our Senior Director of Chemistry since November 2000. Previously, Dr. Senter served as our Director of Chemistry from August 1998 to November 2000. Dr. Senter was Director of Chemistry at Cytokine Networks, Inc., a biotechnology company, from November 1997 to August 1998 and Senior Principal Scientist at Bristol-Myers Squibb Pharmaceutical Research Institute from July 1985 to November 1997. Dr. Senter received a Ph.D. in Chemistry from the University of Illinois and an A.B. in Biochemistry from the University of California. He is the Associate Editor of Bioconjugate Chemistry and serves on the editorial board of four scientific journals. Dr. Senter has authorized 65 scientific publications and holds twelve patents.

Alan F. Wahl has served as our Senior Director of Biochemistry since November 2000. Previously, he served as our Director of Biochemistry from May 1998 to November 2000. Dr. Wahl was a Principal Scientist with Zymogenetics, Inc., a biotechnology company, from December 1997 to May 1998 and a Principal Scientist Group Leader at the Bristol-Myers Squibb Pharmaceutical Research Institute from July 1989 to November 1997. He received his post-doctoral training at Stanford University School of Medicine from January 1986 to June 1989. Dr. Wahl received a Ph.D. and M.S. in Biochemistry from the University of Rochester and a B.S. in Biology from the Rochester Institute of Technology.

Charles P. Waite, Jr. has served as a director and our Chairman of the Board since April 1998. Mr. Waite has been a General Partner of OVP Venture Partners, formerly Olympic Venture Partners, since 1987. In addition to Seattle Genetics, Mr. Waite serves on the boards of Rosetta Inpharmatics, a bioinformatics software company; SignalSoft Corporation, a wireless location services provider; Verity, a software solution provider; Watchguard Technologies, an internet security service provider; and Loudeye Technologies, an internet media infrastructure service provider. Mr. Waite received his A.B. in History from Kenyon College and his M.B.A. from Harvard University.

Michael F. Powell has served as one of our directors since April 1998. Dr. Powell has served as Managing Director of Sofinnova Venture Partners IV since 1998. Previously, he was a Group Leader at Genentech from December 1990 to June 1997 and Director of Product Development for Cytel Corporation, a biotechnology firm, from September 1987 to December 1990. He is an Adjunct Professor at the University of Kansas and an editorial board member of several pharmaceutical journals. Dr. Powell received his Ph.D. in Chemistry from the University of Toronto in 1981 and was a postdoctoral fellow in Bio-Organic Chemistry at the University of California. In 1993, Dr. Powell was honored as a Fellow by the American Association of Pharmaceutical Scientists. Dr. Powell is the author of nearly 100 publications and books, including a treatise on vaccine design.

48

Karl Erik Hellström has served as one of our directors since April 1998. Dr. Hellström has been a principal investigator at the Pacific Northwest Research Institute since 1998. Dr. Hellström previously served as Vice President of Oncology Drug Discovery and Vice President of Immunotherapeutics at the Bristol-Myers Squibb Pharmaceutical Research Institute from October 1983 to September 1997. From August 1975 to September 1983, he was Head of the Tumor Immunology Program at the Fred Hutchinson Cancer Research Center after serving as Professor of Pathology at the University of Washington Medical School starting in September 1966 and where he continues to retain an Affiliate Professorship. Dr. Hellström received his M.D. and Ph.D. degrees in tumor biology/immunogenetics from the Karolinska Institute in Stockholm, Sweden. He has published over 450 scientific papers and has received several awards, including the Yearly Award from the American Cancer Society.

Louis C. Bock has served as one of our directors since January 2000. Mr. Bock is a Managing Director of BA Venture Partners VI, LLC, which is the general partner of BAVP, LP and an affiliate of Banc of America Securities LLC. Mr. Bock joined BA Venture Partners in September 1997 from Gilead Sciences, Inc., a biopharmaceutical company, where he held positions in research, project management, business development and sales from September 1989 to September 1997. Prior to Gilead, Mr. Bock was a research associate at Genentech from November 1987 to September 1989. He received his B.S. in Biology from California State University, Chico and an M.B.A. from California State University, San Francisco.

Marc E. Lippman has served as one of our directors since June 2000 and a member of our Scientific Advisory Board since June 1998. Effective February 2001 Dr. Lippman will become the John G. Searle Professor and Chairman of the Department of Internal Medicine at the University of Michigan School of Medicine. Presently, Dr. Lippman is the Director of the Lombardi Cancer Research Center since July 1988, and Professor and Chairman of the Department of Oncology since July 1999 and Professor of Medicine at Georgetown University Medical School in Washington, D.C. since July 1988. Since July 1995, he has served as Chief of the Division of Hematology-Oncology at Georgetown University Medical School. He was previously Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute from July 1976 to July 1988. Dr. Lippman has authored over 500 publications and one of the standard texts on breast cancer. He serves as chair of the Scientific Advisory Board for the Perseus-Soros Fund and is a director of Raven Biotechnology. Dr. Lippman received his B.A., magna cum laude, from Cornell in 1964 and his M.D. from Yale where he was elected to Alpha Omega Alpha in 1968.

Scientific Advisors

We have consulting arrangements with scientists who serve as our advisors. We chose our advisors for their expertise in fields that are important to the research and development of our products. We generally compensate our scientific advisors for their services with a combination of cash payments and stock options. We are supporting research projects in the laboratories of some of our scientific advisors and we intend to continue to support these and similar projects. We also provide additional compensation to some of our scientific advisors for their participation in these collaborations.

In addition to Marc E. Lippman, our scientific advisors presently include the following persons:

Albert F. LoBuglio, M.D. has served as a member of our Scientific Advisory Board since June 1998. Dr. LoBuglio, a medical oncologist, has been the Director of the Comprehensive Cancer Center at the University of Alabama, Birmingham since 1983. From July 1990 to June 1994 and July 1996 to June 2000, he served as a member of the Board of Scientific Councilors at the National Cancer Institute. He also serves as a scientific advisory board member for BioCryst Pharmaceuticals, Inc.; Eos Biotechnology; Abgenix, Inc.; IDEC Pharmaceuticals, Corp.; Enzon, Inc.; Glaxo-Wellcome, Inc.; and Serologicals Corporation. Dr. LoBuglio attended Canisius College from September 1955 to June 1962 and received his M.D. from Georgetown University School of Medicine in June 1962. He received his training in Internal Medicine at the University of Pittsburgh from July 1962 to June 1965 and Hematology/Oncology training at the Harvard-Thorndike Memorial Laboratories from July 1965 to June 1967.

49

Oliver Press, M.D. has served as a member of our Scientific Advisory Board since June 1998. Dr. Press is a Professor of Medicine in the Division of Medical Oncology at the University of Washington, an Adjunct Professor in Biological Structure at the University of Washington and a Member of the Fred Hutchinson Cancer Research Center. He is the Acting Program Director for the High Dose Chemotherapy Service at the University of Washington Medical Center and an Associate Director of the Medical Scientist Training Program. He has published over 120 scientific articles and currently is the principal investigator on several national protocols for treatment of B cell lymphomas and Hodgkin's disease. Dr. Press received a B.S. in Biology from Stanford University in 1973, a Ph.D. in Biological Structure from the University of Washington in 1977 and an M.D. from the University of Washington in 1979. Dr. Press performed an internship and residency in Internal Medicine at Massachusetts General Hospital from June 1979 to June 1982 and served as an instructor at Harvard Medical School from June 1979 to June 1982. Dr. Press subsequently served as the Medical Chief Resident at the University of Washington from June 1982 to June 1983 and as an oncology fellow at the Fred Hutchinson Cancer Research Center and the University of Washington from July 1983 to July 1985.

Board Composition

Our bylaws currently provide for a board of directors consisting of eight members. Pursuant to the terms of a stockholders' voting agreement that we entered with certain of our stockholders in connection with the sale of our shares of preferred stock, Messrs. Waite, Powell, Hellström, Bock, Fell and Siegall were elected to our board of directors. This agreement will terminate by its terms upon the closing of this offering and the terms of office of the board of directors will be divided into three classes upon the closing of this offering. As a result, a portion of our board of directors will be elected each year. The division of the three classes, the initial directors and their respective election dates are as follows:

- the class 1 directors will be Messrs. Powell, Bock and Hellström, and their term will expire at the annual meeting of stockholders to be held in 2002;
- the class 2 directors will be Messrs. Siegall and Waite, and their term will expire at the annual meeting of the stockholders to be held in 2003; and
- the class 3 directors will be Messrs. Fell and Lippman, and their term will expire at the annual meeting of stockholders to be held in 2004.

At each annual meeting of stockholders after the initial classification, the successors to directors whose terms are to expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of the board of directors may have the effect of delaying or preventing changes in control or management of our company.

Board Compensation

Except for reimbursement for reasonable travel expenses relating to attendance at board of directors meetings, directors are not compensated for their services as directors. Under our 1998 stock option plan, nonemployee directors are eligible to receive stock option grants at the discretion of the board of directors or any other administrator of the plan. In addition, following the closing of this offering, directors will be participating in the 2000 director's stock option plan. See "Benefit Plans."

Board Committees

In April 2000, the board of directors established the Compensation Committee. The Compensation Committee recommends compensation for personnel to the Board and administers our stock plans. The

Compensation Committee currently consists of Messrs. Waite, our Chairman of the Board, Bock and Hellström.

In June 2000, the board of directors established the Audit Committee. The Audit Committee reviews the results and scope of the audit and other services provided by our independent auditors. The Audit Committee currently consists of Messrs. Waite, our Chairman of the Board, Bock and Powell.

Executive Compensation

The following table provides summary information concerning the compensation received for services rendered during the fiscal years ended December 31, 1999 and December 31, 2000 by our Chief Executive Officer and our next most highly compensated executive officers and our next most highly compensated employee who would have been included if he or she had been an executive officer, each of whose aggregate compensation during our last fiscal year exceeded \$100,000.

Summary Compensation Table

Name and Principal Position	Year	Annual Compensation			Long-Term Compensation		All Other Compensation(\$)
		Salary(\$)	Bonus(\$)	Other	Securities Underlying Options(#)		
H. Perry Fell Chief Executive Officer	1999	155,000	25,000	—	—	—	
	2000	200,000	40,000	—	300,000	—	
Clay B. Siegall President and Chief Scientific Officer	1999	155,000	25,000	—	—	—	
	2000	200,000	40,000	—	300,000	—	
Tim J. Carroll(1) Chief Financial Officer	1999	—	—	—	—	—	
	2000	73,333	8,000	—	400,000	—	
Amy P. Sing Senior Director, Medical Affairs	1999	150,000	3,979	—	125,000	—	
	2000	161,933	15,816	—	75,000	—	
Peter S. Senter Senior Director, Chemistry	1999	106,925	1,248	—	—	—	
	2000	114,383	8,691	—	45,000	—	

- (1) Mr. Carroll commenced employment with us in July 2000. Mr. Carroll's salary on an annualized basis is \$160,000.

Option Grants in Fiscal 2000

The following table outlines information regarding stock options granted to our named officers in 2000. Amounts in the following table under potential realizable value represent hypothetical gains that could be achieved for the respective options if exercised at the end of the option term. For purposes of this analysis, the SEC mandates the use of 5% and 10% assumed annual rates of compounded stock price appreciation and these rates do not represent an estimate or projection of our future common stock prices. The amounts under potential realizable value represent assumed rates of appreciation in the value of our common stock from the initial public offering price of \$7.00 per share. Actual gains, if any, of stock options exercises will

51

depend on future performance of our common stock and overall stock market conditions. We may not achieve the amounts reflected in the following table.

Name	Individual Grants					Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term	
	Number of Shares of Common Stock Underlying Options Granted	Percent of Total Options Granted to Employees in 2000	Exercise Price Per Share(\$)	Expiration Date	Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term		
					5%(\$)	10%(\$)	
H. Perry Fell	300,000	18.4%	\$ 3.00	11/2/10	\$ 2,465,346.88	\$ 4,376,072.84	
Clay B. Siegall	300,000	18.4	3.00	11/2/10	2,465,346.88	4,376,072.84	
Tim J. Carroll	400,000	24.5	0.29	8/31/10	4,333,500.30	6,803,983.02	
Amy P. Sing	20,000	1.2	0.29	2/3/10	210,545.66	321,822.31	
	20,000	1.2	0.29	8/31/10	216,675.01	340,199.15	
	35,000	2.1	3.00	11/2/10	287,623.80	510,541.83	
Peter S. Senter	15,000	*	0.29	8/31/10	162,506.26	255,149.36	
	30,000	1.8	3.00	11/2/10	246,534.69	437,607.28	

* Less than one percent of total options granted to employees in 2000.

In 2000, we granted options to purchase an aggregate of 1,630,500 shares to employees and directors under our 1998 stock option plan at an exercise price determined in good faith by our board of directors based on our board's estimate of fair value on the date of grant.

Option Values at December 31, 2000

The following table presents the number and value of securities underlying unexercised options that are held by each of our named officers as of December 31, 2000.

Amounts shown under the column "Value of Unexercised In-the-Money Options at December 31, 2000" are based on the initial public offering price of \$7.00 per share, without taking into account any taxes that may be payable in connection with the transaction, multiplied by the number of shares underlying the option, less the exercise price payable for these shares.

Name	Shares Acquired on Exercise	Value Realized(1)	Number of Securities Underlying Unexercised Options at December 31, 2000		Value of Unexercised In-the-Money Options at December 31, 2000(2)	
			Exercisable	Unexercisable	Exercisable	Unexercisable
H. Perry Fell	—	—	—	300,000	—	\$ 1,200,000
Clay B. Siegall	—	—	—	300,000	—	\$ 1,200,000
Tim S. Carroll	400,000	—	—	—	—	—
Amy P. Sing	200,000	\$ 23,750	—	—	—	—
Peter S. Senter	72,187	\$ 8,015	1,563	46,250	\$ 10,785	\$ 316,275

- (1) Equal to the deemed fair market value of the purchased shares on option exercise date as determined in good faith by our board of directors, less the exercise price paid for such shares.

- (2) Value is determined by subtracting the exercise price from the initial public offering price of \$7.00 for the common stock, and multiplying by the number of shares underlying the option.

52

Benefit Plans

1998 Stock Option Plan

Our 1998 stock option plan provides for the grant of incentive stock options to employees (including employee directors) and nonstatutory stock options to employees, directors and consultants. The purposes of the 1998 stock option plan are to attract and retain the best available personnel, to provide additional incentives to our employees and consultants and to promote the success of our business. Our board of directors originally adopted and our stockholders approved the 1998 stock option plan in December 1997. The 1998 stock option plan was amended in December 1999 by our board of directors and stockholders to increase the number of reserved shares to 2,130,000 shares. The 1998 stock option plan, as amended, reserved 2,130,000 shares. The 1998 stock option plan was further amended by the board of directors in November 2000 to increase the number of reserved shares to a total of 4,400,000 shares and to provide for, among other things, an automatic annual increase on the first day of each of our fiscal years beginning in 2002 and ending in 2008 equal to the lesser of:

- 1,200,000 shares;
- 4% of our outstanding common stock as of the last day of the immediately preceding fiscal year; or
- such lesser number as the board of directors determines.

This amendment to the 1998 stock option plan will be submitted to our stockholders for approval prior to the completion of this offering. Unless terminated earlier by the board of directors, the 1998 stock option plan shall terminate in December 2008.

As of December 31, 2000, options to purchase 1,313,818 shares of common stock were outstanding at a weighted average exercise price of \$2.07 per share, 627,605 shares had been issued upon early exercise subject to our right to repurchase pursuant to restricted stock purchase agreements, 249,972 shares had been issued upon exercise of outstanding vested options and 2,208,605 shares remained available for future grant.

The 1998 stock option plan may be administered by the board of directors or a committee appointed by the board of directors. The administrator determines the terms of options granted under the 1998 stock option plan, including the number of shares subject to the option, exercise price, term and exercisability. In no event, however, may an employee receive awards for more than 1,000,000 shares under the 1998 stock option plan in any fiscal year. Incentive stock options granted under the 1998 stock option plan must have an exercise price of at least 100% of the fair market value of the common stock on the date of grant and at least 110% of such fair market value in the case of an optionee who holds more than 10% of the total voting power of all classes of our stock. Prior to this offering, nonstatutory stock options granted under the 1998 stock option plan were required to have an exercise price of at least 85% of the fair market value of the common stock on the date of grant and at least 110% of such fair market value in the case of an optionee who holds more than 10% of the total voting power of all classes of our stock. After the date of this offering, the exercise price of nonstatutory stock options will no longer be subject to these restrictions, although nonstatutory stock options granted to our Chief Executive Officer and our four other most highly compensated officers will generally equal at least 100% of the grant date fair market value if we intend to have options to those individuals will qualify as performance-based compensation under applicable tax law. Payment of the exercise price may be made in cash or such other consideration as determined by the administrator.

The administrator determines the term of options, which may not exceed ten years or five years in the case of an incentive stock option granted to a holder of more than 10% of the total voting power of all classes of our stock. Generally, an option granted under the 1998 stock option plan is non-transferable other than by will or the laws of descent or distribution and may be exercised during the lifetime of the optionee only by such optionee. However, the administrator may, in its discretion, provide for the limited transferability of

nonstatutory stock options granted under the 1998 stock option plan under certain circumstances. The administrator determines when options become exercisable. Options granted under the 1998 stock option plan generally must be exercised within three months after termination of the optionee's status as an employee, director or consultant of Seattle Genetics, within six months if such termination is due to the death of the optionee, or within twelve months if such termination is due to the disability of the optionee, but in no event later than the expiration of the option's term. Options granted under the 1998 stock option plan generally vest over a four year period at a rate of 25% of the total number of shares subject to the option twelve months after the date of grant with the remaining shares vesting in equal monthly installments thereafter.

If we are acquired by another corporation in a transaction in which options outstanding under the 1998 stock option plan are not assumed or replaced with substitute options by our acquiror, then our outstanding options shall terminate upon consummation of the acquisition. Outstanding awards, as well as the number of shares remaining available for issuance under the plan, the automatic annual increase in shares and the annual employee grant limitation, will adjust in the event of a stock split, stock dividend or other similar change in our capital stock. The board of directors has the authority to amend or terminate the 1998 stock option plan provided that no action that impairs the rights of any holder of an outstanding option may be taken without the holder's consent. In addition, we will obtain stockholder approval for any plan amendments to the extent required by applicable law.

2000 Employee Stock Purchase Plan

Our 2000 employee stock purchase plan was adopted by the board of directors in November 2000 and will be submitted for approval by our stockholders prior to completion of this offering. A total of 300,000 shares of common stock has been reserved for issuance under the 2000 purchase plan, none of which have been issued as of the date of this offering. The number of shares reserved for issuance under the 2000 purchase plan will be subject to an automatic annual increase on the first day of each of our fiscal years beginning in 2002 and ending in 2010 that is equal to the lesser of:

-

300,000 shares;

- 1% of our outstanding common stock on the last day of the immediately preceding fiscal year;

- or such lesser number of shares as the board of directors determines.

The 2000 purchase plan becomes effective upon the date of this offering. Unless terminated earlier by the board of directors, the 2000 purchase plan shall terminate in 2010.

The 2000 purchase plan, which is intended to qualify under Section 423 of the Internal Revenue Code, will be implemented by a series of offering periods of approximately 24 months' duration, with new offering periods (other than the first offering period) commencing generally on February 1 and August 1 of each year. Each offering period will consist of consecutive purchase periods of approximately six months' duration. At the end of each purchase period an automatic purchase will be made for participants. The initial offering period is expected to commence on the date of this offering and end on January 31, 2003; the initial purchase period is expected to begin on the date of this offering and end on July 31, 2001. Each eligible employee will be granted an option on the effective date of this offering to purchase shares in the initial offering period in an amount equal to the maximum number of shares that an individual can purchase under the terms of the 2000 purchase plan.

The 2000 purchase plan will be administered by the board of directors or by a committee appointed by the board. Our employees (including officers and employee directors), or employees of any majority-owned subsidiary designated by the board, are eligible to participate in the 2000 purchase plan if they are employed by us or any such subsidiary for at least 20 hours per week and more than five months per year. The 2000 purchase plan permits eligible employees to purchase common stock through payroll deductions, which in any event may not exceed 20% of an employee's eligible cash compensation. The purchase price

54

is equal to the lower of 85% of the fair market value of the common stock at the beginning of each offering period or at the end of each purchase period. Employees may end their participation in the 2000 purchase plan at any time during an offering period, and participation ends automatically on termination of employment.

An employee cannot be granted an option under the 2000 purchase plan if immediately after the grant such employee would own stock and/or hold outstanding options to purchase stock equaling 5% or more of the total voting power or value of all classes of our stock or stock of our subsidiaries, or if such option would permit an employee's rights to purchase stock under the 2000 purchase plan at a rate that exceeds \$25,000 of fair market value of such stock for each calendar year in which the option is outstanding. In addition, no employee may purchase more than 2,000 shares of common stock under the 2000 purchase plan in any one purchase period.

If we merge or consolidate with or into another corporation or sell all or substantially all of our assets, each right to purchase stock under the 2000 purchase plan will be assumed or an equivalent right substituted by the successor corporation. However, the board of directors will shorten any ongoing offering period so that employees' rights to purchase stock under the 2000 purchase plan are exercised prior to the transaction in the event that the successor corporation refuses to assume each purchase right or to substitute an equivalent right. Outstanding options will be adjusted if we effect a stock split, stock dividend or similar change in our capital structure. The board of directors has the power to amend or terminate the 2000 purchase plan and to change or terminate an offering period as long as such action does not adversely affect any outstanding rights to purchase stock thereunder. However, the board of directors may amend or terminate the 2000 purchase plan or an offering period even if it would adversely affect outstanding options in order to avoid our incurring adverse accounting charges.

2000 Directors' Stock Option Plan

The 2000 directors' stock option plan was adopted by the board of directors in November 2000 and will be submitted for approval by our stockholders prior to completion of this offering. It will become effective upon the date of this offering. A total of 400,000 shares of common stock have been reserved for issuance under the 2000 directors' plan, all of which remain available for future grants. The directors' plan is designed to work automatically without administration; however, to the extent administration is necessary, it will be performed by the board of directors. To the extent they arise, it is expected that conflicts of interest will be addressed by abstention of any interested director from both deliberations and voting regarding matters in which such director has a personal interest. Unless terminated earlier by the board of directors, the directors' plan will terminate in 2010.

The directors' plan provides that each person who is a non-employee director on the date of this offering and who has not previously been granted a stock option by the Company, will be granted a nonstatutory stock option to purchase 25,000 shares of common stock on the date of this offering. The plan further provides that each person who becomes a non-employee director after the completion of this offering will be granted a nonstatutory stock option to purchase 25,000 shares of common stock on the date on which such individual first becomes a member of our board of directors. Each initial option shall vest at the rate of 25% of the total number of shares subject to such option twelve months after the date of grant with the remaining shares vesting thereafter in equal monthly installments. Thereafter, on the dates of each annual stockholder meeting, each non-employee director who has been a member of the board of directors for at least six months will be granted a nonstatutory stock option to purchase 5,000 shares of common stock. Each annual option shall vest at the rate of 100% of the total number of shares subject to such option on the day before the one-year anniversary of the grant date.

All options granted under the directors' plan will have a term of 10 years and an exercise price equal to the fair market value on the date of grant. If a non-employee director ceases to serve as a director for any reason other than death or disability, he or she may, but only within 90 days after the date he or she ceases

55

to be a director, exercise options granted under the directors' plan. If he or she does not exercise the option within such 90-day period, the option shall terminate. If a directors' service terminates as a result of his or her disability or death, or if a director dies within three months following

termination for any reason, the director or his or her estate will have twelve months after the date of termination or death, as applicable, to exercise options that were vested as of the date of termination. Options granted under the directors' plan are generally non-transferable by the option holder other than by will or the laws of descent or distribution and each option is exercisable, during the lifetime of the option holder, only by that option holder.

If we are acquired by another corporation, each option outstanding under the directors' plan will be assumed or equivalent options substituted by our acquiror, unless our acquiror does not agree to such assumption or substitution, in which case the options will terminate upon consummation of the transaction to the extent not previously exercised. In connection with an acquisition, each director holding options under the directors' plan will have the right to exercise his or her options immediately before the consummation of the merger as to all shares underlying the options. Outstanding options will be adjusted if we effect a stock split, stock dividend, or other similar change in our capital structure. Our board of directors may amend or terminate the directors' plan as long as such action does not adversely affect any outstanding option and we obtain stockholder approval for any amendment to the extent required by applicable law.

Limitation of Liability and Indemnification Matters

Our certificate of incorporation limits the liability of our directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except liability for:

- any breach of their duty of loyalty to the corporation or its stockholders;
- acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
- unlawful payments of dividends or unlawful stock repurchases or redemptions; or
- any transaction from which the director derived an improper personal benefit.

This limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.

Our certificate of incorporation and bylaws provide that we shall indemnify our directors and executive officers and may indemnify our other officers and employees and other agents to the fullest extent permitted by law. We believe that indemnification under our bylaws covers at least negligence and gross negligence on the part of indemnified parties. Our bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in such capacity, regardless of whether the bylaws would permit indemnification.

We have entered into agreements to indemnify our directors and officers, in addition to indemnification provided for in our bylaws. These agreements, among other things, provide for indemnification of our directors and officers for expenses specified in the agreements, including attorneys' fees, judgments, fines and settlement amounts incurred by any such person in any action or proceeding arising out of such person's services as our director or officer, any of our subsidiaries or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors and officers.

Transactions with Executive Officers, Directors and Five Percent Stockholders

Since our incorporation in July 1997, we have engaged in certain transactions with our executive officers, directors and holders of more than five percent of our voting securities and their respective affiliates. The following table summarizes the shares of preferred stock purchased by our executive officers, directors and 5% stockholders and persons and entities associated with them in private placement transactions. Each share of each series of preferred stock converts automatically upon closing of the offering into one share of common stock.

Entities Affiliated with Directors	Common Stock	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock
Entities affiliated with OVP Venture Partners (1)	—	2,000,000	850,340
Entities affiliated with Sofinnova Venture Partners (2)	—	2,000,000	680,272
Entities affiliated with BAVP, LP (3)	—	—	2,040,816
Other 5% Stockholders			
Indosuez Ventures	—	1,750,000	510,204
Cascade Investment, LLC	—	—	2,721,088
Vulcan Ventures, Inc	—	—	2,721,088
H. Perry Fell (4)	1,720,000	—	—
Clay B. Siegall (4)	1,720,000	—	—

(1) Charles P. Waite, our Chairman of the Board, is a general partner of OVP Venture Partners.

- (2) Michael F. Powell, a director, is the Managing Director of Sofinnova Management IV, LLC, a general partner of Sofinnova Venture Partners IV, LP.
- (3) Louis C. Bock, a director, is the Managing Director of BA Ventures VI, LLC, which is the general partner of BAVP, LP and an affiliate of Banc of America Securities LLC.
- (4) Issued in December 1997 at \$0.001 per share.

Principal Stockholders

The following table sets forth information regarding the beneficial ownership of our common stock as of December 31, 2000 and as adjusted to reflect the sale of the common stock offered by this prospectus, as to:

- each person who is known to us to own beneficially more than 5% of its common stock.
- each of our directors and named executive officers;
- each of the individuals listed in the "Summary Compensation Table" above; and
- all current directors and named executive officers as a group.

Except as otherwise noted, the address of each person listed in the table is c/o Seattle Genetics, 22215 26th Avenue SE, Suite 3000, Bothell, WA 98021, and the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable. The table includes all shares of common stock issuable within 60 days of December 31, 2000 upon the exercise of options and other rights beneficially owned by the indicated stockholders on that date. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting and investment power with respect to shares. To our knowledge, except under applicable community property laws or as otherwise indicated, the persons named in the table have sole voting and sole investment control with respect to all shares beneficially owned. The applicable percentage of ownership for each stockholder is based on 21,968,149 shares of common stock outstanding as of December 31, 2000 and 29,253,863 shares of common stock outstanding after completion of this offering, together with applicable options for that stockholder. Shares of common stock issuable upon exercise of options and other rights beneficially owned are deemed outstanding for the purpose of computing the percentage ownership of the person holding these options and other rights, but are not deemed outstanding for computing the percentage ownership of any other person.

Name and Address of Beneficial Owner	Number of Shares Beneficially Owned	Percentage of Shares Beneficially Owned	
		Prior to this Offering	After this Offering(1)
5% Shareholders			
OVP Venture Partners (2) 2420 Carillon Point Kirkland, WA 98033	2,850,340	13.0%	9.7%
Cascade Investment, LLC (3) 2365 Carillon Point Kirkland, WA 98033	2,721,088	12.4%	9.3%
Vulcan Ventures, Inc. (4) 110 110 th Avenue, Suite 550 Bellevue, WA 98044	2,721,088	12.4%	9.3%
Sofinnova Venture Partners (5) 140 Geary Street, 10 th Floor San Francisco, CA 94108	2,680,272	12.2%	9.2%
Indosuez Ventures (6) 2180 Sand Hill Road, Suite 450 Menlo Park, CA 94025	2,260,204	10.3%	7.7%
BAVP, LP (7) 950 Tower Lane, Suite 700 Foster City, CA 94404	2,040,816	9.3%	7.0%

Name and Address of Beneficial Owner	Number of Shares Beneficially Owned	Percentage of Shares Beneficially Owned	
		Prior to this Offering	After this Offering(1)
Directors and Named Executive Officers			
H. Perry Fell	1,720,000	7.8%	5.9%
Clay B. Siegall	1,720,000	7.8%	5.9%
Tim J. Carroll (8)	400,000	1.8%	1.4%
Amy P. Sing (9)	201,000	*	*
Peter S. Senter (10)	79,936	*	*
Charles P. Waite (2)	2,850,340	13.0%	9.7%
Louis C. Bock (7)	2,040,816	9.3%	7.0%
Karl Erik Hellström (11)	937,500	4.3%	3.2%
Michael F. Powell (5)	2,680,272	12.2%	9.2%
Marc E. Lippman (12)	51,666	*	*
All directors and named executive officers as a group (11 persons) (13)	12,737,621	57.7%	43.5%

*

Less than one percent of the outstanding shares of common stock.

- (1) Assumes Genentech purchases 285,714 shares of our common stock, Medarex purchases 285,714 shares of our common stock and that the underwriters do not exercise their over-allotment option.
- (2) Includes 1,900,000 shares of Series A convertible preferred stock and 850,340 shares of Series B convertible preferred stock held by Olympic Venture Partners IV, LP, and 100,000 shares of Series A convertible preferred stock held by Olympic Venture Partners IV Entrepreneurs Fund, LP. Charles P. Waite, one of our directors, is a general partner of each of these partnerships, shares voting and dispositive power with respect to the shares held by each such entity and disclaims beneficial ownership of such shares in which he has no pecuniary interest.
- (3) Includes 2,721,088 shares of Series B convertible preferred stock held by Cascade Investment, LLC, of which the beneficial owner is William H. Gates, III. Cascade has expressed an interest in purchasing 850,000 shares of the common stock being offered by this prospectus. These shares would be purchased through the underwriters at the initial public offering price. In the event Cascade purchases these shares, after the offering it will beneficially own 12.2% of the shares of common stock outstanding.
- (4) Includes 2,721,088 shares of Series B convertible preferred stock held by Vulcan Ventures, Inc., of which the beneficial owner is Paul G. Allen.
- (5) Includes 1,945,000 shares of Series A convertible preferred stock and 661,565 shares of Series B convertible preferred stock held by Sofinnova Venture Partners IV, LP, and 55,000 shares of Series A convertible preferred stock and 18,707 shares of Series B convertible preferred stock held by Sofinnova Venture Associates IV, LP. Michael F. Powell, one of our directors, is a Managing Director of each of these partnerships, shares voting and dispositive power with respect to the shares held by each such entity and disclaims beneficial ownership of such shares in which he has no pecuniary interest.
- (6) Includes 1,750,000 shares of Series A convertible preferred stock and 510,204 shares of Series B convertible preferred stock held by STF III, LP, an affiliate of Indosuez Ventures. Nancy D. Burrus, a partner of Indosuez Ventures, shares voting and dispositive power with respect to the shares held by such entity and disclaims beneficial ownership of such shares in which she has no pecuniary interest.
- (7) Includes 2,040,816 shares of Series B convertible preferred stock held by BA Ventures Partners VI, LLC. Louis C. Bock, one of our directors, is the Managing Director of BA Venture Partners VI, LLC, which is the general partner of BAVP, LP, shares voting and dispositive power with respect to the shares held by such entity and disclaims beneficial ownership of such shares in which he has no pecuniary interest. BAVP, LP is an affiliate of Banc of America Securities LLC.

- (8) Includes 400,000 shares issued upon exercise of an option held by Mr. Carroll, all of which are subject to a repurchase right that lapses over the vesting schedule of Mr. Carroll's option.
- (9) Includes 200,000 shares issued upon exercise of options held by Dr. Sing, 140,104 of which are subject to a repurchase right that lapses over the vesting schedule of Dr. Sing's options.
- (10) Includes 72,187 shares issued upon exercise of options held by Dr. Senter, 30,000 of which are subject to a repurchase right that lapses over the vesting schedule of Dr. Senter's options and 6,250 shares issuable upon exercise of options held by Dr. Senter that are

exercisable within 60 days of December 31, 2000.

- (11) Includes 37,500 shares issuable upon exercise of an immediately exercisable option held by Dr. Hellström.
- (12) Includes 37,500 shares issued upon exercise of an option held by Dr. Lippman, all of which are subject to a repurchase right that lapses over the vesting schedule of Dr. Lippman's options and 14,166 shares issuable upon exercise of an option held by Dr. Lippman that is exercisable within 60 days of December 31, 2000.
- (13) Includes 62,288 shares issuable upon exercise of options that are immediately exercisable or are exercisable within 60 days of December 31, 2000.

60

Description of Capital Stock

The following summary of our capital stock and some of the provisions of our certificate of incorporation and other agreements to which we and our stockholders are parties, is not intended to be complete and is qualified by reference to our certificate of incorporation and any other agreements included as exhibits to the registration statement of which this prospectus is a part. See "Where You Can Find More Information."

Common Stock

As of December 31, 2000, there were 21,968,149 shares of common stock outstanding, as adjusted to reflect the conversion of all outstanding shares of Series A convertible preferred stock and Series B convertible preferred stock, held of record by 60 stockholders. Options to purchase 1,313,818 shares of common stock were also outstanding. Upon the closing of this offering, there will be 29,253,863 shares of common stock outstanding, including the 285,714 shares to be purchased directly by Genentech and the 285,714 shares to be purchased by Medarex in a concurrent private placement, and assuming no exercise of the underwriter's overallotment option and excluding exercise of outstanding options under our stock option plans.

The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Subject to preferences that may be applicable to any outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available for that purpose. In the event of liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to the prior distribution rights of any outstanding preferred stock. The common stock has no preemptive or conversion rights or other subscription rights. The outstanding shares of common stock are, and the shares of common stock to be issued upon completion of this offering will be, fully paid and non-assessable.

Preferred Stock

Upon the closing of the offering, all outstanding shares of preferred stock will be converted into 17,387,072 shares of common stock and automatically retired. Thereafter, the board of directors will have the authority, without further action by the stockholders, to issue up to 5,000,000 shares of preferred stock, in one or more series. The board of directors will also have the authority to designate the rights, preferences, privileges and restrictions of each such series, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series.

The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of us without further action by the stockholders. The issuance of preferred stock with voting and conversion rights may also adversely affect the voting power of the holders of common stock. In certain circumstances, an issuance of preferred stock could have the effect of decreasing the market price of the common stock. As of the closing of the offering, no shares of preferred stock will be outstanding. We currently have no plans to issue any shares of preferred stock.

Registration Rights

The holders of 21,112,786 shares of common stock, assuming the conversion of all outstanding preferred stock upon the closing of this offering, are entitled to certain rights with respect to the registration of such shares under the Securities Act. These rights are provided under the terms of an agreement between us and the holders of these securities. Subject to limitations in the agreement, the holders of at least 40% of these securities then outstanding may require, on two occasions beginning six months after the date of this prospectus, that we use our best efforts to register these securities for public resale if Form S-3 is not

61

available. If we register any of our common stock either for our own account or for the account of other security holders, the holders of these securities are entitled to include their shares of common stock in that registration, subject to the ability of the underwriters to limit the number of shares included in the offering. The holders of these securities then outstanding may also require us, not more than twice in any twelve month period, to register all or a portion of these securities on Form S-3 when the use of that form becomes available to us, provided, among other limitations, that the proposed aggregate selling price, net of any underwriters' discounts or commissions, is at least \$1,000,000. We will be responsible for paying all registration expenses, and the holders selling their shares will be responsible for paying all selling expenses.

Washington and Delaware Anti-Takeover Law and Charter and Bylaw Provisions

Provisions of the Delaware General Corporation Law and our charter documents could make our acquisition and the removal of incumbent officers

and directors more difficult. These provisions are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control to negotiate with us first. We believe that the benefits of increased protection of its potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms.

We are subject to the provisions of Section 203 of Delaware General Corporation Law. In general, the statute prohibits a publicly-held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years after the date that the person became an interested stockholder unless, subject to exceptions, the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a "business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the stockholder. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns, or within three years prior, did own, 15% or more of the corporation's voting stock. These provisions may have the effect of delaying, deferring or preventing a change in control without further action by our stockholders.

Our certificate of incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders and may not be taken by written consent. Our bylaws provide that special meetings of stockholders can be called only by the board of directors, the chairman of the board, if any, the president and holders of 50% of the votes entitled to be cast at a meeting. Moreover, the business permitted to be conducted at any special meeting of stockholders is limited to the business brought before the meeting by the board of directors, the chairman of the board, if any, the president or any such 50% holder. Our bylaws set forth an advance notice procedure with regard to the nomination, other than by or at the direction of the board of directors, of candidates for election as directors and with regard to business to be brought before a meeting of stockholders.

Furthermore, the laws of the State of Washington, where our principal executive offices are located, impose restrictions on certain transactions between certain foreign corporations and significant stockholders. Chapter 23B.19 of the Washington Business Corporation Act prohibits a "target corporation," with certain exceptions, from engaging in certain "significant business transactions" with a person or group of persons who beneficially own 10% or more of the voting securities of the target corporation, or an "acquiring person," for a period of five years after such acquisition, unless the transaction or acquisition of such shares is approved by a majority of the members of the target corporation's board of directors prior to the time of acquisition. Such prohibited transactions include, among other things, a merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the acquiring person, termination of 5% or more of the employees of the target corporation as a result of the acquiring person's acquisition of 10% or more of the shares or allowing the acquiring person to receive disproportionate benefit as a stockholder. After the five-year period, a significant business transaction may take place as long

62

as it complies with certain fair price provisions of the statute. A target corporation includes a foreign corporation if:

- the corporation has a class of voting stock registered pursuant to Section 12 or 15 of the Exchange Act,
- the corporation's principal executive office is located in Washington, and
- any of (a) more than 10% of the corporation's stockholders of record are Washington residents, (b) more than 10% of its shares are owned of record by Washington residents, (c) 1,000 or more of its stockholders of record are Washington residents, (d) a majority of the corporation's employees are Washington residents or more than 1,000 Washington residents are employees of the corporation, or (e) a majority of the corporation's tangible assets are located in Washington or the corporation has more than \$50.0 million of tangible assets located in Washington.

A corporation may not opt out of this statute and, therefore, we anticipate this statute will apply to us. Depending upon whether we meet the definition of a target corporation, Chapter 23B.19 of the Washington Business Corporation Act may have the effect of delaying, deferring or preventing a change in control of Seattle Genetics.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is ChaseMellon Shareholder Services LLC. The Transfer Agent's address is 520 Pike Street, Suite 1220, Seattle, WA 98101, and telephone number is (206) 674-3030.

Nasdaq National Market Listing

Our common stock has been approved for listing on the Nasdaq National Market under the symbol "SGEN."

63

Shares Eligible for Future Sale

Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common stock in the public market could adversely affect prevailing market prices. Upon completion of this offering, we will have outstanding an aggregate of 29,253,863 shares of common stock. Of these shares, all of the shares sold through the underwriters in this offering will be freely tradable without restriction or further registration under the Securities Act, unless these shares are purchased by affiliates. The 285,714 shares sold directly to Genentech will not require further registration under the Securities Act. The remaining 21,968,149 shares of common stock held by existing stockholders and the 285,714 shares acquired by Medarex are restricted securities. Restricted securities may be sold in the public market only if registered or if they qualify for an exemption from registration under the Securities Act.

Our executive officers, directors and certain stockholders, including Medarex and Genentech, have agreed pursuant to lock-up agreements that, with limited exceptions, for a period of 180 days from the date of this prospectus, they will not sell any shares of common stock without the prior written consent of J.P. Morgan Securities Inc. Transfers that are permitted under the lock-up agreement include transfers: of bona fide gifts; to immediate family members or a trust for the benefit of immediate family members; or to the constituent or affiliated entities of a corporation, limited liability company or partnership. When considering whether to release a stockholder from the lock-up agreement, J.P. Morgan Securities Inc. will take into account many factors, including: the size and price of the proposed transaction; the daily trading volume of our common stock; the identity of the prospective seller and such entities' relationship to us; and the current market price of our common stock.

As a result of these lock-up agreements and the rules under the Securities Act, the restricted shares will be available for sale in the public market, subject to certain volume and other restrictions, as follows:

Days after the Effective Date	Number of Shares Eligible for Sale	Comment
On Effectiveness	0	Shares not locked-up and eligible for sale under Rule 144
180 days	21,968,149	Lock-up released; shares eligible for sale under Rules 144 and 701
Periodically thereafter	285,714	Shares eligible after expiration of one year holding period

Additionally, of the 1,313,818 shares that may be issued upon the exercise of options outstanding as of December 31, 2000, approximately 202,501 shares are subject to options that are exercisable 180 days after the date of this prospectus. In addition, the 285,714 shares sold directly to Genentech will be available for sale in the public market after the 180 day lock-up is released.

Registration Rights

On the date 180 days after the completion of this offering, the holders of 21,112,786 shares of our common stock will have rights to require us to register their shares under the Securities Act. Upon the effectiveness of a registration statement covering these shares, the shares would become freely tradable.

Stock Options

Immediately after this offering, we intend to file a registration statement under the Securities Act covering approximately 11,622,423 shares of common stock under our stock option and employee stock purchase plans. We expect the registration statement to be filed and become effective as soon as practicable after the closing of this offering. Accordingly, shares registered under such registration statement will be available for sale in the open market after the effectiveness of the registration statement, unless they are held by persons that have signed a lock-up agreement described in the "Underwriting" section below.

Underwriting

J.P. Morgan Securities Inc. is acting as sole book running lead manager for this offering. J.P. Morgan Securities Inc. and CIBC World Markets Corp. are acting as joint lead managers for this offering.

We and the underwriters named below have entered into an underwriting agreement covering the common stock to be offered in this offering. J.P. Morgan Securities Inc., CIBC World Markets Corp. and Banc of America Securities LLC are acting as representatives of the underwriters. Each underwriter has agreed to purchase the number of shares of common stock set forth opposite its name in the following table.

	Number of Shares
Underwriters	
J.P. Morgan Securities Inc.	2,551,429
CIBC World Markets Corp.	2,232,500
Banc of America Securities LLC	1,594,643
A.G. Edwards & Sons, Inc.	167,857
Ragen MacKenzie Incorporated	167,857
Total	6,714,286

The underwriting agreement provides that if the underwriters take any of the shares presented in the table above, then they must take all of these shares. No underwriter is obligated to take any shares allocated to a defaulting underwriter except under limited circumstances.

The underwriters are offering the shares of common stock, excluding the shares of common stock that we are offering directly to Genentech, Inc. and Medarex, Inc., subject to the prior sale of shares, and when, as and if such shares are delivered to and accepted by them. The underwriters will initially offer to sell shares to the public at the initial public offering price shown on the cover page of this prospectus. The underwriters may sell shares to securities dealers at a discount of up to \$0.29 per share from the initial public offering price. Any such securities dealers may resell shares to certain other brokers or dealers at a discount of up to \$0.10 per share from the initial public offering price. After the initial public offering, the underwriters may vary the public offering price and other selling terms.

If the underwriters sell more shares than the total number shown in the table above, the underwriters have the option to buy up to an additional

1,007,143 shares of common stock from us to cover such sales. They may exercise this option during the 30-day period from the date of this prospectus. If any shares are purchased with this option, the underwriters will purchase shares in approximately the same proportion as shown in the table above.

The following table shows the per share and total underwriting discounts and commissions that we will pay to the underwriters. These amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. We will not pay any underwriting discount or commission to the underwriters for the 285,714 shares that may be issued to Genentech, Inc. directly by us pursuant to an agreement we have with them.

	No Exercise	Full Exercise
Per share	\$ 0.49	\$ 0.49
Total	\$ 3,290,000	\$ 3,783,500

The representatives have advised us that, on behalf of the underwriters, they may make short sales of our common stock in connection with this offering, resulting in the sale by the underwriters of a greater number of shares than they are required to purchase pursuant to the underwriting agreement. The short position resulting from those short sales will be deemed a "covered" short position to the extent that it does not

65

exceed the 1,007,143 shares subject to the underwriters' over-allotment option and will be deemed a "naked" short position to the extent that it exceeds that number. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the trading price of the common stock in the open market that could adversely affect investors who purchase shares in this offering. The underwriters may reduce or close out their covered short position either by exercising the over-allotment option or by purchasing shares in the open market. In determining which of these alternatives to pursue, the underwriters will consider the price at which shares are available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option. Any "naked" short position will be closed out by purchasing shares in the open market. Similar to the other stabilizing transactions described below, open market purchases made by the underwriters to cover all or a portion of their short position may have the effect of preventing or retarding a decline in the market price of our common stock following this offering. As a result, our common stock may trade at a price that is higher than the price that otherwise might prevail in the open market.

The representatives have advised us that, pursuant to Regulation M under the Securities Act of 1933, they may engage in transactions, including stabilizing bids or the imposition of penalty bids, that may have the effect of stabilizing or maintaining the market price of the shares of common stock at a level above that which might otherwise prevail in the open market. A "stabilizing bid" is a bid for or the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A "penalty bid" is an arrangement permitting the representatives to claim the selling concession otherwise accruing to an underwriter or syndicate member in connection with the offering if the common stock originally sold by that underwriter or syndicate member is purchased by the representatives in the open market pursuant to a stabilizing bid or to cover all or part of a syndicate short position. The representatives have advised us that stabilizing bids and open market purchases may be effected on the Nasdaq National Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.

One or more of the underwriters may facilitate the marketing of this offering online directly or through one of its affiliates. In those cases, prospective investors may view offering terms and a prospectus online and, depending upon the particular underwriter, place orders online or through their financial advisors.

We estimate that the total expenses of this offering, excluding underwriting discounts, will be approximately \$1,300,000.

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933.

We and our executive officers, directors and certain stockholders have agreed that, with limited exceptions, during the period beginning from the date of this prospectus and continuing to and including the date 180 days after the date of this prospectus, none of us will, directly or indirectly, offer, sell, offer to sell, contract to sell or otherwise dispose of any shares of common stock or any of our securities which are substantially similar to the common stock, including but not limited to any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock or any such substantially similar securities or enter into any swap, option, future, forward or other agreement that transfers, in whole or in part, the economic consequence of ownership of common stock or any securities substantially similar to the common stock, other than pursuant to employee stock option plans existing on the date of this prospectus, without the prior written consent of J.P. Morgan Securities Inc.

At our request, the underwriters have reserved shares of common stock for sale to our directors, officers, employees, consultants and family members of the foregoing. We expect these persons to purchase no more than five percent of the common stock offered in this offering. The number of shares available for sale to the general public will be reduced to the extent such persons purchase such reserved shares.

It is expected that delivery of the shares will be made to investors on or about March 12, 2001.

66

There has been no public market for the common stock prior to this offering. We and the underwriters have negotiated the initial offering price. In determining the price, we and the underwriters considered a number of factors in addition to prevailing market conditions, including:

- the history of and prospects for our industry and for biotechnology
- companies generally;
-

- an assessment of our management;
- our present operations;
- our historical results of operations;
- the trend of our revenues and earnings; and
- our earnings prospects.

We and the underwriters considered these and other relevant factors in relation to the price of similar securities of generally comparable companies. Neither we nor the underwriters can assure investors that an active trading market will develop for the common stock, or that the common stock will trade in the public market at or above the initial offering price.

From time to time in the ordinary course of their respective businesses, some of the underwriters and their affiliates may in the future engage in commercial banking and/or investment banking transactions with us and our affiliates. An affiliate of Banc of America Securities LLC owns shares of our convertible preferred stock that will convert into 2,040,816 shares of common stock upon the closing of this offering, which will represent approximately 7.0% of our outstanding common stock upon completion of this offering, assuming no exercise of the underwriters' over-allotment option and excluding exercise of outstanding options under our stock option plans.

In view of the fact that persons affiliated or associated with the Banc of America Securities LLC beneficially own more than 10% of our convertible preferred stock, the offering is being conducted in accordance with Rule 2720 of the National Association of Securities Dealers, Inc. Conduct Rules which provides that the offering price to the public may not be higher than that recommended by a qualified independent underwriter who has participated in the preparation of the registration statement and prospectus and has exercised the usual standards of due diligence. J.P. Morgan Securities Inc. has agreed to serve as qualified independent underwriter and the offering price to the public is not higher than the price recommended by J.P. Morgan Securities Inc.

Plan Of Distribution

Genentech has agreed to purchase directly from us, pursuant to a license agreement, \$2.0 million of common stock at a price per share equal to the initial public offering price per share. The purchase price for such shares will be paid directly to us at or prior to the closing of the sale of the other shares offered hereby. In the event and to the extent that Genentech does not purchase such shares, the underwriters will purchase those shares on the same terms and conditions as the other shares being offered by this prospectus, and those shares will be offered to the public at the initial public offering price per share and otherwise on the same basis as the other shares offered hereby. The underwriters will not receive any fees or commissions with respect to any shares sold to Genentech pursuant to the license agreement. The number of shares available for sale to the general public in the offering will be reduced by the number of shares sold to Genentech.

Concurrent Private Placement

In February 2001, we entered into a common stock purchase agreement with Medarex, Inc., under which we agreed to sell to Medarex shares of our common stock in a private placement concurrent with and conditioned upon the sale of shares in this offering. The price of the shares in the concurrent private

67

placement will be the initial public offering price per share. The number of shares we will sell to Medarex is equal to \$2.0 million worth of common stock priced at the initial public offering price per share.

Transfer Restrictions. The shares of common stock acquired in the concurrent private placement by Medarex are restricted securities that may only be sold in the public market if registered or after the expiration of a one year holding period. In addition, Medarex has agreed not to sell, transfer, encumber or otherwise dispose of any of the shares of common stock acquired in the concurrent private placement in a public or private sale for a period of 180 days following the closing of the offering without the consent of J.P. Morgan Securities Inc.

Registration Rights. We have committed to grant Medarex registration rights relating to the shares of common stock they will purchase in the concurrent private placement. Medarex has agreed not to make any demand for, or exercise any right to, the registration of its common stock for 180 days without the consent of J.P. Morgan Securities Inc. See "Description of Capital Stock, Registration Rights."

Legal Matters

The validity of the common stock offered hereby will be passed upon for us by Venture Law Group, a Professional Corporation, Kirkland, Washington. Sonya F. Erickson, a director of Venture Law Group, is the Assistant Secretary of Seattle Genetics. As of the date of this prospectus, a director of Venture Law Group and an investment partnership affiliated with Venture Law Group own an aggregate of 204,000 shares of our common stock and 15,306 shares of our Series B convertible preferred stock, which shares of Series B convertible preferred stock will convert into 15,306 shares of our common stock upon completion of this offering. Certain legal matters in connection with this offering will be passed upon for the underwriters by Cahill Gordon & Reindel, New York, New York.

Experts

The financial statements as of December 31, 1999 and 2000, for each of the three years in the period ended December 31, 2000 and for the period from inception (January 1, 1998) to December 31, 2000 included in this prospectus have been so included in reliance on the report of

PricewaterhouseCoopers LLP, independent accountants, given on the authority of said firm as experts in auditing and accounting.

Where You Can Find More Information

We have filed with the Securities and Exchange Commission a Registration Statement on Form S-1 under the Securities Act with respect to the common stock offered hereby. This prospectus does not contain all of the information set forth in the Registration Statement and the exhibits and schedules. For further information with respect to us and the common stock offered hereby, reference is made to the Registration Statement and to the exhibits and schedules. Statements made in this prospectus concerning the contents of any document referred to herein are not necessarily complete. With respect to each such document filed as an exhibit to the Registration Statement, reference is made to the exhibit for a more complete description of the matter involved. The Registration Statement and the exhibits and schedules may be inspected without charge at the public reference facilities maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549, and at the regional offices of the Commission located at Seven World Trade Center, 13th Floor, New York, NY 10048, and the Northwestern Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of all or any part of the Registration Statement may be obtained from the SEC's offices upon payment of fees prescribed by the SEC. The SEC maintains a World Wide Web site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the site is <http://www.sec.gov>.

68

Seattle Genetics, Inc.

(a development stage company)

Index to Financial Statements

	<u>Page</u>
Report of Independent Accountants	F-2
Balance Sheets as of December 31, 1999 and 2000	F-3
Statements of Operations for the years ended December 31, 1998, 1999 and 2000 and cumulative from inception (January 1, 1998) to December 31, 2000	F-4
Statements of Stockholders' (Deficit) Equity for the years ended December 31, 1998, 1999 and 2000	F-5
Statements of Cash Flows for the years ended December 31, 1998, 1999 and 2000 and cumulative from inception (January 1, 1998) to December 31, 2000	F-6
Notes to Financial Statements	F-7

F-1

Seattle Genetics, Inc.

Report of Independent Accountants

To the Board of Directors
and Stockholders of
Seattle Genetics, Inc.

In our opinion, the accompanying balance sheets and the related statements of operations, of stockholders' (deficit) equity and of cash flows present fairly, in all material respects, the financial position of Seattle Genetics, Inc. (a development stage company) at December 31, 1999 and 2000, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2000 and the period from inception (January 1, 1998) to December 31, 2000 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

PricewaterhouseCoopers LLP

Seattle, Washington
January 19, 2001, except
for Note 13, as to
which the date is
February 2, 2001

Seattle Genetics, Inc.

(a development stage company)

Balance Sheets

	December 31,		Pro forma stockholders' equity at December 31, 2000
	1999	2000	
			(unaudited)
Assets			
Current assets			
Cash and cash equivalents	\$ 30,362,568	\$ 2,618,986	
Short-term investments	—	21,711,460	
Subscription notes receivable	2,545,001	—	
Interest receivable	—	279,070	
Prepaid expenses and other current assets	74,389	759,339	
	<u>32,981,958</u>	<u>25,368,855</u>	
Total current assets	32,981,958	25,368,855	
Property and equipment, net	352,255	894,304	
Other assets	28,391	189,419	
Restricted investments	—	3,421,247	
	<u>33,362,604</u>	<u>29,873,825</u>	
Total assets	\$ 33,362,604	\$ 29,873,825	
Liabilities, Mandatorily Redeemable Convertible Preferred Stock, and Stockholders' (Deficit) Equity			
Current liabilities			
Book overdraft	\$ 29,516	\$ —	
Accounts payable	90,844	141,992	
Accrued liabilities	65,910	668,698	
	<u>186,270</u>	<u>810,690</u>	
Total current liabilities	186,270	810,690	
Commitments and contingencies			
Mandatorily redeemable convertible preferred stock, \$0.001 par value, 17,450,000 shares authorized:			
Series A convertible preferred stock, 7,000,000 designated, 6,950,000 (1999 and 2000) and 0 (pro forma) shares issued and outstanding (liquidation preference of \$6,950,000 for 1999 and 2000)	6,918,187	6,924,550	
Series B convertible preferred stock, 10,500,000 designated, 10,265,304 (1999) and 10,437,072 (2000), and 0 (pro forma) shares issued and outstanding (liquidation preference of \$30,179,995 and \$30,684,992, for 1999 and 2000 respectively)	30,117,936	30,631,457	
Stockholders' (deficit) equity			
Common stock, \$0.001 par value, 30,000,000 (1999) and 100,000,000 (2000) shares authorized, 3,723,708, 4,581,077 and 21,968,149 issued and outstanding, respectively	3,723	4,581	\$ 21,968
Additional paid-in capital	1,715,663	14,798,044	52,336,664
Notes receivable from stockholders	(3,096)	(408,384)	(408,384)
Deferred stock compensation	(651,921)	(10,193,778)	(10,193,778)
Accumulated other comprehensive income	—	69,196	69,196
Deficit accumulated during the development stage	(4,924,158)	(12,762,531)	(12,762,531)
	<u>(3,859,789)</u>	<u>(8,492,872)</u>	<u>\$ 29,063,135</u>
Total stockholders' (deficit) equity	(3,859,789)	(8,492,872)	\$ 29,063,135
Total liabilities, mandatorily redeemable convertible preferred stock, and stockholders' (deficit) equity	\$ 33,362,604	\$ 29,873,825	

The accompanying notes are an integral part of these financial statements.

Seattle Genetics, Inc.

(a development stage company)

Statements of Operations

	Years ended December 31,			Cumulative
	1998	1999	2000	from inception (January 1, 1998) to December 31, 2000
Revenues				
License agreements	\$ —	\$ 1,000,000	\$ —	\$ 1,000,000
Government grants	—	—	98,632	98,632
Total revenues	—	1,000,000	98,632	1,098,632
Expenses				
Research and development (excludes noncash stock-based compensation expense of \$73,555, \$392,533, \$972,841 and \$1,438,929, respectively)	1,331,175	2,469,191	4,947,087	8,747,453
General and administrative (excludes noncash stock-based compensation expense of \$273,512, \$333,299, \$2,165,099 and \$2,771,910, respectively)	671,448	858,699	1,872,164	3,402,311
Noncash stock-based compensation expense	347,067	725,832	3,137,940	4,210,839
Total operating expenses	2,349,690	4,053,722	9,957,191	16,360,603
Loss from operations	(2,349,690)	(3,053,722)	(9,858,559)	(15,261,971)
Investment income, net	243,212	236,042	2,020,186	2,499,440
Net loss	(2,106,478)	(2,817,680)	(7,838,373)	(12,762,531)
Deemed dividend upon issuance of Series B mandatorily redeemable preferred stock in April 2000	—	—	(484,386)	
Accretion on mandatorily redeemable preferred stock	(4,772)	(6,363)	(19,520)	
Net loss attributable to common stockholders	\$ (2,111,250)	\$ (2,824,043)	\$ (8,342,279)	
Basic and diluted net loss per share	\$ (0.94)	\$ (1.03)	\$ (2.54)	
Weighted-average shares used in computing basic and diluted net loss per share	2,235,997	2,749,212	3,289,731	
Pro forma basic and diluted net loss per share			\$ (0.38)	
Weighted-average shares used in computing pro forma basic and diluted net loss per share			20,627,995	

The accompanying notes are an integral part of these financial statements.

F-4

Seattle Genetics, Inc.

(a development stage company)

Statements of Stockholders' (Deficit) Equity

	Common stock		Additional paid-in capital	Notes receivable from stockholders	Deferred stock compensation	Accumulated other comprehensive gain (loss)	Deficit accumulated during the development stage	Total stockholders' (deficit) equity
	Shares	Amount						
Issuance of common stock in December 1997 at \$0.001 per share in exchange for notes receivable	3,096,000	\$ 3,096	\$ —	\$ (3,096)	\$ —	\$ —	\$ —	\$ —
Issuance of common stock in December 1997 at \$0.001 per share for cash	584,000	584	—	—	—	—	—	584
Issuance of common stock for employee bonus in October 1998 at \$0.001 per share	5,500	5	8,135	—	—	—	—	8,140

Deferred stock compensation related to grants of stock options	—	—	848,525	—	(848,525)	—	—	—
Amortization of deferred stock compensation	—	—	—	—	338,927	—	—	338,927
Accretion on mandatorily redeemable preferred stock	—	—	(4,772)	—	—	—	—	(4,772)
Net loss and comprehensive loss	—	—	—	—	—	—	(2,106,478)	(2,106,478)
Balances at December 31, 1998	3,685,500	3,685	851,888	(3,096)	(509,598)	—	(2,106,478)	(1,763,599)
Issuance of common stock for employee bonus in May 1999 at \$0.001 per share	18,000	18	38,862	—	—	—	—	38,880
Stock option exercises	20,208	20	2,001	—	—	—	—	2,021
Deferred stock compensation related to grants of stock options	—	—	829,275	—	(829,275)	—	—	—
Amortization of deferred stock compensation	—	—	—	—	686,952	—	—	686,952
Accretion on mandatorily redeemable preferred stock	—	—	(6,363)	—	—	—	—	(6,363)
Net loss and comprehensive loss	—	—	—	—	—	—	(2,817,680)	(2,817,680)
Balances at December 31, 1999	3,723,708	3,723	1,715,663	(3,096)	(651,921)	—	(4,924,158)	(3,859,789)
Deemed dividend upon issuance of Series B mandatorily redeemable preferred stock	—	—	484,386	—	—	—	—	484,386
Deemed dividend upon issuance of Series B mandatorily redeemable preferred stock	—	—	(484,386)	—	—	—	—	(484,386)
Stock option exercises	857,369	858	422,104	(405,288)	—	—	—	17,674
Deferred stock compensation related to grants of stock options	—	—	12,679,797	—	(12,679,797)	—	—	—
Amortization of deferred stock compensation	—	—	—	—	3,137,940	—	—	3,137,940
Accretion on mandatorily redeemable preferred stock	—	—	(19,520)	—	—	—	—	(19,520)
Unrealized gain on short-term investments	—	—	—	—	—	69,196	—	69,196
Net loss	—	—	—	—	—	—	(7,838,373)	(7,838,373)
Comprehensive loss	—	—	—	—	—	—	—	(7,769,177)
Balances at December 31, 2000	4,581,077	\$ 4,581	\$ 14,798,044	\$ (408,384)	\$ (10,193,778)	\$ 69,196	\$ (12,762,531)	\$ (8,492,872)

The accompanying notes are an integral part of these financial statements.

F-5

Seattle Genetics, Inc.

(a development stage company)

Statements of Cash Flows

	Years Ended December 31,			Cumulative from inception (January 1, 1998) to December 31, 2000
	1998	1999	2000	
Cash flows from operating activities				
Net loss	\$ (2,106,478)	\$ (2,817,680)	\$ (7,838,373)	\$ (12,762,531)
Adjustments to reconcile net loss to net cash used in operating activities				
Amortization of deferred compensation	338,927	686,952	3,137,940	4,163,819
Depreciation	36,600	122,560	186,548	345,708
Realized loss on sale of securities	—	—	6,747	6,747
Amortization/accretion on securities available for sale	—	—	(49,714)	(49,714)
Common stock bonus provided to employees	8,140	38,880	—	47,020
Change in operating assets and liabilities				
Interest receivable	—	—	(279,070)	(279,070)
Prepaid expenses and other assets	(18,071)	(84,709)	(289,214)	(391,994)
Accounts payable	43,325	47,519	51,148	141,992
Accrued liabilities	39,275	26,635	602,788	668,698
Net cash used in operating activities	(1,658,282)	(1,979,843)	(4,471,200)	(8,109,325)

Cash flows from investing activities				
Purchases of investments			(30,108,959)	(30,108,959)
Proceeds from sale and maturities of investments			5,088,414	5,088,414
Purchase of property and equipment	(384,803)	(126,612)	(728,597)	(1,240,012)
Net cash used in investing activities	(384,803)	(126,612)	(25,749,142)	(26,260,557)
Cash flows from financing activities				
Proceeds from issuance of common stock	584	2,021	17,674	20,279
Net proceeds from issuance of Series A preferred stock	6,907,052			6,907,052
Proceeds from subscription receivable			2,545,001	2,545,001
Net proceeds from issuance of Series B preferred stock		27,572,935	500,364	28,073,299
Prepaid public offering costs			(556,763)	(556,763)
Book overdraft		29,516	(29,516)	
Net cash provided by financing activities	6,907,636	27,604,472	2,476,760	36,988,868
Net increase (decrease) in cash and cash equivalents	4,864,551	25,498,017	(27,743,582)	2,618,986
Cash and cash equivalents, at beginning of year	—	4,864,551	30,362,568	
Cash and cash equivalents, at end of year	\$ 4,864,551	\$ 30,362,568	\$ 2,618,986	\$ 2,618,986
Supplemental disclosure of cash information				
Non-cash investing and financing activities				
Issuance of common stock in exchange for notes receivable	\$ 3,096	\$ —	\$ 405,288	\$ 408,384
Issuance of Series B preferred stock for subscription notes receivable	\$ —	\$ 2,545,001	\$ —	\$ 2,545,001

The accompanying notes are an integral part of these financial statements.

F-6

Seattle Genetics, Inc.

(a development stage company)

Notes to Financial Statements

1. Organization and summary of significant accounting policies

Nature of business

Seattle Genetics, Inc., the Company, was incorporated in the State of Delaware on July 15, 1997 for the purpose of discovering and developing monoclonal antibody-based drugs to treat cancer and related diseases. The Company's four monoclonal antibody-based technologies include: monoclonal antibodies, antibody drug conjugates, single chain immunotoxins and antibody-directed enzyme pro-drug therapy. The Company is considered to be a development stage company because the Company is engaged primarily in research, recruiting personnel and raising capital.

Although the Company was incorporated in July 1997, virtually no costs were incurred prior to 1998. Accordingly, for purposes of these financial statements, January 1, 1998 was utilized as the date of inception.

Cash and cash equivalents

The Company generally considers all highly liquid investments purchased with original or remaining maturities of three months or less at the date of purchase to be cash equivalents.

Investments

Investments in securities with maturities of less than one year or where management's intent is to use the investments to fund current operations are classified as short-term investments. Management classifies, at the date of acquisition, its marketable securities into categories in accordance with the provisions of Statement of Financial Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities." Currently, the Company classifies its securities as available-for-sale which are reported at fair market value with the related unrealized gains and losses included as a separate component in stockholders' (deficit) equity. Realized gains and losses and declines in value of securities judged to be other than temporary are included in other income (expense). Cost of investments for purposes of computing realized and unrealized gains and losses are based on the specific identification method.

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Interest and dividends on all securities are included in interest income.

The Company's short-term investments are diversified among high-credit quality securities in accordance with the Company's investment policy.

Restricted investments

Restricted investments consist of money market accounts backed by U.S. government securities and U.S. government agencies. These investments are carried at fair value, and are restricted as to withdrawal in accordance with the lease of the Company's facility to be occupied in 2001. Restricted investments are held in the Company's name with a major financial institution.

F-7

Prepaid public offering costs

In connection with its proposed public offering of common stock, the Company has capitalized \$556,763 of related costs as of December 31, 2000. These costs are included in prepaid and other current assets in the accompanying balance sheets and will be charged to common stock upon completion of the offering or, if the offering is not completed, to operations.

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and that affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made in prior years' financial statements to conform to classifications used in the current year.

Property and equipment

Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Laboratory equipment	5 years
Computer equipment	3 years
Furniture and fixtures	5 years

Tenant improvements are amortized over the shorter of the applicable lease or useful life of the asset. Gains and losses from the disposal of property and equipment will be reflected in the statement of operations in the year of disposition. Expenditures for additions and improvements are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Impairment of long-lived assets

In accordance with the provisions of Statement of Financial Accounting Standards No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of" ("SFAS No. 121"), the Company reviews long-lived assets, including intangible assets and property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. While the Company's current operating and cash flow losses are indicators of impairment, the Company believes the future cash flows to be received from the long-lived assets exceed the assets' carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2000.

F-8

Revenue recognition

Revenues from license fees and milestone payments, which are received for the delivery of rights or services, that represent the culmination of a separate earnings process are recognized when due and amounts are considered collectible. Revenues from license fees and milestones which are received in connection with other rights or services which represent continuing obligations of the Company will be deferred and recognized systematically over the period that the fees or payments are earned.

Effective June 30, 1999 the Company and Genentech, Inc. ("Genentech") entered into a development and license agreement (the "Agreement"). The Agreement provides for payments to the Company by Genentech, the transfer of information by the Company to Genentech, the license of developed products to Genentech, certain milestone payments by Genentech to the Company, the payment of royalties by Genentech to the Company and an investment in the Company's preferred stock by Genentech. The Agreement provides that the development of the acquired technology is solely the responsibility of Genentech. In addition, the Agreement provides that no tasks or costs may be assigned to the Company without the approval of the Company's representative. The Company does not anticipate that the costs or tasks will be assigned to it in the future.

Revenues to date consist primarily of amounts recognized in connection with the Company's Agreement with Genentech. Upon the granting of the rights and licenses representing the culmination of the earnings process, the Company recognized revenue in the amount of payments received. The Company has no further service obligations in connection with the delivery of rights and licenses. Future payments to be received under the Genentech Agreement will be recognized as revenue when contingencies related to those amounts have been resolved.

Research and development expenses

Research and development expenses consist of costs incurred for company sponsored as well as collaborative research and development activities. These costs include direct and overhead expenses for drug discovery and research, pre-clinical trials and, more recently, for costs

associated with clinical trial activities. Costs to acquire technologies which are utilized in research and development and which have no alternative future use are expensed when incurred. Research and development expenses under government grants approximate the revenue recognized under such agreements.

Patent costs

Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.

Fair value of financial instruments

Recorded amounts for cash and cash equivalents, accounts payable and accrued liabilities approximate fair value because of the short-term nature of these instruments.

F-9

Concentration of credit risk

Cash and cash equivalents are invested in deposits with a major brokerage firm. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the brokerage firm is financially sound and, accordingly, minimal credit risk exists. The Company invests its excess cash in accordance with its investment policy, which is approved by the Board of Directors and reviewed periodically to minimize credit risk.

Income taxes

The Company provides for deferred income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is more likely than not that the net deferred tax asset will not be recovered.

Stock-based compensation

The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of Accounting Principles Board Opinion No. 25 ("APB No. 25"), *Accounting for Stock Issued to Employees* and complies with the disclosure provisions of Statement of Financial Accounting Standards No. 123 ("SFAS No. 123"), *Accounting for Stock-Based Compensation*. Under APB No. 25, compensation expense is based on the excess, if any, of the estimated fair value of the Company's stock at the date of grant over the exercise price of the option. Deferred compensation is being amortized in accordance with Financial Accounting Standards Board Interpretation No. 28 on an accelerated basis over the vesting period of the individual options. The Company accounts for equity instruments issued to nonemployees in accordance with the provisions of SFAS No. 123 and consensus of the Emerging Issues Task Force number 96-18.

Comprehensive income/loss

The Company has adopted the provisions of Statement of Financial Accounting Standards No. 130, "Reporting Comprehensive Income" (SFAS No. 130) effective January 1, 1998. SFAS No. 130, requires the disclosure of comprehensive income and its components in the financial statements. Comprehensive income is the change in stockholders' (deficit) equity from transactions and other events and circumstances other than those resulting from investments by owners and distributions to owners.

Segment reporting

Effective January 1998, the Company adopted Statement of Financial Accounting Standards No. 131, "Disclosure about Segments of an Enterprise and Related Information" ("SFAS No. 131"). SFAS No. 131 establishes annual and interim reporting standards for an enterprise's operating segments and related disclosures about its products, services, geographic areas, and major customers. The Company has determined that it operates in only one segment.

F-10

Recent accounting pronouncements

In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 133 (SFAS No. 133), *Accounting for Derivative Financial Instruments and for Hedging Activities*, which provides a standard for the recognition and measurement of derivatives and hedging activities. SFAS No. 133 is effective for fiscal years beginning after June 15, 2000 and will not have an impact on the Company's results of operations or financial condition when adopted because the Company holds no derivative financial instruments and does not currently engage in hedging activities.

In December 1999, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 101 (SAB 101), *Revenue Recognition*, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements filed with the SEC. SAB 101 outlines the basic criteria that must be met to recognize revenue and provides guidance for disclosures related to revenue recognition policies. Management believes that the Company's revenue recognition policies are in accordance with the provisions of SAB 101.

In March 2000, the Financial Accounting Standards Board issued Interpretation No. 44 (FIN No. 44), "Accounting for Certain Transactions Involving Stock Compensation," an interpretation of the Accounting Principles Board Opinion 25 (APB 25). Among other things, this interpretation clarifies the definition of "employee" for purposes of applying APB 25, "Accounting for Stock Issued to Employees," the criteria for determining whether a plan qualifies as a noncompensatory plan, and the accounting for an exchange of stock compensation awards in a business combination. This interpretation is effective July 1, 2000, but certain conclusions in this interpretation cover specific events that occur after either December 15, 1998 or January 12, 2000. The adoption of FIN No. 44 did not have a material impact on the Company's financial position or results of operations.

Unaudited pro forma stockholders' equity

Upon the closing of the Company's initial public offering, all of the mandatorily redeemable convertible preferred stock outstanding will automatically be converted into common stock on a one-to-one basis. The unaudited pro forma stockholders' equity presented on the balance sheet reflects the effect of such conversion.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period, less the weighted-average number of unvested shares of common stock issued that are subject to repurchase. The Company has excluded all convertible preferred stock, outstanding options to purchase common stock and common stock subject to repurchase from the calculation of diluted net loss per share, as such securities are antidilutive for all periods presented. Basic and diluted pro forma net loss per share, as presented in the statements of operations, has been computed as described above and also gives effect to the conversion of the convertible preferred stock (using the if-converted method) from the original date of issuance.

F-11

The following table presents the calculation of basic and diluted and pro forma basic and diluted (unaudited) net loss per share:

	Years ended December 31,		
	1998	1999	2000
Net loss attributable to common stockholders	\$ (2,111,250)	\$ (2,824,043)	\$ (8,342,279)
Basic and diluted			
Weighted-average shares used in computing basic and diluted net loss per share	2,235,997	2,749,212	3,289,731
Basic and diluted net loss per share	\$ (0.94)	\$ (1.03)	\$ (2.54)
Pro forma (unaudited)			
Net loss attributable to common stockholders as above			\$ (8,342,279)
Pro forma adjustment for deemed dividend			484,386
Pro forma adjustment for accretion on mandatorily redeemable preferred stock			19,520
Pro forma net loss attributable to common stockholders			\$ (7,838,373)
Shares used above			3,289,731
Pro forma adjustment to reflect weighted-average effect of assumed conversion of convertible preferred stock			17,338,264
Weighted-average shares used in computing pro forma basic and diluted net loss per common share			20,627,995
Pro forma basic and diluted net loss per common share			\$ (0.38)
Antidilutive securities not included in net loss per share calculation			
Convertible preferred stock	6,950,000	17,215,304	17,387,072
Options to purchase common stock	367,500	618,000	1,313,818
Unvested shares of common stock subject to repurchase	1,192,917	717,917	870,522
	8,510,417	18,551,221	19,571,412

F-12

2. Investments

The following table summarize the Company's investments in securities at December 31, 2000:

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Mortgage-backed securities	\$ 8,641,351	\$ 25,364	\$ (13,297)	\$ 8,653,418
U.S. corporate obligations	7,897,028	34,499	—	7,931,527
U.S. government securities and agencies	8,525,132	23,386	(756)	8,547,762
Total	\$ 25,063,511	\$ 83,249	\$ (14,053)	\$ 25,132,707
Reported as:				
Short-term investments				\$ 21,711,460
Restricted investments				3,421,247
Total				\$ 25,132,707

At December 31, 2000, investments, excluding mortgage backed securities, had scheduled maturities within one to two years.

3. Prepaid expenses and other current assets

Prepaid expenses and other current assets consists of the following at December 31:

	1999	2000
Prepaid public offering costs	\$ —	\$ 556,763
Prepaid rent	—	44,764
Prepaid insurance	11,667	11,656
Prepaid license agreements	41,250	35,417
Prepaid service contracts	12,063	43,947
Prepaid employee benefits	8,222	26,093
Other	1,187	40,699
	\$ 74,389	\$ 759,339

F-13

4. Property and equipment

Property and equipment consists of the following at December 31:

	1999	2000
Laboratory equipment	\$ 352,076	\$ 799,486
Computer equipment and purchased software	106,870	355,190
Furniture and fixtures	52,469	64,650
Tenant Improvements	—	20,686
	511,415	1,240,012
Less: Accumulated depreciation	(159,160)	(345,708)
	\$ 352,255	\$ 894,304

5. Accrued liabilities

Accrued liabilities consists of the following at December 31:

	1999	2000
Professional services	\$ —	\$ 258,394
License agreement	—	200,000
Clinical trial costs	41,742	125,746
Compensation and benefits	16,795	53,038
Use tax	7,373	19,128
Other	—	12,392

	\$ 65,910	\$ 668,698
--	-----------	------------

6. Income taxes

The difference between the income tax benefit and the amount calculated based on the statutory federal tax rate of 34% is primarily due to the tax benefits of net operating losses being offset by a valuation allowance.

At December 31, 2000, for income tax reporting purposes, the Company had federal net operating loss carryforwards of approximately \$8,177,000, which will begin to expire, if not previously utilized, in 2019. A valuation allowance has been recorded for the entire net deferred tax asset as a result of uncertainties regarding realization of the asset, including the limited operating history of the Company, the lack of profitability to date and the uncertainty over future operating profitability. The Internal Revenue Code contains provisions which may limit the net operating loss carryforwards available to be used in any given year if certain changes in ownership interest occur.

F-14

The effects of temporary differences and carryforwards that give rise to deferred tax assets and liabilities at December 31 are as follows:

	1999	2000
Deferred tax assets		
Net operating loss carryforwards	\$ 1,143,000	\$ 2,780,000
License fees	188,000	172,000
Other	2,000	385,000
	1,333,000	3,337,000
Deferred tax liabilities		
Depreciation	(16,000)	(40,000)
	1,317,000	3,297,000
Less: Valuation allowance	(1,317,000)	(3,297,000)
Net deferred tax asset	\$ —	\$ —

7. Commitments and contingencies

During 1998, the Company was leasing its office space on a month-to-month basis.

During 1999, the Company entered into an operating lease for 15,000 square feet of office and laboratory space. The lease has an initial term to February 2002 with two, one-year renewal periods at the Company's option.

In December 2000 the Company entered into an operating lease for 63,900 square feet of office and laboratory space. The lease provides for monthly lease payments to commence in June 2001. The initial lease term is ten years with two, seven year renewal options, subject to certain conditions. The lessor has committed to fund up to \$6.4 million of improvements to the building.

As part of this lease transaction, the Company has restricted \$3.4 million of its investments as collateral for certain obligations of the lease. These investment securities are restricted as to withdrawal and are managed by a third party. The lease terms provide for decreases in the amounts pledged based upon the Company's net worth, as defined, and decreases commencing in the fourth year of the lease.

Additionally, the Company has entered into lease obligations through 2005 for office equipment.

F-15

Future annual minimum lease payments under all noncancelable operating leases are as follows:

Years ending December 31,	
2001	\$ 1,672,625
2002	2,007,900
2003	2,002,234
2004	2,042,113
2005	2,081,409
Thereafter	11,974,000

Rent expense totaled \$47,233, \$542,139, \$544,190 and \$1,133,562 for years ended 1998, 1999, 2000 and for the period from inception (January 1, 1998) to December 31, 2000, respectively.

In March 1998, the Company entered into a license agreement with Bristol-Myers Squibb Company for the use of certain patented and proprietary licensed technology including rights to 24 different patents, eight monoclonal antibodies, chemical linkers, a ribosome-inactivating protein and enabling technologies. Unless otherwise terminated, as provided for in the agreement, the agreement will continue on a country by country basis until the later of a specified number of years after the first commercial sale in such country, depending on the particular patent or the expiration of the last to expire patent right in the country in question. Under the terms of the agreement, the Company was required to make an initial payment for the licensed technology, which has been recorded as a research and development expense because the technologies are utilized in the Company's research and development activities and do not have alternative future uses. In addition, the Company will be required to make royalty payments based on the net sales of each product, depending upon the technology used in the product. In addition, the Company has sublicensed rights to single-chain antigen binding molecules from Enzon, Inc. on a semi-exclusive basis subject to the rights of several existing Enzon licensees, as well as the Company's obligation to make biannual payments to maintain this semi-exclusivity through 2003. Under the terms of the Company's sublicense with Enzon, the Company is also required to make milestone payments and pay royalties on net sales of products incorporating technology sublicensed from Enzon. The Company's obligation to pay royalties under this agreement terminates on a country-by-country basis upon the last to expire of the licensed patents in such country. The agreement is also subject to earlier termination if either party breaches its material obligations thereunder.

The Company has also entered into licensing or contract manufacturing arrangements with Creative BioMolecules, Inc., Mabtech AB, University of Miami, Brookhaven Science Associates LLC, the Public Health Service, Arizona State University and ICOS Corporation. The Company's obligation to pay royalties to Mabtech AB and University of Miami terminate upon a specified number of years after the first commercial sale of a product incorporating their respective technologies. The Company's obligation to pay royalties to Creative BioMolecules, Inc., Brookhaven Science Associates LLC, the Public Health Service and Arizona State University terminate upon the last to expire of their respective licensed patents. The Company may terminate the ICOS agreement upon sixty days' notice and by the payment of reasonable expenses incurred. These arrangements are subject to early termination if either party breaches its material

F-16

obligations thereunder. License and contract manufacturing payments will aggregate to approximately \$4,000,000 in 2001 and will range from \$5,000 to \$100,000, individually, over the following four years depending on dates of FDA approvals and performance under the agreements. Furthermore, the agreements also provide for payments upon the achievement of certain milestones and the payment of royalties based on commercial product sales.

8. Stockholders' (deficit) equity

Restricted common stock

In December 1997, the Company issued 3,440,000 shares of common stock to its founders, in exchange for cash and full recourse notes receivable, subject to a repurchase option. The notes bear interest at an annual rate of 5.6% and matured on December 17, 1999. The notes were extended for another year and were paid in January 2001.

Also in December 1997, the Company issued 240,000 shares of common stock to certain of its employees and consultants, subject to a repurchase option. In the event of a termination of employment or consulting relationship with the Company for any reason, the Company has the exclusive option, for a period of 60 days following the termination of the relationship, to repurchase all or any portion of the shares held by the founders or certain employees and consultants which have not been released from the repurchase option, at the original purchase price. The number of shares subject to the repurchase option, and the related vesting, is detailed in each stock purchase agreement, with the vesting generally over a four-year period.

In addition, in the event of a proposed sale of all or substantially all of the assets of the Company, or the merger of the Company with or into another company, in which there is an involuntary termination of the stockholders' employment or consulting relationship within one year of the change in control, the repurchase option will be removed from all remaining shares of common stock. At December 31, 1999 and 2000, there were 717,917 and 870,522 shares of common stock outstanding subject to the Company's repurchase option, respectively.

In December 1999, the Company also amended its articles of incorporation to increase the authorized amount of common stock to 30,000,000 shares and to increase the authorized amount of preferred stock to 17,450,000 shares, whereby Series A convertible preferred stock shall consist of 6,950,000 shares authorized and Series B convertible preferred stock of 10,500,000 shares authorized.

On November 16, 2000, the Company's Board of Directors passed resolutions as follows:

- Authorizing the officers of the Company to undertake a firm commitment underwritten public offering of shares of the Company's common stock.
- Amending and restating the Company's certificate of incorporation to authorize 100,000,000 shares of Common Stock and undesignated Preferred Stock consisting of 5,000,000 shares, subject to shareholder approval.

F-17

Stock bonus plan

In December 1997, the Company's Board of Directors approved the 1998 Employee Stock Bonus Plan (the Bonus Plan) to provide incentives to employees of the Company, to encourage such employees to remain employed by the Company and to encourage employee stock ownership in the Company. The Bonus Plan was amended as of May 28, 1999 to the extent that 23,500 shares have now been reserved for issuance, which, when granted, are subject to the Company's right of first refusal upon later sale of the stock. During 1998 and 1999, the Company granted 5,500 and 18,000 shares of stock to its employees, respectively, which was recorded as compensation expense based on the estimated fair value of the stock on the date of grant.

2000 Employee Stock Purchase Plan

The Company's 2000 employee stock purchase plan was adopted by the board of directors in November 2000 and will be submitted for approval by the Company's stockholders prior to completion of the Company's initial public offering and will terminate in 2010. A total of 300,000 shares of common stock has been reserved for issuance under the 2000 purchase plan, none of which have been issued as of December 31, 2000. The number of shares reserved for issuance under the 2000 purchase plan will be subject to an automatic annual increase on the first day of each of the fiscal years beginning in 2002 and ending in 2010 that is equal to the lesser of:

- 300,000 shares;
- 1% of the Company's outstanding common stock on the last day of the immediately preceding fiscal year;
- or such lesser number of shares as the board of directors determines.

The 2000 employee stock purchase plan, which is intended to qualify under Section 423 of the Internal Revenue Code, will be implemented by a series of offering periods of approximately 24 months' duration, with new offering periods (other than the first offering period) commencing generally on February 1 and August 1 of each year. Each offering period will consist of consecutive purchase periods of approximately six months' duration. At the end of each purchase period an automatic purchase will be made for participants. The initial offering period is expected to commence on the date of this offering and end on January 31, 2003; the initial purchase period is expected to begin on the date of this offering and end on July 31, 2001. Each eligible employee will be granted an option on the effective date of this offering to purchase shares in the initial offering period in an amount equal to the maximum number of shares that an individual can purchase under the terms of the 2000 purchase plan.

F-18

9. Mandatorily redeemable convertible preferred stock

Convertible preferred stock at December 31, 2000 consists of the following:

Series	Shares			Amount, net of unamortized issuance cost
	Designated	Outstanding	Liquidation amount	
A	6,950,000	6,950,000	\$ 6,950,000	\$ 6,924,550
B	10,500,000	10,437,072	30,684,992	30,631,457
	17,450,000	17,387,072	\$ 37,634,992	\$ 37,556,007

The holders of Series A and Series B convertible preferred stock are entitled to receive noncumulative dividends when, as and if declared by the Board of Directors, at the rate of 8% per share per annum of the original issue price and in preference to any dividends declared and paid on common stock. The original issue price of Series A and Series B convertible preferred stock is \$1.00 and \$2.94, respectively. As of December 31, 1999 and 2000, no dividends have been declared or paid.

In the event of liquidation or dissolution of the Company, the holders of Series A and Series B preferred stock are entitled to receive a distribution amount prior to and in preference to holders of common stock equal to the sum of \$1.00 and \$2.94 per share, respectively, plus declared but unpaid dividends. The remaining assets of the Company shall be distributed pro-rata among the holders of Series A and Series B convertible preferred stock and the holders of common stock based upon the number of common shares held by each, assuming conversion of all Series A and Series B preferred stock into common stock, until the holders of Series A and Series B preferred stock shall have received an aggregate of \$2.00 and \$5.88 per share including amounts paid above, respectively, and, thereafter, the remaining assets will be distributed pro rata among the holders of common stock.

Each share of Series A and Series B preferred stock is convertible into common stock at the option of the holder on a one-for-one basis, subject to adjustment in certain instances. Such conversion is automatic upon the closing of a public offering of the Company's common stock having aggregate gross proceeds of at least \$20,000,000 and at a purchase price of not less than \$7.35 per share (as adjusted to reflect stock splits, stock dividends, or other recapitalizations). Each share of Series A and Series B convertible preferred stock will also automatically convert upon the election or written consent of a majority of the holders of Series A and Series B convertible preferred stock, voting together as a single class, provided that such majority vote must include the consent of the holders of a majority of the then outstanding Series B convertible preferred stock.

The holder of each share of Series A or Series B convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock, into which each share of Preferred Stock is convertible, except for certain conditions as discussed in the Third Amended and Restated Certificate of Incorporation. The holders of Series A and Series B preferred stock have certain registration rights.

At any time after December 22, 2004, the Series A or Series B preferred stock will be redeemable at the election of the holders of not less than a majority of the then outstanding Series A and Series B preferred stock, voting as a single class. The preferred shares will be redeemable at a price equal to the original

F-19

purchase price of each Series plus all declared and accumulated but unpaid dividends on such shares, payable in three equal annual installments beginning on the redemption date.

The Company recorded a deemed dividend of \$484,000 in April 2000 upon the issuance of Series B convertible preferred stock. At the date of issuance, the Company believed the per share price of \$2.94 represented the fair value of the preferred stock and was in excess of the fair value of its common stock. Subsequent to the commencement of the initial public offering process, the Company re-evaluated the fair value of its common stock as of April 2000 and determined that the estimated fair value was greater than \$2.94 per share. The deemed dividend increased the loss allocable to common stockholders, in the calculation of basic net loss per share for the year ended December 31, 2000.

The issuance costs of the Series A and Series B convertible preferred stock is being amortized by periodic charges for accretion. These accretion amounts increase net loss attributable to common shareholders.

10. Stock option plan

In December 1997, the Company authorized the 1998 Stock Option Plan, the Plan, whereby 1,500,000 shares of the Company's common stock have been reserved for issuance to employees, officers, consultants and advisors of the Company. During 1999, the Company amended the Plan by increasing the total number of shares reserved under the Plan to 2,130,000. During 2000, the Company amended the Plan by increasing the total number of shares reserved under the Plan to 4,400,000 and to provide for, among other things, an annual increase in the number of reserved shares on the first day of each of the Company's fiscal years beginning in 2002 and ending in 2008. Options granted under the Plan may be either incentive stock options or nonstatutory stock options as determined by the Board of Directors. The term of the Plan is ten years.

Incentive stock options may be issued only to employees of the Company and have a maximum term of ten years from the date of grant. The exercise price for incentive stock options may not be less than 100% of the estimated fair market value of the common stock at the time of the grant. In the case of options granted to holders of more than 10% of the voting power of the Company, the exercise price may not be less than 110% of the estimated fair market value of the common stock at the time of grant, and the term of the option may not exceed five years. Options become exercisable in whole or in part from time to time as determined by the Board of Directors, which will administer the Plan.

Generally, options granted under the Plan vest 25% one year after the beginning of the vesting period and thereafter, ratably over three years.

Had the Company recorded compensation expense based on the estimated grant-date fair value consistent with the provisions of SFAS No. 123 for awards granted under the Plan during 1998, 1999 and 2000, there would have been an increase of \$1,840, \$4,540 and \$96,750 on the Company's net loss reported in 1998, 1999 and 2000, respectively. The effects on loss per share would have been increases of \$0.00, \$0.00 and \$0.03 in 1998, 1999 and 2000, respectively.

For purposes of the computation of the pro forma effects on the net loss above, the fair value of each employee option is estimated using the Black-Scholes method and using the following weighted-average assumptions: dividend yield of 0%, volatility of 0% for options granted before the Company's initial filing of

F-20

its registration statement and 70% for options granted thereafter, risk-free interest rate of 5.56% at the date of grant, and an expected life of four years. For purposes of estimating the fair value of options granted to non-employees, the same assumptions were used and the contractual lives of the options were used for expected lives.

The weighted-average fair values of options granted were as follows:

	Period from January 1, 1998 (inception) to December 31, 1998		Year ended December 31, 1999		Year ended December 31, 2000	
	Weighted- average exercise price	Weighted- average fair value	Weighted- average exercise price	Weighted- average fair value	Weighted average exercise price	Weighted average fair value
Exercise price less than market value of stock	\$ 0.10	\$ 1.15	\$ 0.10	\$ 2.09	\$ 1.90	\$ 8.21

Activity under the Plan is as follows:

Options outstanding		
Shares available for grant	Number of shares	Weighted- average exercise price

Shares reserved at Plan inception	1,500,000	—	—
Options granted	(367,500)	367,500	\$ 0.10
Balances, December 31, 1998	1,132,500	367,500	\$ 0.10
Additional shares reserved	630,000	—	—
Options granted	(323,000)	323,000	\$ 0.10
Options exercised	—	(20,208)	\$ 0.10
Options forfeited	52,292	(52,292)	\$ 0.10
Balances, December 31, 1999	1,491,792	618,000	\$ 0.10
Additional shares reserved	2,270,000	—	—
Options granted	(1,630,500)	1,630,500	\$ 1.90
Options exercised	—	(857,369)	\$ 0.49
Options forfeited	77,313	(77,313)	\$ 0.19
Balances, December 31, 2000	2,208,605	1,313,818	\$ 2.07

F-21

The following table summarizes information about all stock options outstanding at December 31, 2000:

Options outstanding				Options exercisable	
Exercise price	Number of shares	Weighted-average remaining contractual life	Weighted-average exercise price	Number exercisable	Weighted-average exercise price
\$ 0.10	272,818	7.80 years	\$ 0.10	86,976	\$ 0.10
\$ 0.29	269,500	9.55	\$ 0.29	0	0
\$ 3.00	620,500	9.84	\$ 3.00	0	0
\$ 5.00	151,000	9.98	\$ 5.00	0	0
	1,313,818	9.37	\$ 2.07	86,976	\$ 0.10

2000 Directors' Stock Option Plan

The 2000 directors' stock option plan was adopted by the board of directors in November 2000 and has been submitted for approval by the Company's stockholders. It will become effective upon the date of the Company's initial public offering. A total of 400,000 shares of common stock have been reserved for issuance under the 2000 directors' plan, all of which remain available for future grants.

The directors' plan provides that each person who is a non-employee director on the date of the Company's initial public offering and who has not previously been granted a stock option by the Company, will be granted a nonstatutory stock option to purchase 25,000 shares of common stock on the date of this offering. The plan further provides that each person who becomes a non-employee director after the completion of the Company's initial public offering will be granted a nonstatutory stock option to purchase 25,000 shares of common stock on the date on which such individual first becomes a member of the board of directors. Each initial option shall vest at the rate of 25% of the total number of shares subject to such option twelve months after the date of grant with the remaining shares vesting thereafter in equal monthly installments. Thereafter, on the dates of each annual stockholder meeting, each non-employee director who has been a member of the board of directors for at least six months will be granted a nonstatutory stock option to purchase 5,000 shares of common stock. Each annual option shall vest at the rate of 100% of the total number of shares subject to such option on the day before the one-year anniversary of the grant date.

All options granted under the directors' plan will have a term of 10 years and an exercise price equal to the fair market value on the date of grant.

11. Related party transactions

In June 1999, the Company entered into a development and license agreement with Genentech and received \$1,000,000 for sale of the right to use certain of the Company's proprietary antibodies. The development and licensing agreement provides for additional payments of up to \$61.0 million to the Company upon the achievement of milestones, includes a right of first refusal and noncompetition provisions with respect to certain of the Company's technology, and provides for royalties on the eventual sale of covered products. Genentech has the option under certain circumstances to license certain of the Company's proprietary

F-22

antibodies. This agreement is subject to termination by Genentech upon 90 days notice or by either party if the other party enters bankruptcy or breaches its material obligations. Genentech became a related party in December 1999 due to its investment in the Company's Series B convertible preferred stock.

12. Employee benefit plan

In July 1998, the Company's Board of Directors approved the adoption of a 401(k) Plan for all of its employees. The Plan will allow eligible employees to defer up to 15%, but no greater than \$10,000, of their pretax compensation at the discretion of the employee. The Plan does not provide for Company matching of employee contributions.

13. Subsequent event

In February 2001, the Company entered into a collaboration agreement with Medarex, Inc. to produce fully human monoclonal antibodies to certain breast cancer and melanoma antigen targets in order to develop and commercialize monoclonal antibody-based products. The agreement calls for joint development of at least half of Seattle Genetics' breast cancer antigens and a specific melanoma antigen which are identified by Seattle Genetics over the next three years. Under the terms of the agreement there will be sharing of all development, manufacturing, and clinical costs of jointly developed products and of net profits and losses. Each party has the right to opt out of the joint development of any antigen target and receive instead certain milestone and royalty payments. The agreement is subject to termination if either side breaches its material obligations thereunder.

F-23

SEATTLE GENETICS LOGO



QuickLinks

[Table of Contents](#)
[Prospectus Summary](#)
[Seattle Genetics, Inc.](#)
[The Offering](#)
[Summary Financial Data](#)
[Risk Factors](#)
[Special Note Regarding Forward-Looking Statements](#)
[About This Prospectus](#)
[Use of Proceeds](#)
[Dividend Policy](#)
[Capitalization](#)
[Dilution](#)
[Selected Financial Data](#)
[Management's Discussion and Analysis of Financial Condition and Results of Operations](#)
[Business](#)
[Management](#)
[Transactions with Executive Officers, Directors and Five Percent Stockholders](#)
[Principal Stockholders](#)
[Description of Capital Stock](#)
[Shares Eligible for Future Sale](#)
[Underwriting](#)
[Plan Of Distribution](#)
[Concurrent Private Placement](#)
[Legal Matters](#)
[Experts](#)
[Where You Can Find More Information](#)
[Seattle Genetics, Inc. Report of Independent Accountants](#)